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Abstract 
Mister Donald Singer 
THE ROLE OF CD133 IN MOUSE INCISOR TOOTH EPITHELIUM 
Since its discovery, CD133 has been used to identify, isolate and characterise 
many different stem cell types across a wide variety of tissues. Nonetheless, to 
date not much has been elucidated about its function in these cells. The 
continuously growing mouse incisor contains a large population of epithelial stem 
cells that drive the constant need for enamel generation. Using this model, this 
project aims to elucidate the role of CD133 in epithelial stem cell renewal and 
activation. 
After validating the presence of CD133 in the developing mouse incisor 
epithelium, this project compared the dental epithelial stem cell dynamics of 
wildtype mice versus CD133 KO mice. Mutant mice displayed significant 
anomalies across the whole dental epithelium, ultimately, leading to defects in 
the enamel, the product of fully differentiated ameloblasts. 
Subcellular analysis of the dental incisor epithelium in CD133 KO mice revealed 
disturbed primary cilia homeostasis. Primary cilia are crucial in interpreting 
extracellular cues and CD133 KO primary cilia specifically fail to transmit Shh-
mediated signals. Further investigation of the functions of CD133 revealed that 
CD133 is important for the sequential recruitment of Arl13b and Hdac6 to the 
primary cilium regulating proper ciliogenesis. 
Establishment of an in vitro cell culture model of dental epithelial cells allowed 
the investigation of nuclear CD133 under normal physiological conditions. To 
date, nuclear CD133 has been reported in a variety of cancers. This study 
provides insight into the formation of the CD133-Glis2 complex in the nucleus. 
This complex regulates the expression of Stat3, an important regulator of stem 
cells, in the dental epithelium. 
In summary, this study has elucidated the importance of CD133 on primary cilium 
homeostasis, which in turn regulates stem cell renewal and activation in the 
developing incisor epithelium. 
 
iv 
 
Table of Contents 
Copyright Statement ........................................................................................... ii 
Abstract .............................................................................................................. iii 
Table of Figures ................................................................................................. ix 
Table of Abbreviations ...................................................................................... xii 
Acknowledgements ............................................................................................. 3 
Authors Declaration ............................................................................................ 4 
Chapter 1. Introduction and Background ............................................................ 5 
1.1 Stem cells .................................................................................................. 5 
1.1.1 Definition and characteristics of stem cells ......................................... 5 
1.1.2 Multipotent adult or somatic stem cells ............................................... 8 
1.1.3 Somatic stem cells and the extracellular micro-environment ............ 11 
1.1.4 Identification of somatic stem cells ................................................... 17 
1.1.5 Clinical relevance and limitations on the use of stem cells. .............. 20 
1.2 The primary cilium ................................................................................... 24 
1.2.1 Cilia Structure ................................................................................... 24 
1.2.2 Ciliogenesis and the cell cycle .......................................................... 27 
1.2.3 The primary cilium in stem cells ........................................................ 30 
1.2.4 The primary cilium as a signalling centre .......................................... 31 
1.3 CD133 ..................................................................................................... 36 
1.3.1 Discovery and Structure ................................................................... 36 
1.3.2 Other members of the Prominin family ............................................. 38 
1.3.3 Genomic organisation and transcriptional regulation of CD133 ........ 38 
v 
 
1.3.5 Expression of CD133 in tissues ........................................................ 43 
1.3.6 Subcellular Localisation of CD133 .................................................... 47 
1.3.7 CD133 in Disease ............................................................................. 50 
1.3.8 Interactions of CD133 and its functions ............................................ 54 
1.4 The mouse incisor as a model to study stem cell activation .................... 58 
1.4.1 General mechanisms and Morphology of Tooth Development ......... 58 
1.4.2 Initiation of Tooth Development ........................................................ 60 
1.4.3 Cap and bell stage of tooth development .......................................... 62 
1.4.4 Maturation of Tooth Epithelial Cells .................................................. 63 
1.4.5 The dental epithelium in the continuously growing mouse incisor .... 65 
1.4.6 Molecular regulation of labial cervical loop stem cells....................... 67 
2 Aims and objectives ....................................................................................... 72 
2.1 Aims ........................................................................................................ 72 
2.2 Objectives ................................................................................................ 72 
3 Impact of the work .......................................................................................... 74 
4 Results ........................................................................................................... 76 
4.1 The developing mouse incisor as a model to investigate epithelial stem 
and transit-amplifying cells ............................................................................ 76 
4.2 Primary cilia dynamics are linked to the cell cycle in the cervical loop .... 78 
4.3 CD133 mRNA is present in the developing mouse incisor tooth epithelium
 ...................................................................................................................... 79 
4.4 At least two different populations of CD133 exist within the mouse incisor 
tooth epithelium. ............................................................................................ 82 
vi 
 
4.5 CD133 C-terminal antibody validation ..................................................... 88 
4.6 Mice lacking CD133 exhibit enamel development defects ...................... 90 
4.7 Volume of stem cell and transit-amplifying cells region is affected in 
CD133 KO tooth epithelium. .......................................................................... 94 
4.8 CD133 KO primary cilia are more abundant and display altered dynamics 
compared to their WT counterparts ............................................................... 96 
4.9 Establishment of mouse dental epithelial primary cells ........................... 97 
4.10 CD133 KO cells fail to survive in vitro ................................................. 102 
4.11 Reduced levels of CD133 favour Shh-mediated apoptosis ................. 104 
4.12 CD133 is involved in cell cycle progression ........................................ 106 
4.13 Arl13b and Hdac6 are expressed in primary cilia in the dental epithelium
 .................................................................................................................... 111 
4.14 CD133 and Arl13b are co-expressed in dental epithelial primary cilia . 115 
4.15 Arl13b expression is decreased in CD133 KO dental epithelium ........ 116 
4.16 Expression of Shh effectors in the mouse incisor tooth ....................... 118 
4.17 CD133 translocates to the nucleus ...................................................... 124 
4.18 Glis2 and CD133 physically interact in the nucleus ............................. 125 
4.19 CD133 and Glis2 are connected to Jak/Stat and p53 signalling pathways
 .................................................................................................................... 127 
4.20 Assessment of the Jak/Stat signalling pathway in the mouse incisor 
tooth ............................................................................................................ 132 
4.21 Bmi1 acts upstream of CD133-mediated ciliogenesis in the dental 
epithelium .................................................................................................... 135 
vii 
 
5 Discussion.................................................................................................... 141 
6. Future research ........................................................................................... 152 
7 Materials & Methods .................................................................................... 154 
7.1 Mice ....................................................................................................... 154 
7.2 Extraction and culture of Cervical Loop epithelial cells .......................... 154 
7.3 Passaging of CLE cells.......................................................................... 155 
7.4 Freezing and thawing of CLE cells for long term storage ...................... 155 
7.5 Knockdown of CD133 in CLE using esiCD133 ...................................... 156 
7.6 Colony Forming Assay .......................................................................... 156 
7.7 Lentiviral production, shRNA Knockdown and Selection ....................... 157 
7.8 Generation of Ki67p-Fucci lentiviral reporters, cell transfection and 
infection ....................................................................................................... 158 
7.9 Flow cytometry ...................................................................................... 159 
7.10 Laser Capture Microdissection for RNA extraction .............................. 159 
7.11 RNA extraction & cDNA production ..................................................... 160 
7.12 Real-Time qPCR ................................................................................. 161 
7.13 Immunofluorescence ........................................................................... 162 
7.14 Confocal imaging ................................................................................. 163 
7.15 Three-dimensional reconstruction of primary cilia ............................... 163 
7.16 Three-dimensional reconstruction of the cervical loop ........................ 163 
7.17 Total protein extraction ........................................................................ 163 
7.18 Cytoplasmic and nuclear protein extraction ......................................... 164 
viii 
 
7.19 Protein quantification ........................................................................... 164 
7.20 Western blotting .................................................................................. 165 
7.21 Duolink® Proximity Ligation Assay ...................................................... 167 
7.22 Co-Immunoprecipitation ...................................................................... 168 
7.23 Chromatin Immunoprecipitation........................................................... 169 
7.24 Scanning Electron Microscopy ............................................................ 170 
7.25 X-Ray microscopy-based microCT analysis ........................................ 171 
7.26 Statistics .............................................................................................. 171 
8 Appendices .................................................................................................. 172 
8.1 B27 Serum-free Medium Composition .................................................. 172 
8.2 DMEM/F12 Medium Composition.......................................................... 173 
8.3 Gene list RT2 Pathway finder ................................................................ 175 
8.4 Primary antibodies used in this study .................................................... 178 
8.5 Secondary antibodies used in this study ............................................... 179 
8.6 esiRNA and shRNA sequences used in this study ................................ 180 
8.7 Primers used in this study ..................................................................... 181 
8.8 PCR programme details ........................................................................ 182 
8.8.1 Real-Time qPCR ............................................................................. 182 
8.8.2 cDNA Reverse Transcription PCR .................................................. 182 
9 List of References ........................................................................................ 183 
 
  
ix 
 
Table of Figures 
Figure 1: Potency of stem cells refers to its lineage differentiation potential. ...... 6 
Figure 2: Factors in the extracellular microenvironment that affect stem cells. . 12 
Figure 3: Role of secreted factors in specifying cell fate ................................... 15 
Figure 4: Structure of cilia. ................................................................................ 25 
Figure 5: primary cilia formation and absorption is linked to the cell cycle. ....... 28 
Figure 6: Membrane topology of CD133. .......................................................... 37 
Figure 7: Promoter organisation of human CD133. ........................................... 40 
Figure 8: Facultative exons in CD133 isoforms................................................. 42 
Figure 9: The developmental anatomy of early tooth morphogenesis in the 
rodent incisor and molar tooth types before eruption. ....................................... 61 
Figure 10: Ameloblast differentiation and enamel deposition. ........................... 64 
Figure 11: Overview of the adult mouse incisor and its regulation of stem cells in 
the labial cervical loop. ...................................................................................... 69 
Figure 12: The mouse incisor tooth is an excellent model to study quiescent 
stem cell to transit-amplifying cell transition ...................................................... 77 
Figure 13: Primary cilium characteristics in the cervical loop of P7 C57BL/6 
mice. ................................................................................................................. 80 
Figure 14: CD133 mRNA levels in the mouse incisor epithelium of P7 C57BL/6 
mice .................................................................................................................. 83 
Figure 15: CD133 differential epitope expression in the mouse incisor. ........... 86 
Figure 16: CD133 mRNA expression in the dental mesenchyme. .................... 87 
Figure 17: In vivo and in vitro validation of CD133 ICD antibody. ..................... 89 
Figure 18: Macro and microscopic characterisation of CD133 KO phenotype in 
the enamel. ....................................................................................................... 91 
Figure 19: Phenotypical characterisation of CD133 KO ameloblasts. ............... 93 
x 
 
Figure 20: Phenotypical characterisation of the SC and TAC region in CD133 
KO dental epithelium......................................................................................... 95 
Figure 21: Primary cilia characteristics in WT versus CD133 KO dental 
epithelium. ........................................................................................................ 99 
Figure 22: Isolation and cell culture of CLE primary cells. .............................. 101 
Figure 23: CD133 KO CLE cells fail to survive and proliferate in vitro. ........... 103 
Figure 24: Downregulation of CD133 affects the outcome of Shh in CLE cells.
 ........................................................................................................................ 105 
Figure 25: Knockdown of CD133 leads to reduced proliferation and survival in 
vitro. ................................................................................................................ 107 
Figure 26: Ki67p-FUCCI cell cycle indicator. .................................................. 108 
Figure 27: Gating strategy. ............................................................................. 110 
Figure 28: Effect of increased levels of CD133 and Shh on CLE cell cycle state.
 ........................................................................................................................ 112 
Figure 29: Arl13b and Hdac6 protein expression in the dental epithelium of P7 
C57BL/6 mice. ................................................................................................ 114 
Figure 30: CD133 and Arl13b are co-expressed in primary cilia. .................... 117 
Figure 31: CD133 affects Arl13b expression in the dental epithelium. ............ 119 
Figure 32: CD133 physically interacts with Arl13b through lysine-138 in MDCK 
cells................................................................................................................. 120 
Figure 33: Expression of Gli and Glis family members in the stem cell and  
transit-amplifying cell region of the mouse incisor tooth.................................. 122 
Figure 34: Subcellular localisation of Glis2 in the dental epithelium. .............. 123 
Figure 35: The presence of CD133 in the nucleus. ......................................... 126 
Figure 36: PLA reveals CD133-Glis2 interaction in the nucleus of the dental 
epithelium. ...................................................................................................... 128 
xi 
 
Figure 37: Heatmap of PCR array genes present in the mouse incisor. ......... 129 
Figure 38: In vivo and in vitro validation of PCR array. ................................... 131 
Figure 39: Jak/Stat expression in the dental epithelium of the mouse incisor 
tooth. ............................................................................................................... 133 
Figure 40: BMI1 is expressed in the dental epithelium of P7 mouse incisor tooth 
and partially controls CD133 and Glis2 expression. ........................................ 136 
Figure 41: Phenotypical similarities in primary cilia dynamics between Bmi1GFP 
and CD133 KO mice.........................................................................................138  
xii 
 
Table of Abbreviations 
Abbreviation Full name 
AA  amino acid 
AcTub  acetylated α-Tubulin 
Ambn Ameloblastin 
AmelX Amelogenin 
Ant Anterior 
APC  Adenomatous polyposis coli 
Arl13b  ADP ribosylation factor-like GTPase 13B 
Arnt  Aryl hydrocarbon receptor nuclear translocator 
ASPA  Animals Scientific Procedures Act 1986 
Bmi1  B lymphoma Mo-MLV insertion region 1 homolog 
BMP  Bone morphogenetic protein 
bp  basepair 
BrdU  5-bromo-2’-deoxyuridine  
CD  Cluster of differentiation antigen 
cDNA Complementary deoxyribonucleic acid 
CDS  Coding sequence 
Cdt1  Chromatin licensing and DNA replication factor 1 
CEP97  Centrosomal protein 97 
ChIP  Chromatin immunoprecipitation 
CLE Cervical loop epithelial 
CoIP  Co-immunoprecipitatation 
CP110  Centriolar coiled-coil protein 110 
CTGF  Connective tissue growth factor 
DAPI 4',6-diamidino-2-phenylindole 
DEPC  Diethylpyrocarbonate 
DKK1 Dickkopf WNT signaling pathway inhibitor 1 
DMEM  Dulbecco modified Eagle’s medium 
DNA Deoxyribonucleic acid 
DPLA  Duolink® proximity ligation assay 
E  embryonic day 
ECL Extracellular loop 
EGFP  Enhanced green fluorescent protein 
EGFR Epidermal growth factor receptor 
ELK1  ETS transcription factor 
EpCAM  Epithelial cell adhesion molecule 
esiRNA  Endoribonuclease-prepared short interference RNA 
EX  Extracellular 
EYFP  Enhanced yellow fluorescent protein 
FBS  Fetal bovine serum 
FGF  Fibroblast growth factor 
FITC Fluorescein isothiocyanate 
FSC Forward scatter 
FUCCI Fluorescence-acquired ubiquitination cell cycle indicator 
xiii 
 
GapDH  Glyceraldehyde-3-phosphate dehydrogenase 
GFP Green fluorescence protein 
Gli1  Glioma-associated oncogene homolog 1 
Glis  Gli-similar 
GSK3β Glycogen synthase kinase 3 beta 
H2B-GFP Histone 2B-GFP  
HBSS  Hank's balanced salt solution 
HCC  Hepatocellular carcinoma 
HDAC Histone deacetylase 
HERS  Hertwig’s epithelial root sheath 
Hh  Hedgehog 
HIF1/2a  Hypoxia-inducible factors 1/2 alpha 
HLA-DR  Major histocompatibility complex, class II, DR 
Hox  Homeobox 
HRP  Horseradish peroxidase 
IC Intracellular 
ICD Intracellular C-terminal domain 
IGF1R  Insulin-like growth factor 1 receptor 
IP Immunoprecipitation 
IR Infrared 
Irf1  Interferon regulatory factor 1 
Jak  Janus kinase 
kb  kilobasepair 
kDa  kiloDalton 
Ki67  Marker of proliferation Ki-67 
KIF24 Kinesin family member 24 
KLK4  Kallikrein-related peptidase 4 
KO Knockout 
lacZ  β-galactosidase 
LCM Laser capture microdissection 
Lef  Lymphoid enhancer binding factor 
Lgr5 Leucine-rich repeat-containing G protein-coupled receptor 5 
Lrp  LDL receptor related protein 
MAP2K1  Mitogen-activated protein kinase kinase 1 
MARK4  Microtubule affinity regulating kinase 4 
MDCK Madin-Darby canine kidney 
MMP3  Matrix metalloprotease 3 
MOB1  Mps one binder kinase activator-like 1 
mRNA  messenger ribonucleic acid 
MSX2  Msh Homeobox 2 
Nanog  Nanog homeobox 
ND  Not detected 
NEDD9  
Neural precursor cell expressed, developmentally down-regulated 
9 
NEK2  NIMA-related kinase 2 
neo  Neomycin phosphotransferase 
xiv 
 
NLS Nuclear localisation signal 
NOD/SCID  Non-obese diabetic/severe combined immunodeficiency 
NSCLC  Non-small cell lung cancer cells 
Oct4 POU class 5 homeobox 1 
P Postnatal day 
p53  Tumour suppressor protein p53 
PAX2  Paired box 2 
PBS  Phosphate-buffered saline 
PCDH21  Protocadherin 21 
PcG  Polycomb group 
PCR  Polymerase chain reaction 
PDGFR  Platelet-derived growth factor receptor 
PDZ  PSD95/Dlg/ZO-1 
PEN  Polyethylene naphthalate 
PFA  Paraformaldehyde 
PGR  Progesterone receptor 
PI3K  Phosphoinositide 3-kinase 
PIFO  Pitchfork 
Pitx2  Paired-like homeodomain 2 
PLA Proximity ligation assay 
PLK4  Polo-Like Kinase 4 
Post posterior 
Prc  Plolycomb repressive complex 
Pse  Posterior sex comb 
PTCH  Patched 
PVDF  Polyvinylidene fluoride 
qPCR quantitative polymerase chain reaction 
RFP Red fluorescence protein 
ROI Region of interest 
RTK  Receptor tyrosine kinase  
SEM Scanning electron microscope 
Shh  Sonic hedgehog 
shRNA short hairpin-ribonucleic acid 
Smo  Smoothened 
Socs3 Suppressor of cytokine signaling 3 
Sox2  Sex-determining region Y-box 2 
Spry  Sprouty 
SSC  Sideward scatter 
STAT  Signal transducer and activator of transcription  
TEK   Tyrosine kinase, endothelial 
Tgfβr  Transforming growth factor beta receptor  
TTBK2  Tau tubulin kinase 2 
UV Ultraviolet 
VDAC3  Voltage-dependent anion channel 3 
Wnt  Wingless-Type MMTV integration site 
WT Wildtype 
1 
 
 
 
 
  
2 
 
 
 
 
 
To  
My mother 
and  
especially to 
my partner 
Lauren 
and 
my son 
Jack 
 
  
3 
 
Acknowledgements 
I would like to express huge thanks to my supervisors: Dr Bing Hu, Prof 
Christopher Tredwin, and Dr Denis Corbeil for their seemingly endless font of 
advice and enthusiasm; and Prof. Ophir Klein and Dr. Massimo Attanasio for their 
significant contributions. 
I remain indebted to the BBSRC, Marie Curie Actions and NSFC for their kind 
provision of funds, without which this project would not have been possible. 
My friends and family were a constant source of encouragement and support, as 
they always have been, and for this, I will always remain extremely thankful. My 
mother has always provided a reference point to aspire to and have shaped me 
into the person I am today. 
Finally, I would like to thank my partner, Lauren, and my son Jack for their 
patience and forbearance during this long project, as well as their tolerance of my 
regular absence.  
4 
 
Authors Declaration 
At no time during the registration for the degree of Doctor of Philosophy has the 
author been registered for any other University award without prior agreement of 
the Doctoral College Quality Sub-Committee.  
Work submitted for this research degree at the University of Plymouth has not 
formed part of any other degree either at the University of Plymouth or at another 
establishment.  
This study was financed with the aid of the European Union Marie Skłodowska-
Curie actions (618930, OralStem FP7-PEOPLE-2013-CIG) a studentship from 
the Peninsula Dental School, University of Plymouth and carried out in 
collaboration with Technische Universität Dresden, University of California, UT 
Southwestern Medical Center, King's College London, and University of Oxford.  
Publications (or presentation of other forms of creative and performing work):  
Prominin-1 governs stem cell activation by orchestrating ciliary dynamics. The 
EMBO Journal (2018). DOI: 10.15252/embj.201899845 
Presentation and Conferences Attended: ARSC 2014 Cornwall, BSODR 2015 
Cardiff, ICDCSC 2016 Paris, ERSRAD 2016 Bradford, ARSC 2016 Cornwall, 
BSODR 2017 Plymouth, IADR 2018 London 
Word count of main body of thesis: 51214 
Signed……………………………………. 
Date………………………………………. 
  
5 
 
Chapter 1. Introduction and Background 
1.1 Stem cells 
1.1.1 Definition and characteristics of stem cells 
The existence of stem cells came to light from pioneering studies of Till and 
McCullogh on haematopoietic stem cells 1. Since then, stem cells are defined as 
undifferentiated cells that are capable of giving rise to indefinitely more cells of 
the same type (self-renewal), and from which certain other kinds of cell arise by 
differentiation (potency, Figure 1)2,3. Factors that define ‘stemness’ are self-
renewal or replication capacity, clonality, and potency 4,5. 
Self-renewal 
Most in vitro cultures of somatic cells are only capable of a finite number of 
population doubling eventually undergoing replication arrest or senescence 6,7. 
Stem cells can create more stem cells. This phenomenon is called self-renewal 
and tissue homeostasis is dependent on the accurate regulation of stem cell 
activity to counter tissue damage and to proliferate according to tissue 
requirements 8. 
Potency 
Potency (Figure 1) refers to the capacity of stem cells to which they can 
differentiate into various cell types and is classified as follows: 
A. Totipotency 
Totipotent stem cells are considered as the only ‘true’ stem cells and are capable 
of differentiating into any cell type in the body as well as the extra-embryonic or  
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Figure 1: Potency of stem cells refers to its lineage differentiation potential.  
Totipotent stem cells can generate all cells required to form an organism and its associated 
placenta. Pluripotent stem cells have the ability to produce cells that contribute to all three 
germ layers and are able to form a complete organism apart from the placenta. Multipotent 
stem cells are already committed to a specific germ layer and can only produce progeny of 
that germ layer. Unipotency refers to stem cells that can only lead to one type of specialised 
cell. 
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placental cells 9. A zygote or fertilised egg and the blastocyst are the only source 
of totipotent stem cells that are capable of generating cells of all three germ layers 
(i.e., endoderm, mesoderm and ectoderm). Embryonic stem cells originate from 
the inner cell mass are currently being scrutinised as rapid progress in the stem 
cell field (i.e., cell reprogramming) are challenging these concepts10. 
B. Pluripotency 
Pluripotent stem cells are derived from totipotent stem cells and can differentiate 
into any cell type of the organism except for extra-embryonic tissue. Embryonic 
stem cells derived from inner cell mass, embryonic germ cells and cord blood-
derived stem cells are considered pluripotent and, therefore, capable of giving 
rise to tissues of all three germ layers11–13. 
C. Multipotency 
Multipotent stem cells have a restricted differentiation potential compared to their 
pluripotent counterpart. Adult or somatic stem cells are considered multipotent as 
they can only generate cells of the tissue they reside in14. Examples include 
neuronal stem cells capable of generating neurons, oligodendrocytes and 
astrocytes, and haematopoietic stem cells which produce most blood cells15,16. 
D. Unipotency 
Unipotent or precursor cells can only produce one cell type and have, therefore, 
a very limited differentiation potential. For example, cardiac precursor cells 
differentiate into cardiac muscle fibres only. 
E. Induced pluripotency 
In 2006, Yamanaka’s lab showed that with the introduction of four transcription 
factors somatic cells could be reprogrammed to a more primitive state17. Since 
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then, different cell types and other combinations of reprogramming factors have 
been used to generate induced pluripotent stem cells18. Despite their enormous 
potential, the only clinical trial using induced pluripotent stem cells to treat 
macular degeneration was stopped after discovering that the used induced 
pluripotent stem cells carried potentially cancer-inducing mutations19. Currently, 
induced pluripotent stem cells provide an unlimited supply of once-inaccessible 
human tissues for research and are mostly used for modelling and investigating 
human diseases, on top of drugs screening. 
1.1.2 Multipotent adult or somatic stem cells 
Adult or somatic stem cells are undifferentiated cells, found in most organs of the 
body following development. They proliferate on appropriate cues to replenish 
dying cells and regenerate damaged tissues. Unlike embryonic stem cells, they 
can be found in juvenile as well as adult humans and animals. Scientific attention 
in somatic stem cells is focused on their ability to divide or self-renew for a 
prolonged period and produce all the cell types of the organ from which they 
derive. Unlike with embryonic stem cells, the use of human somatic stem cells in 
research and therapy is not considered controversial, as they are derived from 
adult tissue samples rather than human embryos. 
Somatic stem cells are present throughout most tissues in the body, including but 
not limited to the bone marrow, the hair follicle, intestines and peripheral blood. 
They can be epithelial, nervous, adipose or mesenchymal in nature. The central 
view of a somatic stem cells, as with most other types of stem cells follows the 
traditional model that it is rare and spends the majority of its time in a ‘quiescent’, 
non-proliferative state as replication of its DNA carries the risk of mutation20,21. 
This can be experimentally distinguished from proliferating cells by the retention 
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of DNA labels22,23. However, the vast majority of cells in any tissue is in fact non-
dividing. This dogma of a rare, quiescent stem cell capable of replenishing the 
whole tissue in a unidirectional manner stems from the haematopoietic stem cell, 
which was discovered in the 1960’s24.  
The inhabitants of Nagasaki and Hiroshima who were exposed to low radiation 
fallout after the atomic bomb explosions died over time to a compromised 
haematopoietic system. Their weakened immune system did not allow the 
survivors to produce enough leukocytes to fight off infections or sufficient 
thrombocytes to prevent excessive bleeding. Follow up experiments on mice 
exposed to lethal radiation revealed that they could be saved when their spleen 
was protected from the lethal radiation25. In 1956, three research groups 
discovered independently the cause of regeneration of the haematopoietic 
system in the exposed mice. They determined that the transplanted cells were 
the progenitor cells responsible for the renewal of the haematopoietic system 
rather than acting indirectly by secreting factors that might enhance the repair of 
the compromised immune system of the host26–28. In the 1960’s, increased use 
of radiation therapy to treat cancer sparked research into the sensitivity of bone 
marrow to radiation. Till and McCullogh used genetically labelled spleen cells to 
describe the two fundamental characteristics that are still used today to define 
adult stem cells: a quiescent cell with prolonged self-renewal capabilities and the 
ability to differentiate into all cells of the leukocyte and erythrocyte lineage (in the 
case of haematopoietic stem cells)1.  
Since then, the paradigm of a rare, quiescent haematopoietic stem cells that 
gives rise to all types of blood cells has served as a template to interpret 
experimental observations for all adult tissues. In addition to haematopoietic stem 
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cells in the bone marrow, the intestinal crypt and hair follicle have been widely 
used as a model to study somatic stem cells in self-renewal and activation. 
The intestinal crypt as a model 
The intestinal epithelium lining the crypt contains continuously proliferating 
Leucine-rich repeat-containing G-protein coupled receptor 5 (Lgr5) -positive stem 
cells that are located at the base of the crypt, whereas a ‘backup’ quiescent stem 
cell sits at position +4 counted from the crypt base29. Until recently, these +4 cells 
were thought to be the source of the proliferative Lgr5 cells but genetic tracing 
studies revealed a second alternative mechanism: +4 cells are daughters, which 
have left the cell cycle prior to terminal differentiation into secretory cells30,31. 
However, loss of the Lgr5+ stem cells after injury can persuade +4 cells to 
repopulate the Lgr5+ cells at the crypt’s base and regain a stem cell phenotype. 
In normal homeostasis, these quiescent +4 cells are transient and short-lived as 
they will become secretory cells and die. In injury, these cells show remarkable 
plasticity and serve as a ‘backup’ stem cell pool to replenish the Lgr5+ multipotent 
stem cells. This observation challenges the concept of a unidirectional flow from 
stem cell to differentiated cell. 
The hair follicle as a model 
The hair follicle serves as an excellent model to study stem cell biology. Each 
hair follicle consists of a permanent part including the sebaceous gland, the 
dermal papilla (DP) and the bulge region, and a cycling segment that cycles 
through telogen (resting phase), anagen (growth phase) and catagen (retraction 
phase)32.  
Cells present in the bulge, a reservoir of epithelial stem cells, are able to retain 
Histone 2B-GFP signal and the majority of them express CD34, a well-known 
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stem cell marker. Grafting of these cells into nude mice resulted in the generation 
of entire hair follicles33–35. The mesenchymal dermal papilla at the base of the 
hair follicle signals to the quiescent stem cells in the bulge and regulates their 
activation. Interestingly, not all bulge stem cells become activated during the 
anagen phase, suggesting that this stem cell population is heterogeneous in 
terms of the cell cycle state and that not all cells are involved in regeneration of 
the hair follicle36. 
1.1.3 Somatic stem cells and the extracellular micro-environment 
The extracellular micro-environment or niche impacts cell behaviour within a 
tissue, including stem cells. The extracellular micro-environment in which a stem 
cell resides affects the cells survival, self-renewal and differentiation37. Many 
components form part of the extracellular micro-environment including resident 
cells38, secreted and membrane-bound factors30,38–40 and insoluble matrix 
molecules41,42 (Figure 2). All these features can lead to changes within the 
extracellular micro-environment (e.g. recruitment of immune cells) or stem cells 
itself such as proliferation, differentiation and apoptosis.  
Resident niche cells 
In most tissues, the stem cell niche holds many different cell types. This is clearly 
illustrated in the case of the haematopoietic system within the bone marrow. 
Osteoblastic, neuronal and endothelial cells, megakaryocytes, macrophages as 
well as other immune cells all contribute to defining distinct haematopoietic stem 
cell niches43. In the colon and intestine, critical players in maintaining the niche 
are the progeny of the stem cells. For instance, in the colon, goblet cells which 
express epidermal growth factor (EGF), c-KIT and NOTCH ligands co-localise 
with and thus support the stem cells in their niche44.  In the small intestine, stem 
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Figure 2: Factors in the extracellular microenvironment that affect stem cells.  
The extracellular micro-environment is a complex, heterotypic and dynamic structure 
including different cellular components, secreted factors, immunological response, 
physical interactions and metabolic control. Stem cells and the extracellular micro-
environment act in a bi-directional and reciprocal manner. Many features are shared 
between stem cells and their niches in different tissues (Adapted from 37). 
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cells maintain their stemness partially through paracrine signalling of Wingless-
Type MMTV Integration Site 3a (WNT3a), EGF and NOTCH45,46. Consequently, 
separate niches exist in different parts of the intestinal tract, which contribute to 
tissue homeostasis.  In the hair follicle, neural Sonic hedgehog (SHH) is vital in 
maintaining the biological potential of the bulge stem cell in the telogen phase47. 
Inflammation  
Endothelial cells, connective tissue and nerve cells are considered permanent 
residents within the stem cell niche. Whereas immune cells and cells, responding 
to tissue damage, would be more transient in nature to fight pathogens or to 
promote healing. Migration of cells of the adaptive and innate immune system 
can affect stem cell behaviour. Most stem cell niches are ‘immune-privileged’ 
meaning that mechanisms exist that protect the cells from immune response 48. 
For instance, in the bone marrow, regulatory T-cells create pockets of immune 
privilege where haematopoietic stem cells reside to evade immune responses49. 
This protective mechanism is currently being exploited in clinical trials to prevent 
rejection of transplanted tissues. 
Secreted factors 
Communication between stem cells and other resident cells in the niche is 
partially facilitated by secreted factors including cytokines and hormones 50,51. 
These factors control many processes during development including cell 
proliferation, differentiation, morphogenesis, tissue organization, and 
angiogenesis. Furthermore, in adult tissues, they are involved in wound healing, 
regulating metabolism and maintaining homeostasis52. Permanent activation of 
growth factor signalling is often seen in and tumourigenesis 53. Two of the most 
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prominent secreted factors in controlling stem cell fate are WNT and Sonic 
hedgehog (SHH)54.  
Most stem cell populations are partially regulated by WNT signalling and changes 
in WNT activity in the stem cell compartment has inherent effects both on those 
cells and on other resident cells55. For instance, an increase in WNT activity in 
the epidermis leads to an increase in stem cell number and induces hair follicle 
differentiation, whereas the dermis takes on the features of neonatal dermis56–58.  
Another pathway that is important in the stem cell niche is hedgehog signalling. 
SHH is the best-studied ligand in hedgehog signalling and is a classic example 
of a morphogen. Typically, the secreted ligand diffuses through the surrounding 
tissues creating a concentration gradient. This gradient determines the patterning 
of organs such as the limb59, midline structures of the brain 60 and teeth 61 and 
represents the process of differentiation of stem cells into different cell types.  
Hypoxia and metabolism  
Many stem cell populations exist in a hypoxic microenvironment that facilitates 
their survival and maintenance. Hypoxic cells undergo glycolysis instead of 
mitochondrial oxidative phosphorylation62. This switch in metabolism prevents the 
generation of reactive oxygen species in stem cells, thereby, minimizing the risk 
of DNA damage63. Indeed, In vitro culture of different mammalian stem cells 
under hypoxia promotes their proliferation, survival and functions after grafting. 
Likewise, in the bone marrow, hypoxia improves quiescence and renewal in 
haematopoietic stem cells64,65. It is clear that cellular metabolism plays a 
fundamental role in proliferation, differentiation and quiescence and the shift in 
glycolysis, mitochondrial oxidative phosphorylation and oxidative stress 
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Figure 3: Role of secreted factors in specifying cell fate 
Lineage relationship between secreted factors, and germ layer and tissue specification from 
pluripotent stem cells. Secreted factors are marked in red. Adapted from Benvenisty et al450. 
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during the maturation of somatic stem cells can be used for novel metabolic 
therapies to enhance regeneration66.  
Extracellular matrix  
The extracellular micro-environmentnis the 3D structure in which the stem cell 
resides and is a significant factor of the stem cell niche in virtually all tissues. Its 
composition and the nature of its interactions with stem cells differ substantially, 
even within the same tissue67. Extracellular micro-environment components are 
produced and secreted by resident cells and, typically, consists of an intertwining 
network of fibrous proteins and glycosaminoglycans. 
It is well established now that the extracellular micro-environment tethers stem 
cells as well as direct their fate68. Anchoring of stem cells within the extracellular 
micro-environment leads to changes in intracellular signalling pathways of which 
many have been uncovered. The extracellular micro-environment also retains 
secreted factors, acting as a reservoir to increase the local concentration to which 
recipient cells are exposed 69. Integrins are the major molecules involved in 
interactions between the cell and the extracellular micro-environment, and 
abnormal integrin signalling has been linked to many pathologies including 
cancer70. Integrins bind to their extracellular substrates, such as Laminins and 
Fibronectin, to direct differentiation of stem cells of all three germ layers and are 
to be considered as a candidate for in vitro differentiation of stem cells alongside 
the use of soluble factors to overcome the low success rate of generating mature 
cell types71. 
Physical factors  
Historically, changes in stem cell behaviour, both in vivo and in vitro, has been 
ascribed predominantly to genetic and molecular factors such as growth factors 
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and transcription factors. Stem cell fate, however, also depends on signals from 
the extracellular micro-environment such as substrate elasticity and stiffness, 
shear forces and physical shape often mediated by Integrin substrate 
interactions. These mechanical forces have been used to expand stem cell 
populations, such as skeletal muscle stem cells and haematopoietic stem 
cells72,73. Chemical agents that affect the balance between elastic (e.g., 
cartilage, connective tissue) and rigid (e.g., bone) factors are already being 
used to treat metastatic bone cancers and osteoporosis. Also, distinctive niche 
topographies are known to promote cytoskeletal rearrangement in stem cells 
and this, in turn, induces specific differentiation signalling pathways74,75.  
1.1.4 Identification of somatic stem cells 
Those extrinsic factors provided by the extracellular environment affect 
intracellular pathways or intrinsic factors within somatic stem cells leading to 
changes in its proliferation and differentiation. Intrinsic factors represent mainly 
transcription factors, which act to ‘translate’ the extracellular cues into appropriate 
gene transcription to facilitate renewal, proliferation or differentiation. The 
importance of transcription factors in achieving stem cell identity has been 
demonstrated more than ten years ago with the introduction of four transcription 
factors into murine embryonic fibroblasts pushing them into a pluripotent state17. 
Somatic stem cells express intrinsic factors in a tempo-spatial manner that makes 
them distinguishable from other cells within their niche.  
One such factor is SOX2, a member of the SRY-related High Mobility Group 
family. SOX2 is essential during early embryonic development as has been 
demonstrated by the failure of SOX2 KO embryos to develop past the epiblast 
stage 76. Moreover, it has been shown that SOX2 also marks long-lived somatic 
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stem cells to regulate homeostasis in a broad range of adult epithelial tissues 
including the stomach, cervix, testes, lens and several glands77. During 
development of the mouse incisor, SOX2 expression is universal during early 
tooth morphogenesis and becomes increasingly restricted to the proximal tip of 
the incisor, which has been shown to harbour label-retaining cells, a marker for 
quiescence. SOX2+ dental epithelial cells give rise to all epithelial lineages and 
persists throughout the animal’s life78. SOX2 maintains stemness in concert with 
partner transcription factors in a tissue-specific way. A classic example is POU 
Class 5 Homeobox 1 (POU5F1, previously known as OCT3/4) which regulates 
the expression of genes necessary to maintain pluripotency and in embryonic 
development79. SOX2 is also implicated in chromatin remodelling in neural stem 
cells through binding to the ATPase Cadherin 7 (CDH7), member of the of the 
chromodomain helicase DNA-binding domain family of ATP-dependent 
chromatin remodellers.  
Another chromatin remodeller associated with somatic stem cells is the polycomb 
group gene B Lymphoma Mo-MLV Insertion Region 1 Homolog (BMI1) that forms 
a complex to negatively regulate gene expression through ubiquitination of 
histone 2A. Only tri-methylated histones at lysine 27 are targets of the complex 
leading to the formation of heterochromatin80. However, recently it has been 
shown that BMI1 can positively influence gene expression independently of the 
complex81. In the continuously growing mouse incisor, BMI1+ cells mark the 
same region as SOX2+ cells and deletion of BMI1 results in fewer stem cells and 
aberrant enamel production due to derepression of the Ink4a/Arf locus and 
several homeobox genes82. Several pathways converge on BMI1 to regulate 
stem cell dynamics in a variety of tissues. For instance, hedgehog signalling is 
dependent on BMI1 to regulate stem cell renewal and proliferation in mammary 
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glands83. Whereas in the intestinal crypt, BMI1 is downstream of both Notch and 
WNT signalling and deletion of BMI1 leads to loss of the stem cell pool and 
increase of differentiation into goblet cells84. 
Lgr5, a class A G-protein coupled receptor involved in Wnt-signalling, has gained 
traction as a somaric stem cell marker when it was discovered that the receptor 
marks slow-cycling cells in the intestinal crypt, capable of generating all six 
differentiated epithelial cell types that line the crypt451, 452 (see chapter 1.1.3: the 
intestinal crypt as a model). Since then its use as a somatic stem cell marker has 
expanded to other tissues including the mouse incisor. In the mouse incisor, 
LGR5 marks a subpopulation of Sox2+ stem cells and loss of Sox2 leads to a 
diminished LGR5+ cell population and reduction of the stem cell population in 
general. However, Sox2- cells within the stellate reticulum quickly replenish the 
Sox2+ stem cells including the LGR5+ subpopulation454. This phenomenom is 
also seen in the intestinal crypt where ablation of LGR5+ stem cells are rescued 
by a BMI1+ stem cell population to restore tissue homeostasis412.Isolation of stem 
cells is often achieved using cell surface markers that are categorised as a cluster 
of differentiation antigens (CD). These cell surface markers have established the 
field of haematopoiesis and our understanding of existing subpopulations within 
blood85. CD antigens belong to different classes such as receptors, adhesion 
molecules, glycoproteins and integrins. Currently, there are 371 different proteins 
classed as CD antigens in humans (as of May, 2018)86. Different cell types 
display different CD antigens, and we are just beginning to understand the CD 
antigen signatures that are present in specific cell types. Several CD antigens are 
linked with human and mouse embryonic stem cells. CD9, a tetraspanin 
glycoprotein, is known to be highly expressed in mouse and human embryonic 
stem cells and rapidly lost upon differentiation. Its high expression in stem cells 
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is regulated via the LIF, Interleukin 6 Family Cytokine/ Signal Transducer And 
Activator Of Transcription 3 (LIF/STAT3) pathway87. Other CD antigens that are 
linked with pluripotent embryonic stem cells are CD24, CD30, CD90, CD133, 
CD200, and CD32688–92. In mesenchymal cell populations, it has been well 
established that ≥95% of the cells have to express CD73, CD90, and CD105  and 
≤2% must not express CD34, CD45, CD14 or CD11β, CD79α or CD19 and Major 
Histocompatibility Complex, Class II, DR (HLA-DR)93. Despite their established 
expression profiles in a wide range of cell populations, only a fraction of CD 
antigens has been characterised. For instance, CD133 has been used as a stem 
cell marker in a wide variety of tissues. However, its function within those tissues 
has not been elucidated yet. In addition, in recent years its expression has also 
been shown to be in terminally differentiated cells questioning its use as a stem 
cell marker94. This observation might hold true for many CD antigens of which the 
function has not been determined yet. 
1.1.5 Clinical relevance and limitations on the use of stem cells. 
For over 40 years, the most widely used stem cell therapy is bone marrow 
transplant in patients suffering from leukaemia and lymphoma. This allows the 
patient to receive high dose treatment of chemo and radiation therapy. In recent 
years, other therapies have been approved including the production of skin grafts 
from adult hair follicle stem cells95 or repairing corneal transparency using kerato-
limbal stem cells96. These treatments are generally recognized as safe and 
effective in the medical field. Despite these advancements, there remain certain 
risks that currently limit the use of stem cells. These risks depend on many factors 
such as the source of stem cells as illustrated briefly in Table 1. Embryonic stem 
cells were initially the main type of stem cells used due to their ability to 
differentiate in every somatic cell type. However, embryonic stem cells being 
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allogenic in nature often required immunosuppressants to avoid rejection97,98. In 
addition, these cells also displayed a propensity to form tumours and its use in 
clinics is highly controversial because its generation involves the destruction of 
an embryo99–101.  
The use of induced pluripotent stem cells, another pluripotent stem cell type, in 
clinics is also limited. As with embryonic stem cells, induced pluripotent stem cells 
are likely to form teratomas in recipients102. Moreover, reprogramming 
efficiencies of somatic cells, albeit improved, remain low17,103. However, 
reprogramming efficiencies are currently undergoing intensive research as 
induced pluripotent stem cells avoid two drawbacks in the use of embryonic stem 
cells in clinics: ethical concerns and potentially immune rejection when 
autologous somatic cells are used. At present, the first clinical trial is underway 
using allogenic induced pluripotent stem cells that are reprogrammed to retinal 
cells. A similar clinical trial using autologous induced pluripotent stem cells was 
aborted in 2014 due to the presence of genetic abnormalities in cells prepared 
for the second patient104.  
Despite their potential in regenerative medicine, embryonic stem cells and 
induced pluripotent stem cells present issues that are difficult to overcome. Hence, 
they are underrepresented in clinical trials. Multipotent somatic stem cells are in 
essence already committed to a specific lineage, generating intended cell types 
is comparatively easy, and the possible risk for tumourigenesis is low.  
Mesenchymal stem cells are the most common type of multipotent somatic stem 
cells and are of great interest to the scientific community, as they do not present 
the same ethical and immunological concerns as with induced pluripotent stem 
cells and embryonic stem cells. Mesenchymal stem cells are present in many 
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Embryonic stem 
cells  
Induced 
pluripotent stem 
cells  
Somatic stem cells 
Origin Derived from inner 
cell mass of 
blastocyst 
Derived from 
somatic cells 
Isolated from adult 
tissue 
    
Donor Allogenic tissue Autologous or 
allogenic tissue 
Autologous or 
allogenic tissue 
    
Potency Pluripotent Pluripotent Multipotent     
Differentiation 
potential 
Can differentiate in 
cell types of all 
three germ lineages 
Can differentiate in 
cell types of all 
three germ lineages 
Can differentiate in 
limited cell types 
depending on the 
tissue of origin 
    
Self-renewal 
capacity 
Unlimited self-
renewal 
Unlimited self-
renewal 
Limited self-renewal 
    
Hayflick limit Indefinite growth Indefinite growth Limited lifespan 
(population doublings) 
    
Teratoma risk Significant Significant No     
Ethics Serious ethical 
issues 
No ethical issues No ethical issues 
    
Immuno-
privilege 
Low level of MHC I 
and II 
Not immuno-
priviliged when 
derived from adult 
cells. Normal level 
of MHC I and II. 
Mesenchymal stem 
cells have low 
immunogenicity and 
are 
immunomodulatory. 
Not known for other 
somatic stem cells.     
Risk of immune 
rejection 
Cell lines will be 
allogenic 
HLA-matched 
induced pluripotent 
stem cells have 
less chance of 
immune rejection 
Autologous somatic 
stem cells have less 
chance of immune 
rejection 
Table 1: Characteristics and considerations of different stem cells in therapy 
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tissues including skin, bone marrow, adipose tissue, intestines and the umbilical 
cord and are, therefore, accessible. However, mesenchymal stem cells  often 
make up only a fraction of the adult tissue and are, consequently, difficult to 
isolate but have the potential to differentiate into ectodermal and mesodermal 
lineages such as dopaminergic neurons, cartilage, hepatocytes, smooth muscle, 
pancreatic cells, cardiomyocytes, neuronal cells and osteoblasts105. Similar as 
with mesenchymal stem cells , epithelial stem cells have the same advantages 
and limitations in therapy and their use in forming skin grafts has saved lives of 
many severe burn victims106. In spite of this early success, epithelial stem cell 
isolation and in vitro expansion from other tissues has been met with considerable 
difficulties until recently as is demonstrated in the successful long-term 
engraftment of murine intestinal stem cells into damaged mouse colon107. 
Interestingly, Zhang et al. revealed that the transduction of a single gene could 
turn keratinocytes into corneal-like stem cells capable of replenishing the whole 
cornea in rabbits108.  
This finding necessitates further research to unravel other pathways and factors 
capable of altering stem cell fate and differentiation. Understanding both intrinsic 
and extrinsic cues that control stem cell behaviour in different contexts will lead 
to better treatments for a range of diseases. One organelle that is involved in 
processing extrinsic cues is the primary cilium. Indeed, primary cilia are mediators 
of extracellular signals into appropriate cellular responses and are inherently 
linked to the cell cycle, a process crucial to stem cell fate and differentiation. 
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1.2 The primary cilium 
In some ways, we perceive our surroundings through cilia. For instance, the 
kinocilium in hair cells of the inner ear coordinates the stereociliary bundles that 
sense sound waves; the outer segments of photoreceptor cells are adapted cilia 
and cilia in the olfactory epithelium are involved in the detection of odours. Cilia 
are the oldest known cellular structure since its discovery in 1675 by Antony Van 
Leeuwenhoek109, and up until the very end of the 20th century, most studies 
involving cilia only focused on the structure and motility. In 1898, a second type 
of cilia was discovered. These non-motile or primary cilia were regarded as 
vestigial organelles and were, therefore, mostly ignored by scientists110. It is only 
from the late 1990’s that the importance of primary cilia was recognised as clinical 
studies have linked primary cilia function with diseases including cancer, neural 
tube defects and retinal degeneration111–113. 
1.2.1 Cilia Structure  
The central core or axoneme of cilia consists of a nine parallel microtubule 
doublet core arranged radially around a central core109. Motile cilia (‘9+2’) 
possess two central microtubules linked by dynein arms, facilitating their 
mechanical function, with the microtubule doublets organised around it (Figure 
4b). Primary cilia (‘9+0’) lack the two central microtubules and their associated 
dynein arms, which makes the primary cilium a static organelle (Figure 4d). Motile 
and primary cilia protrude from an adapted centriole or ‘basal body’, which is 
located intracellularly at the base of the cilium. The basal body offers the nine-
fold symmetric model upon which microtubule doublets extend into the cilium114. 
This structure ensures the proper function of cilia by governing its position and 
orientation, act as a gateway for proteins and other molecules, and is involved in 
linking planar cell polarity signals with the axis of mitosis114. 
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Figure 4: Structure of cilia. 
A) Sagittal view of motile cilia. B) Topographical cross-section of a motile cilium 
displaying the typical ‘9+2’ microtubule conformation. C) Sagittal view of a primary cilium. 
D) Topographical cross-section of a primary cilium showing the ‘9+0’ microtubule 
conformation lacking the inner core. 
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Cilia display a number of sub-regions based on their microtubule composition. 
The proximal region of the cilium, termed the ‘ciliary gate’, consists of two 
structurally discrete sub-regions: the transition fibres and the transition zone115. 
Distal from the transition zone is where the axoneme of the cilium is formed. The 
axoneme extends from the transition zone and consists of a large part of a 
doublet zone, which contains motility-associated proteins. At the distal crown of 
the cilium, the doublet zone narrows into the singlet zone.  
α-Tubulin is the main component of the axoneme and undergoes various post 
translational modifications such as, but not limited to acetylation, de-tyrosination 
and glutamylation116. Among these modifications, acetylation of lysine-40 (K40) 
is the best studied and plays a crucial role in the regulation of the primary cilium. 
During ciliogenesis, intraflagellar transport (IFT) complexes are responsible for 
the extension of the axoneme from the centriole. IFT complexes consist of 20 
proteins that are organised in two subcomplexes termed IFT-A and IFT-B117. Bi-
directional movement of the complexes along the axoneme is facilitated by two 
axoneme-based motor proteins: Kinesin-2 carries out anterograde transport of 
ciliary proteins to the ciliary tip whereas retrograde transport towards the cell body 
is driven by Dynein-1b118. IFT is necessary for ciliogenesis as it carries α-Tubulin 
to the tip of the axoneme. Subsequently, acetylation of K40 by α-Tubulin 
Acetyltransferase-1 stabilises α-Tubulin in the primary cilium. Indeed, 
deacetylation of α-Tubulin leads to retraction of the primary cilium. Histone 
deacetylase 6 (HDAC6) is a major player involved in all the known biological 
situations leading to a loss of the primary cilium including heatshock, mitosis and 
cancer119–121. The balance between ciliogenesis and resorption in any given cell 
is concomitantly linked with the cell cycle. 
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1.2.2 Ciliogenesis and the cell cycle 
The formation of cilia and the cell cycle are connected as they both use the same 
machinery. In dividing cells, the basal body consists of a pair of centrioles, a 
mother and daughter centriole. The mother centriole is derived from the 
centrosome of the previous cell cycle and has distinctive ultrastructural and 
molecular features that separate it from the daughter centriole122,123. 
In the S-phase of the cell cycle, centrioles are duplicated once and migrate to 
opposite poles of the cell where they act as a microtubule organising centre to 
ensure proper chromosome segregation 124. Consequently, after cell division, 
each daughter cell receives one pair of centrioles. During the G0/G1-phase, 
migration and docking of the centrioles to the plasma membrane defines the site 
of ciliogenesis. The mother centriole transitions into the basal body, acting as a 
scaffold for axoneme synthesis, whereas the daughter centriole remains docked 
at the proximal end of the mother centriole 125. Prior to the fusion of the basal 
body with the plasma membrane, vesicles secreted by the Golgi apparatus are 
recruited to the distal appendages of the mother centriole to form the ciliary 
vesicle. The distal appendages of the basal body firmly attach to the plasma 
membrane and mark the beginning of the transition zone into which the axoneme 
protrudes. At the end of the G1-phase, the primary cilium is resorbed in two 
waves. The initial wave happens before the G1/S transition and is followed by a 
second, major wave before mitosis. Therefore, cells undergoing mitosis are 
devoid of primary cilia, with only a fraction of the ciliary membrane bound to the 
mother centriole 126. This ciliary resorption allows the centrioles of the basal 
body to act as centrosomes during mitosis. Hence, the suppression of cilia 
formation is critical in proliferating cells, and several signalling pathways linked to 
the cell cycle have evolved to control ciliogenesis. 
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Figure 5: primary cilia formation and absorption is linked to the cell cycle. 
Primary cilia assembly and associated proteins are dynamic throughout the cell cycle 
(G1, S, G2 and M phases), and in quiescence (G0 phase). The basal body is indicated 
by the double cylinders; microtubules are represented by the grey rods, only two doublet 
microtubules are shown for simplicity. Stable, acetylated tubulin is indicated at G1/G0 
with acetyl groups (Ac) shown as brown circles. Proteins discussed in this chapter are 
highlighted in different colours: AURKA–HDAC6 disassembly pathway is shown in red 
and brown, respectively. KIF2A and KIF24 mediate microtubule depolymerisation and 
are coloured in green. ‘P’ in green circles indicates protein phosphorylation. Other 
centrosomal components are coloured in blue and purple. The function of KIF24 during 
the cell cycle is currently unclear, other proteins are assumed to be involved in the 
formation and regulation of the CEP97–CP110 scaffold. AURKA activates KIF2a during 
G1/S and in M-phase it negatively regulates it by phosphorylation. The arrows indicate 
activating effects, whereas bar-headed lines specify inhibitory effects. Dashed arrows 
refer to a post-translational modification of a protein or physical translocation. 
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How is the cell cycle linked to the formation and disassembly of cilia? 
Microtubules are in a constant dynamic flux, and one mechanism to control 
ciliogenesis is to shift the equilibrium between formation and resorption of 
axonemal microtubules. Despite recent efforts, the mechanisms behind this are 
still not completely understood.  A number of ciliary and centrosomal proteins are 
known to regulate this process, and their function often depends on negative 
regulation by cell-cycle kinases such as Polo-Like Kinase-4 (PLK4), Centriolar 
Coiled-Coil Protein-110 (CP110) and Voltage Dependent Anion Channel-3 
(VDAC3)127–129. 
For instance, the CP110-Centrosomal Protein-97 (CEP97) complex is bound to 
the distal region of the mother centriole to prevent ciliogenesis during the cell 
cycle. When cells exit the cell cycle or complete mitosis this inhibitory complex is 
dissociated from the mother centriole for proper cilia formation (Figure 5). 
Microtubule Affinity Regulating Kinase-4 (MARK4) and Tau Tubulin Kinase-2 
(TTBK2) are two protein kinases involved in the dissociation of CP110 and, 
therefore, initiation of ciliogenesis although the exact mechanism is still 
unclear130,131. The CP110-CEP97 complex also plays a role in sequestering a 
kinesin, Kinesin Family Member 24 (KIF24),  at the distal tip of the mother 
centriole leading to the depolymerisation of centriolar microtubules, thus, 
suppressing cilia formation (Figure 5)132. NIMA Related Kinase-2 (NEK2), a S/G2-
phase kinase interacts with and phosphorylates KIF24 to start microtubule 
depolymerisation133.  Despite this, KIF24 remains present at basal bodies after 
cilia formation132. KIF2a, a promoter of mitotic spindle assembly, is also 
implicated in tubulin depolymerisation and is upregulated by the mitotic PLK1, 
and downregulated by Aurora kinase A (Figure 5)134,135. All these examples 
demonstrate the pivotal role of cell-cycle kinases as regulators of cilium formation.  
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The KIF2a–PLK1 signalling pathway seems to be partly redundant to the KIF24–
NEK2 signalling pathway. Also, KIF2a instead localizes to the sub-distal 
appendages of the mother centriole. Taken together, it is more likely that KIF2a 
is involved in centrosomal or cytoplasmic microtubule depolymerisation rather 
than in axonemal depolymerisation, thus preventing cilia formation outside G0-
phase136. This might represent a more general mechanism to allow regulatory 
inputs from the cytoskeleton to affect cell cycle and cilium outcome.  
Aurora kinase A is also involved in a second mechanism of cilium resorption in 
cells entering the cell cycle. Aurora kinase A forms a complex with Neural 
Precursor Cell Expressed, Developmentally Down-Regulated-9 (NEDD9) and 
Pitchfork (PIFO), leading to the phosphorylation of HDAC6137,138. Activation of 
HDAC6 destabilises the ciliary axoneme through deacetylation of its microtubules 
(Figure 5). Several studies have pointed out that HDAC6 is crucial for proper cilia 
resorption138–140. Interestingly, HDAC6 mutant mice do not develop any cilia-
related symptoms141.  
1.2.3 The primary cilium in stem cells 
Despite the link between ciliogenesis and G0 or quiescent phase, the role of 
primary cilia and somatic stem cells has been understudied despite its 
observation in a range of stem cells144-148. In mesenchymal stem cells, primary cilia 
are crucial in proper lineage differentiation. Knockdown of Kinesin-like protein-3a 
(KIF3a) in mouse embryonic fibroblasts, which have a similar differentiation 
potential to mesenchymal stem cells, disrupted the primary cilium structure and 
stimulated canonical WNT signalling, a crucial component in chondrogenic and 
osteogenic differentiation142,143. In epidermal cells that have disrupted cilia display 
no altered WNT signalling despite many other phenotypical changes in KIF3a 
mutant mice such as increased epidermal ridging, hyper-proliferation of the basal 
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progenitor cells and aberrant differentiation into keratinocytes144. Knockdown of 
IFT88, a gene involved in ciliogenesis and autophagy, displays reduced 
differentiation potential upon exposure to chemical-induced differentiation media 
for adipogenic, chondrogenic and osteogenic cell types.as shown by reduced 
expression of early differentiation markers, PPARg, SOX9 and RUNX2, 
respectively145. This result indicates that the primary cilium regulates the chemo-
sensitivity of cells.  
The link between primary cilia and lineage specification of stem cells has been 
confirmed in neural stem cells where it is thought that asymmetric cell division is 
guided by the distribution of the centrioles. The mother centriole maintains the 
stem cell character of the daughter cell whereas, the daughter centriole directs 
the daughter cell to differentiation126. 
1.2.4 The primary cilium as a signalling centre 
The primary cilium extends into the extracellular micro-environment and is, 
therefore, a prime candidate for the detection of signals produced within the 
tissue, suggested by the enrichment of various receptors in the ciliary membrane. 
In fact, there is evidence showing that the translocation of these receptors to the 
primary cilium is crucial for their proper function demonstrating that the primary 
cilium acts as a signalling centre146–148. In the last 15 years, many different 
pathways have been associated with the primary cilium including Notch149, Sonic 
Hedgehog (SHH)130, canonical and non-canonical Wingless-Type MMTV 
Integration Site (WNT)150, Platelet-derived growth factor (PDGF)147, and Hippo151. 
WNT 
WNT molecules bind to different membrane-bound receptors to activate 
canonical and non-canonical WNT signalling pathways, which are different in 
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their downstream steps. Canonical WNT signalling leads to the stabilisation of 
cytosolic β-catenin, which then translocates to the nucleus and induces WNT 
target gene expression. Whereas downstream events of non-canonical WNT 
signalling lead to changes in cell morphology (actin dynamics, cell polarity and 
cell shape,) independent of β-catenin rather than transcription.  
It has been reported that downregulation of cilia-related proteins in vitro or in 
zebrafish increases canonical WNT signalling and/or interrupts processes 
depending on non-canonical WNT signalling. Hence, the primary cilium was 
suggested to mediate the switch between canonical and non-canonical WNT 
signalling pathways157, 158. 
PDGF 
The PDGF signalling pathway is involved in cell proliferation, survival and 
migration152. When cells exit the cell cycle, the PDGFRα, but not PDGFRβ, 
receptor translocates to the primary cilium in fibroblasts. This translocation makes 
the receptor susceptible to binding of its ligand Pdgf-aa and will, in turn, activate 
a downstream cascade of proteins including AKT, Mitogen-activated protein 
kinase-1/3 (MAPK1/3), and Mitogen-activated protein kinase kinase-1/2 
(MAP2K1/2)153. Improper ciliogenesis causes inhibition of PDGF-aa signalling 
resulting in aberrant cell migration and chemotaxis of endothelial cells154. PDGFR 
is a receptor tyrosine kinase (RTK), and other RTK-signalling events have been 
shown to take place in primary cilia such as Epidermal growth factor receptor 
(EGFR), Insulin Like Growth Factor-1 Receptor (IGF1R) and Tyrosine Kinase, 
Endothelial (TEK) signalling155. 
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Notch 
Notch signalling is a process in multicellular organisms by which neighbouring 
cells communicate with each other.  All multicellular animals use Notch signalling, 
and the pathway is involved in cell fate specification, differentiation, proliferation, 
and survival and contributes to the formation, growth, and homeostasis of tissues. 
The connection between Notch signalling and primary cilia has only been made 
recently. In early embryogenesis, components of the Notch signalling pathway, 
such as Notch 3 and Presenilin 2, are located within the primary cilium of E9.5 
epidermal skin cells, and loss of primary cilia leads to impaired Notch signalling 
and negatively affects epidermal differentiation and skin barrier function149. 
Similar findings have been reported in corneal epithelial cells where loss of cilia 
negatively regulated Notch signalling leading to hyperproliferation and reduced 
differentiation156. Interestingly, disruption of the BBSome complex, which is 
responsible for the trafficking of proteins in and out of the primary cilium, leads to 
accumulation and, subsequent, increased activation of Notch in vitro and in 
zebrafish157. 
SHH 
The connection between hedgehog (Hh) signalling and the primary cilium is the 
most investigated of all major pathways and Hh signalling mostly depends on 
proper ciliogenesis130. This is highlighted in mouse knockout models of key cilia 
markers such as Intraflagellar Transport 88 (IFT88) and KIF3a and members of 
the Hh pathway showing similar phenotypes161. Of the three ligands in the family 
SHH is the best characterised. 
When SHH is absent in the extracellular micro-environment , the Hh-binding 
receptor Patched (PTCH) inhibits the translocation of Smoothened (SMO) to the 
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primary cilium130. This inhibition sustains a state of repression of members of the 
GLI family within the primary cilium. GLI forms a complex with SUFU and KIF7 
maintaining a state of repression through PKA, GSK3β and CK1.Upon binding of 
SHH to the Ptch receptor, SMO is able to translocate to the primary cilium in an 
ADP ribosylation factor-like GTPase 13b (ARL13b) -dependent manner162. SMO 
will then interact with GLI, which will trigger a downstream cascade leading to the 
transcription of effector genes.  
Currently, three members are known of the GLI family of transcription factors with 
GLI1, GLI2 and GLI3 all being involved in mediating the Hh signalling pathway. 
GLI1 and GLI2 are considered transcriptional activators whereas GLI3 is a 
transcriptional repressor163. So far, only GLI2 and GLI3 have been shown to be 
present within the primary cilium and their translocation to the nucleus to act as 
transcription factors is the defining moment in Hh signalling. Another family of 
proteins that are structurally similar to GLI and are involved in Hh-signalling is 
GLI-similar (GLIS). This family consists of three members: GLIS1-3, GLIS2, and 
GLIS3 have been shown to be present in the primary cilium. It has been proposed 
that GLIS members perform similar functions as GLI members in the primary 
cilium164. However, not much has been known yet about the particular 
mechanisms of and interaction partners with this family of proteins. 
Besides these core-signalling pathways described in this chapter, new advances 
in proteomics have added more candidates to the list of cilia-related-signalling. 
The ‘ciliome’ consists of about 800 proteins and from recent efforts, it is clear that 
the cilium both interacts with numerous traditional molecular pathways, regulating 
and tweaking cellular outcomes449. One such candidate is CD133, a membrane 
protein often linked with stem and progenitor cells. CD133 clusters within 
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protrusions of the plasma membrane, e.g.: microvilli and primary cilia172. Despite 
its discovery in the 1990’s not much has been elucidated about its functions, 
interactions with other proteins or its translocation to the primary cilium.  
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1.3 CD133  
1.3.1 Discovery and Structure  
CD133, also called Prominin-1 (Prom1), was identified in 1997 via immunisation 
of New Zealand Black mice with foetal liver CD34+ cells. This resulted in an 
immune response and subsequent antibody production against CD133 identified 
as the human orthologue of the murine Prominin-1165,166. Today there are several 
antibodies available targeting different epitopes of the receptor. 
CD133 is a pentaspan membrane glycoprotein (Figure 6) often associated with 
plasma membrane protrusions such as primary cilia, hence, the name prominin 
from the Latin word prominere meaning ‘to protrude’. It is the first member of a 
class of membrane receptors. The canonical sequence of CD133 cDNA encodes 
a transmembrane glycoprotein of 866 amino acids (AA) with a unique structure 
consisting of an extracellular N-terminus (105 AA), two extracellular domains (258, 
and 279 AA), five transmembrane domains (23 AA each), two intracellular 
domains of 29 and 21 AA, and a 59 AA intracellular N-terminal domain (Figure 6). 
This topology closely resembles that of mouse Prom1, an 858 AA protein 
identified by the mouse monoclonal antibody 13A4 167 and expressed in kidneys 
and microvilli of the mouse neuroepithelium. Human CD133 and mouse Prom1 
share roughly 60% homology. Based on the sequence, eight potential N-
glycosylation sites have been identified (Figure 6). Indeed, incubation of whole 
cell protein lysates with PNGase F leads to removal of N-linked oligasaccharides 
from glycoproteins. Subsequent westernblotting of the lysates resulted in a 
reduction in molecular weight of CD133 from ~120kDa to 97kDa168. 
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Figure 6: Membrane topology of CD133. 
CD133 is a plasma membrane glycoprotein containing five transmembrane regions and 
two glycosylated extracellular loops with a molecular weight of 97-120 kDa. CD133’s 
distribution in the plasma membrane is asymmetric as it favours cholesterol-rich lipid 
rafts. 
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1.3.2 Other members of the Prominin family 
In 2003, a second member of the Prominin family, Prominin-2, was discovered. 
This protein has despite its low AA similarity of ~30% the same membrane 
topology as CD133. Also, the genomic makeup of CD133 and prominin-2 is 
nearly identical indicating that Prominin-2 is a paralogue of CD133169. In vitro 
studies of Prominin-2 have shown that it is co-localised with CD133 in plasma 
membrane protrusions of transfected Chinese hamster ovary cells. However, in 
Madin Darby Canine Kidney (MDCK) cells, Prom2 was also present on the basal 
and lateral membrane domains whereas CD133 is restricted to the apical side. 
Together with the observation that its tissue distribution largely overlaps with that 
of CD133 suggests that’s Prominin-2 might have similar functions as CD133. This 
is confirmed by the observation that loss-of-function mutation of CD133 results in 
retinal degradation of the eye but no other pathological effects in other organs197. 
Indeed, Prominin-2 has not been detected in the eye indicating that Prominin-2 
expression might rescue the phenotypical outcome of loss-of-function mutations 
in CD133 in other tissues173. 
In 2011, a novel member of the Prominin family, Prominin-3, was discovered in 
Xenopus laevis and Danio rerio, but not in mammals170. 
1.3.3 Genomic organisation and transcriptional regulation of CD133 
The CD133 gene is a single copy gene and is located on chromosome 4p 15.32 
in humans and 5B3 in mice. It comprises at least 37 exons of which up to ten 
alternative exons are located before the start codon171. The locus spans more 
than 152 kilobasepair (kb) and is under the control of five alternative tissue-
specific promoters (P1 to P5) of which three contain CpG islands emphasising 
complex gene regulation171,172. Although, promoter activity of P4 has not been 
39 
 
demonstrated yet (Figure 7). The genomic makeup of both mammalian CD133 
and Prominin-2 is strikingly similar despite significant differences in AA sequence 
homology. However, the structure of exons does not correlate with the protein 
structural domains as the coding regions of CD133 and Prominin-2 cover 28 and 
23 exons, respectively173. 
The distal promoter P5 which is located outside the CpG island is under control 
of Hypoxia-inducible factors 1/2 alpha (HIF1/2a)174. Overexpression of both 
HIF1/2a in human embryonic kidney and colon cancer cell lines HEK293T and 
WiDr, respectively, leads to a five-fold increase of CD133 expression through the 
ETS transcription factor (ELK1), an effector of MAPK signalling. This result 
provides a mechanism explaining the increased expression of CD133 often seen 
in solid tumours as hypoxia is a hallmark of cancer175,176. Indeed, aberrant 
methylation of the CD133 promoter is frequently observed in several types of 
cancer such as glioblastoma and colorectal tumours whereas the promoter of 
CD133 is essentially unmethylated in healthy tissues 177,178. In vitro analysis of 
the CD133 promoter revealed conflicting results about its methylation status in 
glioblastoma cell lines177,179. Gopisetty showed that hypermethylation leads to 
diminished expression of CD133 in glioblastoma due to loss of Specificity protein 
1 (Sp1) and Myc transcription factor binding sites177. Whereas, Tabu et al. show 
that increased CD133 expression due to hypomethylation is prevalent in high-
grade glioblastoma179. In cancer cell lines, it has been revealed that there is a 
direct correlation between CD133 expression levels and promoter activity. Under 
stress conditions, the tumour suppressor protein p53 (p53) directly binds to 
promoter P1 to act as a negative regulator of CD133 expression in in vitro cultures. 
P1 activity has been demonstrated in most cancer cell lines. p53 serves as a  
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Figure 7: Promoter organisation of human CD133. 
A) Promoter distribution of exon 1 indicating the five currently known promoters of which 
P1-3 are present in a CpG island indicating the potential for epigenetic silencing. Exon 2 
contains the start codon. B) Tissue-specific use of promoters in listed tissues is indicated 
in green. The activity of promoter 4 hasn’t been demonstrated yet 171. 
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scaffold for Histone deacetylase 1 (HDAC1)-mediated Histone 3 deacetylation. 
Attenuation of CD133oncogenic transcription factors such as Nanog Homeobox 
(Nanog), Sex Determining Region Y-Box 2 (Sox2) and POU Class 5 Homeobox 
1 (Oct4)180. 
1.3.4 CD133 isoforms 
Since its initial discovery in 1997 by Yin and Miraglia, CD133 has been shown to 
be expressed in a wide variety of different tissues of both healthy and oncogenic 
nature. A total of 12 CD133 isoforms (s1–s12) have been identified in human and 
rodents169,181–185,186. The inclusion or exclusion of exons predominantly affects 
the N- terminal extracellular (EX) 1 and C-terminal intracellular (IC) 3 domains 
(Figure 8) In the N-terminal domain (EX1) the inclusion or exclusion of exon 3 (a 
9 AA sequence) distinguishes CD133 s1 and s2 isoforms and might possibly alter 
affinity for different ligands. Interestingly, both isoforms can be detected by the 
human stem cell-associated AC133 antibody166,188. However, the most significant 
variability across isoforms is seen in IC3 where a total of 10 splice variants can 
be generated from the inclusion or exclusion of the last four facultative 
exons189,190. Sequence analysis of IC3 revealed that each isoform (minus s6 and 
s12) contain potentially one of three classes of PSD95/Dlg/ZO-1 (PDZ) domain. 
These domains are involved in anchoring receptor proteins in the membrane to 
the cytoskeleton. For instance, mouse s1, s2, s7, s8 and s11 contain the 
sequence PSQR which has the characteristics of class 1 PDZ-binding domain. 
Other isoforms carry different classes of PDZ domains in their IC3 such as s3, s4 
and s5 containing a class 2 PDZ domain (HFTL) and s9 harbouring a class 3 PDZ 
domain (SVQC)191,192. 
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Figure 8: Facultative exons in CD133 isoforms. 
A) Topological domains in CD133 B) Facultative exons (red) within the CD133 coding 
sequence C) The presence (+) or absence (-) of facultative exons in the 12 isoforms 
discovered in human and mouse. CD133 isoforms in human and mouse are identified 
by their GenBank accession number 187. 
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1.3.5 Expression of CD133 in tissues 
Human CD133 messenger RNA (mRNA) transcripts are detected in many cell 
lines and in most tissues apart from mature peripheral blood leukocytes171. 
However, the human AC133 epitope, used initially to discover CD133, is 
restricted to stem- and progenitor cells that include endothelial progenitor cells193, 
hematopoietic stem cells165, foetal brain stem cells194, embryonic epithelium167,168,  
prostatic epithelial stem cells195,  myogenic cells196 and are found in certain 
cancers such as retinoblastoma166,197, teratocarcinoma166 and leukaemia198. This 
discrepancy is again confirmed in mice where the murine counterpart of AC133, 
13A4, detects approximately the same epitope in mouse CD133. Using this 
antibody, CD133 was detected in tubular epithelium of the kidney and in the 
ependymal epithelium in the brain167,199 whereas CD133 mRNA is more 
widespread as is evident from the analysis of β-galactosidase (LacZ) reporter 
gene expression under the control of CD133 promoter in mutant mice94,171. This 
difference in mRNA and protein detection of mammalian CD133 could be 
explained by tissue-specific glycosylation, as AC133 antibody recognizes only a 
specific form of glycosylated CD133165. In contrast, it is known that 13A4 
recognises both unglycosylated as well as glycosylated CD133167. Moreover, 
AC133 and 13A4 antibody may selectively bind to a unique alternatively spliced 
isoform of CD133. Together, these findings explain the earlier observations of 
CD133 expression restricted to stem and progenitor cells. 
Haematopoietic stem cells 
Perhaps one of the best-documented areas of CD133 expression has been in 
haematopoietic stem cells. Haematopoietic stem cells are the progenitors to all 
different cell types from the lymphoid lineages (NK-cells, B-cells, T-cells) to the 
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myeloid lineages (macrophages and monocytes, megakaryocytes/platelets, 
neutrophils, basophils, eosinophils, dendritic cells, erythrocytes)200. 
CD133 is known to mark a pluripotent population of haematopoietic stem cells 
derived from different sources such as human bone marrow, foetal liver and 
peripheral blood201. Yin et al. have shown that the receptor is downregulated to 
undetectable levels as the haematopoietic stem cell matures165.  
Approximately 0.52% of bone marrow and 0.16% of cord blood mononuclear cells 
express CD133202. CD133 is expressed on 83% of cord blood CD34+ cells and 
up to 70% in bone marrow CD34+ cells165. Analysis showed that CD133 is 
undetectable on committed precursors, such as red blood cells, granulocytes and 
pre-B-cells, and that populations of CD133+ cells consist mainly of long-term 
culture initiating cells, the most primitive human haematopoietic cells which can 
be assayed in vitro203. CD133+ cells appear to be precursors to CD34+ cells as 
Gallacher showed that CD133+ cells were the only subset of a CD34-CD38- 
lineage population from human umbilical blood that could generate CD34+ cells 
in vitro with a 400 fold increase of engraftment capability in NOD/SCID (Non-
obese diabetic/severe combined immunodeficiency) mice than that observed in 
the CD133- subset202.This was partially confirmed by Summers’ work which 
produced CD34+ cells from CD133+ CD34- cells in culture204. As the cells 
differentiate, they first begin to express markers such as CD38 and finally express 
differentiation markers such as CD13 and CD33.  
In vivo applications of CD133+ stem cells in tissue regeneration have already 
been shown to be beneficial. Umbilical cord blood or bone marrow-derived 
CD133+ cells have been applied to myocardial tissue regeneration after infarction. 
Two reports showed that CD133+ cells improved myocardium recovery through 
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an increase in angiogenesis and prevention of scar thinning and diastolic 
dilation205,206. 
Other stem cells 
Within human tissue, CD133 expression is widespread and not solely restricted 
to haematopoietic stem or progenitor cells. CD133+ cells isolated from foetal liver, 
umbilical cord blood, bone marrow and mobilized blood were capable of in vitro 
differentiation to neuronal cells and astrocytes, oligodendrocytes and glial cells207. 
CD133+ cells from peripheral blood markedly improved angiogenesis, 
astrogliosis, axon growth and functional recovery in a mouse spinal cord injury 
model compared to CD133- cells208. 
Similarly, CD133+ cells isolated from the human foetal brain or skin tissues were 
capable of forming neurospheres in vitro and to differentiate into neurons and 
glia194. Moreover, when human CD133+ neurosphere cells were transplanted into 
neonatal NOD-SCID  mice, they proliferated, migrated and differentiated into fully 
integrated neurons and glial cells209.  
Grafting of integrin α2β1hi/CD133+ prostate basal cells in immunodeficient mice 
are capable of forming fully differentiated acini structures with evidence of both 
secretory and squamous cells present whereas the CD133- population leads to 
the formation of fibromuscular stroma with a complete absence of functional 
glands195. 
CD133+ cells from the stroma of human cornea have the capacity to proliferate 
in vitro; colonies derived from CD133+ cells could be differentiated into 
fibroblastic cells, indicating that CD133+ cells represent stem cell of the corneal 
stroma210. 
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Initial reports of CD133 expression in the kidney showed that its presence is 
restricted to the interstitium and that they lack the haematopoietic stem cell 
markers CD34 and CD45 but do express Paired Box 2 (Pax2) indicating their 
renal origin211. Interestingly, these cells are capable of differentiating into 
endothelial and epithelial cells expressing markers of both distal and proximal 
epithelium211.  
Furthermore, stem cell therapy involving CD133+ cells derived from bone marrow 
have been used in clinical trials for patients recovering from cardiac arrest212, 
hepatic cirrhosis213 and chronic total occlusion and ischemia214. As of February 
2017, 17 clinical trials are ongoing using CD133+ cells in regenerative 
medicine215. It is clear from the highlighted cases that CD133+ cells possess 
tremendous benefits for tissue engineering but more research is required to 
understand the role of CD133 in these processes.  
CD133 in differentiated cells 
Despite the focus of most research on CD133 in stem and progenitor cells, there 
is considerable evidence of CD133 expression in terminally differentiated cells of 
glandular organs such as the salivary glands, pancreas, mammary glands and 
liver as well as in kidneys216–218. This comes as no surprise as CD133 mRNA 
transcripts, unlike the AC133 epitope, have been observed in Caco-2 cells that 
underwent enterocytic differentiation219. The lack of CD133 protein detection 
using the AC133 antibody is partly due to its dependence on the glycosylation 
status and could be circumvented with the rabbit antiserum αhE2 targeting amino 
acid residues Gly240-Ser388. Using this antiserum, CD133 has been detected in 
the parietal layer of Bowman’s capsule of nephrons present in the juxtamedullary 
region of the cortex similar to 13A4 epitope detection in the adult mouse 
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kidney167,216. Immunoreactivity of αhE2 but not AC133  has also been detected 
on the apical side of lactiferous ductal epithelia in the mammary glands 
corresponding to high CD133 mRNA transcripts216. 
Immervoll and Corbeil both demonstrated for the first time that the human AC133 
epitope, previously thought to be inversely correlated with differentiation, can also 
be detected in differentiated cells, namely at the differentiated apical/endoluminal 
face of ductal pancreatic epithelia with increasing expression towards the acini 
where CD133 staining was more cytoplasmic as opposed to the usual membrane 
detection. Although these cells express the pancreatic differentiation marker 
Carbonic anhydrase II it is believed that these cells positive for the AC133 epitope 
could be in fact dedifferentiated or transdifferentiated cells. However, given that 
approximately 30% of the ductal cells are positive for AC133, it is clear that this 
epitope is not a marker for stem and progenitor cells only. 
1.3.6 Subcellular Localisation of CD133 
Plasma Membrane 
Many examples exist where CD133 and other members of the Prominin family 
are mainly detected in plasma membrane protrusions. For example, mammalian 
CD133 is targeted to the apical membrane, and more specifically, CD133 is highly 
concentrated in microvilli and primary cilia of polarised epithelial cells such as 
kidney proximal and intestinal crypt cells167,168,220,221. Although there is no specific 
retention motif in CD133’s AA sequence, it is thought that this specific localisation 
is due to the direct binding of lipid raft-associated cholesterol to CD133222–224. 
Lipid rafts are characterised by their insolubility to non-ionic detergents such as 
Lubrol WX but remain soluble in Triton X-100222.  Lipid rafts are plasma 
membrane microdomains that are enriched in specific glycosphingolipids, 
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gangliosides, and sterols225. CD133 potentially binds to other lipids present in 
lipid rafts such as GM1 and GD3 gangliosides as is evident from their co-
localisation with CD133 in microvilli of epithelial cells226.  
Several but not all CD133 isoforms contain PDZ-binding domains in their C-
terminal intracellular domain hinting at possible interactions with the cytoskeleton 
through other PDZ-containing proteins that act as adaptor/linker proteins 
between integral membrane proteins and the actin cytoskeleton184,227. 
Interestingly, the specific localisation of CD133 in plasma membrane protrusions 
is not regulated by the C-terminal intracellular domain since it is not prevented by 
deletion of this part220. In addition, localisation of CD133 to the microvilli is not 
affected when its cytoskeletal architecture is disturbed, as seen in Caco2 cells 
displaying diminished and morphologically altered microvilli upon downregulation 
of the actin-bundling protein Villin222. 
Extracellular vesicles 
Proper communication between cells in tissues is critical for tissue formation and 
homeostasis. Exchange of extracellular vesicles between cells is one of many 
ways for them to communicate and can contain RNA, DNA and proteins228. 
Marzesco et al. showed for the first time in the developing mouse brain that 
CD133 immunoreactivity to 13A4 was not only detected at the luminal side of the 
neuro-epithelium but was also observed in the membrane of vesicles in the 
cerebrospinal fluid167,229,230. The same study also investigated various body fluids 
of the adult human and revealed the presence of CD133-containing vesicles of 
various sizes in seminal, saliva, urine and lacrimal fluids. Analysis of the 
properties of the vesicle membrane and the lack of specific extracellular vesicle 
markers such as CD63 for exosomes seem to suggest that these are a new type 
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of vesicle230. Indeed, these vesicles are now termed P2- and P4-type vesicles 
based on their size and are therefore pelleted at different at different centrifugal 
speeds. The largest vesicles, P2 which are released from the midbody, are 
between 0.5-1µm in diameter and appear electron-dense upon immunogold 
electron microscopy whereas the P4-type vesicles are between 50-80nm and 
electron translucent. Interestingly, the secretion of P2 and P4 vesicles is 
temporally linked with the cell’s differentiation status. For instance, P2 vesicle 
release has been shown to be greater in stem cell-derived cell lines compared to 
differentiating, cancer-derived and immortalised cells. P4 vesicles, on the other 
hand, are only secreted in differentiated cells as is seen in confluent Caco2 cells 
or in chemical-induced differentiated haematopoietic stem cells230–232. 
The precise role for both P2 and P4 CD133-positive vesicles is still unclear. 
However, with keeping the biochemical properties of CD133 in mind, two 
probable roles for these vesicles can be hypothesised. Firstly, the plasma 
membrane is known to play an essential part in signal transduction and is 
asymmetrical in composition. The release of vesicles in a spatiotemporal manner 
might change membrane organisation and therefore affect signal transduction. 
Secondly, the release of CD133-positive vesicles might confer intercellular 
communication. For instance, between embryonic day (E) 10,5-12 when microvilli 
are abundant in the floor plate, a signalling centre in the developing nervous 
system, the release of P4 vesicles is increased. Similarly, the abscission of the 
midbody as P2 vesicles is likely to confer information to recipient cells about the 
type of cell division the donor cell underwent, i.e. asymmetric vs symmetric cell 
division221. 
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Nucleus 
Interestingly, nuclear CD133 has also been identified in triple-negative breast 
cancer, rhabdomyosarcoma cell lines and non-small cell lung cancer cells 
(NSCLC) 233–235. Potentially, according to Cantile et al., to function as a regulator 
of transcription. A minor fraction of cell lines and cancer cells are positive for 
nuclear CD133. Depending on the rhabdomyosarcoma cell line it ranges from 3.4% 
to 7.5% of cells that have CD133 in the nucleus 233. In NSCLC, a cancer with high 
mortality rates, CD133 is expressed at high levels and present in ~55% of the 
tumours investigated. However, nuclear CD133 was only sporadically present in 
lung tumours 235. The exact mechanism as to its nuclear translocation and its 
function remains to be elucidated as well as its nuclear presence under normal 
physiological conditions. 
1.3.7 CD133 in Disease 
Photoreceptor Degeneration 
Despite the expression of CD133 in a wide range of tissues ranging from stem 
cells to differentiated cells of all germ layers, the most striking phenotype of loss-
of-function mutation is disk dysmorphogenesis and retinal dystrophy in the 
eye197,236. Photoreceptor cells are part of the retina, a light-sensitive layer of 
tissue able to transform light into nerve signals, which can be interpreted by the 
brain. 
CD133 is expressed in both photoreceptor cells, namely cones and rods. The 
latter is concerned with vision in dim light whereas cones are involved in vision in 
bright light as well as colour perception. In rods, CD133 is specifically expressed 
at the base where newly synthesised membrane evaginations or disks develop 
from the connecting cilium and move up the tract197,237. In cones, CD133 is 
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observed in the outer segment along the whole tract236. Interestingly, 
immunoreactivity of CD133 is different in rods versus cones. The epitope AC133 
which is often used as a human stem cell marker is mainly detected in the outer 
segment of cones whereas CD133 in rods was detected using αhE2, an 
antiserum216. This might indicate that different forms of CD133 are present in 
photoreceptors. 
To date, five mutations in the human PROM1 gene responsible for retinal 
dystrophy affecting both cones and rods have been discovered. Most mutations 
lead to the introduction of a premature stop codon, and all of them share many 
symptoms including but not limited to night blindness, gradual loss of peripheral 
vision and photoreceptor degeneration197,238–242. 
Studies in mice replicating loss-of-function of CD133 gave the first clues as to 
what the function of CD133 is. CD133 KO mice displayed an age-dependent loss 
of photoreceptors. Indeed, by the age of one year, the entire photoreceptor layer 
of mice lacking CD133 was missing resulting in full blindness236. Mice carrying 
the human R373C PROM1 gene have abnormally shaped disk membranes and 
excessively large outer segments by P16. At four months, photoreceptor disks 
were either misaligned and were of excessive size compared to wild-type mice 
or defects in outer segment membrane organisation241. Remarkably, eyecup 
cultures treated with cytochalasin-D, an inhibitor of actin polymerisation, display 
a similar phenotype. Other studies showed that non-functional CD133 leads to 
defects in new disk formation, i.e. disks protruding from the ciliary plasma 
membrane. The interaction between actin, CD133 and Protocadherin 21 
(PCDH21) as shown by co-immunoprecipitation might be crucial for the proper 
formation of new disks. Indeed, PCDH21 and CD133 are both present in newly-
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made disks and in R373C mice non-functional CD133 leads to mislocalisation of 
PCDH21 and its impaired proteolytic cleavage197,241,243. The role of actin with the 
CD133-PCDH21 complex is also not clear but might be important in the proper 
distribution of the complex in a temporospatial manner241. The localisation of 
CD133 in the outer segment of disk evaginations might prevent fusion of disks as 
is evident from the separation of disks in cones. 
Tumour-initiating cells 
The traditional model of carcinogenesis states that any dividing cell of the body 
can give rise to a tumour if enough mutations that permit unlimited proliferation 
potential occur in its genome. This dogma was overturned in the late 90’s by the 
discovery of cells within myeloid lymphoma244 that possess stem cell features 
and were capable of generating the typical heterogenic population seen in many 
tumours245. Later, these stem cell-like tumourigenic cells were also discovered in 
solid tumours. Expansion of mammary stem cells in mouse breast cancer models 
prior to cancer development represent a probable link between normal stem cells 
and tumour-initiating cells  also called cancer stem cell246. Mainly these cells have 
been identified through the expression of cell-specific surface markers. Among 
the most frequently shared markers by tumour-initiating cells of different 
germlines are CD20, CD24. CD34, CD44, CD90, CD117, CD133, Aldehyde 
dehydrogenase (ALDH), nestin, β1-integrin and Epithelial cell adhesion molecule 
(EpCAM)247.  
One of the most commonly used tumour-initiating cell markers across different 
tumour types is CD133. Singh et al. took CD133+ cells from human brain tumours 
and was able to show that they exhibit stem cell-like features, by proving they 
were capable of self-renewal and replication of an original tumour when grafted 
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into an immunodeficient brain of NOD/SCID mice with as little as 100 cells. 
Injection of 100 CD133- cells showed no tumorigenic response248. Confirming this 
result, Chiou et al., revealed that in atypical teratoid rhabdoid tumours, a 
malignant tumour of the central nervous system, the metastasis, malignancy and 
radioresistant capabilities of CD133+ were substantially increased when 
compared to CD133- cells249.  
Interestingly, Rappa et al. investigated CD133 as a possible therapeutic target 
for metastatic melanoma. Retroviral-mediated knockdown of CD133 in FEMX-1 
melanoma cells showed slower growth and reduced capacity to form spheres 
compared to control cells. This suggests that the cells have lost some of their 
oncogenic properties. Knockdown of CD133 severely reduced the capacity of the 
cells to metastasise indicating that CD133 may have a role in the capacity of 
tumour cells to migrate to other tissues250. Indeed, immunohistochemical analysis 
of human hepatocellular carcinoma samples (HCC) showed that the number of 
CD133+ CD44+ HCC cells is increased and linked with portal vein invasion251. 
This was partially confirmed by Horst et al. showing that high levels of CD133 
correlate strongly with synchronous liver metastasis, but knockdown of the 
receptor indicated no change in colony formation or proliferation252. Contrary to 
these findings, different groups have expressed their concerns regarding CD133 
as a tumour-initiating cell marker. Using IL10-/-CD133LacZ/+ mice, Shmelkov 
showed that both CD133+ and CD133- metastatic colon cancer cells were 
capable of long-term tumorigenesis in immunodeficient mice and that the latter 
formed larger tumours94. Interestingly, the same study showed that CD133 
expression in adult CD133LacZ/+ mice is not restricted to stem cells but is also 
present in luminal terminally differentiated cells such as but not restricted to the 
pancreas and kidney. Several studies have confirmed this work claiming that 
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expression of CD133 in colon cancer is not restricted to tumour-initiating cells 253. 
Likewise, in healthy cells of the gastrointestinal tract CD133 is uniformly 
expressed throughout the tissue94,254. Ogden et al. and Yoshikawa et al. revealed 
that CD133 could be a biliary and progenitor cell marker in vivo, concluding that 
CD133 alone is not sufficient to detect tumour-initiating cells in human 
hepatocellular carcinoma cell lines255,256. Therefore, the validity of CD133 being 
an oncogenic marker is still controversial.  
Another major therapeutic problem tumour-initiating cells present is their 
resistance to treatment such as radiation and various chemotherapy, which 
generally target homogeneous populations of rapidly proliferating, differentiating 
tumour cells. Alternative targets are being looked at. These include the drug 
Salinomycin, a potassium ionophore that can reduce the proportion of CD133+ 
subpopulations in human colorectal cancer cell lines HT29 and SW480. 
Furthermore, Salinomycin treatment decreases colony-forming ability and cell 
motility in HT29 cells and decreases vimentin expression and induces E-cadherin 
expression in HT29 cells257. 
It is, therefore, imperative to try to understand the mechanisms contributing to 
this resistance which can only be achieved by identifying the cancer stem cells, 
the signalling pathways and their regulatory mechanisms involved in tumour-
initiating cell maintenance. As discussed earlier, radiation and chemotherapy 
resistance, as well as limited cell numbers, has been a major therapeutic problem 
for combating CD133+ tumour-initiating cells. 
1.3.8 Interactions of CD133 and its functions 
Currently, nearly 5000 papers involving CD133 have been published. Despite this 
vast number of publications, not much has been known about its regulation, 
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molecular binding partners and function within mammalian cells.  
Mice carrying a deletion of exon 2 in CD133 develop blindness over time which 
is a consequence of a progressive degeneration of both cone and rod 
photoreceptors. Strikingly, lack of CD133 does not seem to affect retinal cell 
composition at P10, and it is, therefore, unlikely that CD133 is involved in 
retinogenesis236,258. Instead, CD133 seems to be required for normal 
morphogenesis of photoreceptors. More specifically, the outer segments and 
disks of cone and rod receptors. This seems to coincide with proper distribution 
of the visual pigment Opsin to the outer segment. CD133 preferentially localises 
at the basal part of the outer segment in rods where loss of CD133 leads to 
misalignment of disks and subsequent mislocalisation of Opsin. These 
phenotypes are shared with other models of retinal degradation259,260. These data 
suggest that CD133 acts as an essential regulator of outer segment 
morphogenesis and maintenance.  
An additional phenotype observed in CD133 KO mice is decreased branching 
morphogenesis of the mammary glands that is independent of the oestrus cycle 
but is overcome by pregnancy. In vitro studies on mammary epithelial cells shows 
that CD133 loss leads to hyper-proliferation. Whereas in the NKI295 breast 
cancer cell line CD133 levels were unaltered261. An established molecular 
mechanism of CD133 in the mammary gland is still undefined. During puberty, 
Prolactin and Progesterone are involved in side-branching via the Progesterone 
receptor (PGR). Furthermore, Matrix metalloprotease 3 (MMP3) directs the 
degradation of the basal membrane around the main ducts necessary for 
branching morphogenesis262. This is further confirmed by the similar phenotypes 
displayed by both PGR and MMP3 deficient mice. Moreover, both proteins are 
56 
 
downregulated in CD133 KO mammary glands. Despite all this, a direct 
interaction between these molecules and CD133 has not been found yet. 
Despite the variability between CD133 isoforms in their N-terminal intracellular 
domain (Figure 8) one conserved tyrosine residue (Y828) is present in all 
isoforms263. Y828, together with Y852 is potentially phosphorylated by Src family 
kinases in the human medulloblastoma cell lines Daoy and D283. 
Phosphorylation of Y838 is required for the docking of the p85 regulatory subunit 
of phosphoinositide 3-kinase (PI3K) to IC3 of CD133 leading to activation of the 
PI3K/Akt pathway. This interaction promotes self-renewal and tumour formation 
of glioma stem cells264. 
Two independent studies in cancer have found an interaction between CD133 
and canonical Wingless-Type MMTV Integration Site (Wnt) signalling. Rappa et 
al. have shown that in the melanoma FEMX cell line, short hairpin RNA (shRNA)-
mediated knockdown of CD133 leads to Dickkopf WNT Signaling Pathway 
Inhibitor 1 (DKK1)-mediated inhibition of Wnt signalling250. 
CD133 also interacts with β-catenin, the central molecule of the canonical Wnt-
signaling pathway, via Histone deacetylase 6 (HDAC6) to form a complex leading 
to a two-fold reaction. First, it has been shown that the interaction leads to 
diminished CD133 degradation through negative regulation of the endosomal 
trafficking compartment. Second, the complex formation stabilises β-catenin, 
independent of Glycogen Synthase Kinase 3 Beta (GSK3β), resulting in the 
activation of its signalling targets265. 
The presence of CD133 within membrane protrusions suggest that CD133 is 
potentially involved in the regulation of the plasma membrane as an "organiser" 
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of its topology. CD133+ exosomes, also termed prominosomes, present in the 
ventricular fluid of the developing mouse neural tube concur with the regression 
of microvilli and the formation of large pleiomorphic on embryonic 
neuroepithelium230. Moreover, CD133 interacts directly with cholesterol which is 
a lipid distributed unevenly in the plasma membrane. Cholesterol-rich domains 
within the plasma membrane are termed ‘lipid rafts’ suggesting that CD133 might 
be involved in lipid raft organisation183. This is further confirmed by the work of 
Roper that CD133 becomes associated with lipid rafts in the trans-Golgi network 
prior to sorting to the plasma membrane222. Despite the evidence of CD133 
association with lipid rafts, its role is not clearly defined yet. It is known that lipid 
composition and location affect cell signalling processes. CD133 might have a 
direct effect on these systems as a critical player regulating lipid raft formation, 
integrity and maintenance. 
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1.4 The mouse incisor as a model to study stem cell activation 
1.4.1 General mechanisms and Morphology of Tooth Development  
Teeth are typical organs for vertebrates, whereas in some species they have 
been lost during evolution. As with other ectodermal organs, initial stages in tooth 
development include thickening of the epithelium resulting in bud formation 
associated with the surrounding condensation of the mesenchyme. After this 
stage when morphogenesis begins each ectodermal organ develops differently. 
The more distinct tooth morphogenesis stages include folding and growth of the 
epithelium into the cap stage an intermediate step leading to the bell stage, which 
will finally create the shape of the tooth crown266.  
In many animals, teeth are replaced continuously throughout life. This is different 
in mammals where teeth develop only once, such as in rodents, or twice, as in 
humans, forming primary and secondary dentition. To understand the molecular 
mechanisms behind the formation of secondary dentition, researchers use the 
ferret as a model whereas in non-mammalian vertebrates such as fish their teeth 
are continuously renewed and replaced thus providing an excellent model to 
study tooth development267–269. In birds, evolutionary pressure led them to lose 
their teeth approximately 80 million years ago, but the genes regulating tooth 
development still exist in the jaw as their activation via transplanted mouse neural 
crest xenografts leads to tooth formation in  chicken270–273.  
The dentition of rodents only consists of molars and incisors that are separated 
by an area called the diastema, thus lacking both canines and premolars. 
Interestingly, premolars are being formed during early tooth development but 
never gets past the bud stage where it is removed apoptotically274,275.  
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Broadly, the tooth can be anatomically divided into a root and a crown. During 
development, the morphology of the crown is tightly regulated leading to, for 
instance, complex cusp patterning in the molars. Cusp number and location is 
dependent on the folding of the epithelium and the location of enamel knots, the 
epithelial signalling centres in the tooth276,277. The morphological differences 
between incisors and molars become evident during the late stages of 
development. The mouse enamel knot can be detected by histological means at 
around E14 as a bulging and thickening of the inner dental epithelium. This 
condensed area of epithelial cells expresses many secreted proteins along with 
cell cycle regulators and transcription factors such as SHH, Fibroblast growth 
factors (FGF), Bone Morphogenetic Proteins (BMP), WNT’s, p21 and Msh 
Homeobox 2  (MSX2)276–280. The enamel knot is activated at the late bud stage 
by signals from the condensed mesenchyme. At this stage, mesenchymal BMP4 
and Activin induces enamel knot marker genes, MSX2, Edar and p21 in the oral 
epithelium278,281,282. The enamel knot is finally removed as it undergoes apoptosis 
during the cap stage of tooth development283,284. Thus, crown morphology is 
decided in the bud and cap stage of tooth development. 
The tooth crown is covered with enamel and the underlying dentine. 
Mesenchymal cells contacting the inner dental epithelium begin to differentiate 
into dentine-forming odontoblasts, and the remaining dental papilla cells form the 
dental pulp. The inner dental epithelium differentiates into enamel-depositing 
ameloblasts. Odontoblast and ameloblast differentiation is regulated by 
reciprocal and sequential interactions between the mesenchyme and epithelium. 
In humans, the epithelial stem cell-containing cervical loops lose their stellate 
reticulum and the remaining epithelium, consisting only of inner and outer dental 
epithelia and the basal lamina, forms the Hertwig’s epithelial root sheath (HERS). 
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HERS facilitates root development and induces the formation of dentine and 
cementum, formed by cementoblasts differentiating from dental papilla. Later the 
HERS partially disappear and form epithelial cell rests of Malassez (ERM)285. 
Although, in some cases, HERS is not necessary for the formation of ERM, and 
regulation between the crown and root fate is flexible286.  
In addition to the root, other supporting tissues such as periodontal ligament, 
alveolar bone, gingiva and cementum are needed for the firm attachment of the 
tooth. The dental follicle gives rise to fibroblasts, which produces the extracellular 
matrix, eventually forming the periodental ligament. The periodental ligament 
connects the tooth root to the alveolar bone, but they also act as sensory 
organs285. In rodents, certain teeth grow continuously. For instance, mice have 
continuously growing asymmetrical conical incisors whereas the southern vole 
also has continuously growing molars286. The initial stages of the development 
and differentiation of the continuously growing incisor or molar are similar to that 
of the root-forming mouse molar but the expression of several signalling 
molecules, which are lost in the latter, are maintained in continuously growing 
teeth286.  Interestingly, in vitro cultured mouse molar cells still express the typical 
gene expression pattern of continuously growing teeth suggesting that the molar 
epithelium still can grow continuously287. 
1.4.2 Initiation of Tooth Development  
The reciprocal and sequential interactions between the mesenchyme and 
epithelium governing tooth development regulate proliferation, differentiation and 
apoptosis. The dental lamina or odontogenic band, a horseshoe-shaped 
thickening of the epithelium, forms from cells derived from the first branchial arch 
and is supported by the adjacent neural crest-derived mesenchymal 
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Figure 9: The developmental anatomy of early tooth morphogenesis in the rodent 
incisor and molar tooth types before eruption. 
Penetration of the epithelium (grey) into the adjacent mesenchyme (blue) is the first step 
to the development of the primary dental lamina, which holds the dental placode (green). 
The condensation of the mesenchyme and subsequent budding of the epithelium follow 
the invasion of the epithelium. These initial steps are remarkably similar in the 
development of all ectodermal structures. During the cap stage, the epithelial bud will 
ultimately invaginate the mesenchymal dental papilla, and the stem cell-containing 
epithelial cervical loop (purple) is formed adjacent to the bud. The development of 
different tooth types depends on the different development cues from this point. The 
cervical loop in the epithelium persists in continuously growing teeth, whereas in root-
forming teeth such as human teeth and molars in rodents, they completely disappear. 
Important stages in tooth development are regulated by signalling centres including the 
dental placode, and primary and secondary enamel knots. The enamel knots are 
characterised by the folding of the epithelium, which regulates crown morphogenesis. 
The secondary enamel knots determine cusp number and location. HERS, Hertwig's 
epithelial root sheath, ERM, epithelial cell rests of Malassez. 
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cells288–290.The tooth only develops within this structure, and even development 
of ectopic teeth is limited to the dental lamina237,291,292. Interestingly, in mice with 
loss-of-function of Adenomatous Polyposis Coli (APC), a member of a protein 
complex targeting β-catenin to degradation, teeth can develop in some cases 
outside the lamina293. In mice, the tooth placode begins to form within the dental 
lamina at E11. Instructions to initiate tooth development come from the epithelium 
whereas during later stages the odontogenic potential changes to the dental 
mesenchyme294.  
1.4.3 Cap and bell stage of tooth development 
Between E14 and E18 in embryonic mouse, the morphology of the first lower 
molar changes drastically and moves from the early cap to the bell stage. Five 
phenomena, controlled by epithelial-mesenchymal interactions, characterise this 
period: change in the cellular makeup of the mesenchyme, enlargement of the 
tooth germ; development of the cervical loop; maturation of the enamel organ and 
cusp formation due to the folding of the epithelial-mesenchymal junction295–300.  
During the cap stage at E14-E15, spatial variations in mitotic activity in dental 
epithelial cells and mesenchyme cause the enlargement of the tooth germ and 
changes in the shape of the epithelial-mesenchymal interface. This has been 
shown by the differential uptake of 3H-thymidine or 5-bromo-2’-deoxyuridine 
(BrdU) and changes in expression patterns of p21, an inhibitor of the cell 
cycle278,295,301. More specifically, this involves spatiotemporal control of apoptosis 
in the epithelium, changes in mitosis, alterations in cell adhesion and migration 
of both mesenchyme and epithelium. Moreover, other cell types are involved in 
the remodelling of basement membrane at the epithelial-mesenchymal junction 
and the invasion of exogenous cells in the dental pulp. At the epithelial- 
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mesenchymal interface, cell differentiation is induced first in the mesenchyme 
when pre-dentine is produced by the newly formed odontoblasts. This will induce 
differentiation in the inner dental epithelium into ameloblasts. 
1.4.4 Maturation of Tooth Epithelial Cells 
The subsequent and reciprocal interactions between cranial neural crest-derived 
mesenchyme and oral epithelium lead eventually to differentiation of both 
lineages and the production of teeth-specific mineralised tissues302,303.At the 
epithelial-mesenchymal junction, odontoblasts responsible for dentine matrix 
production are derived from the mesenchymal part whereas ameloblasts, which 
produce the enamel matrix, are epithelial in origin. The first event in dental 
mineralisation is the differentiation of dental pulp cells into odontoblasts which 
secrete a collagen-like matrix that forms the mantle dentine304. Formation of this 
mantle dentine initiates the differentiation of epithelial cells into ameloblasts 
leading to enamel matrix deposition and mineralisation305. When the developing 
tooth still resides in the gum, ameloblasts go through four distinct stages during 
differentiation: the pre-secretory, the secretory, transition and maturation stage306. 
In the pre-secretory stage, before mantle dentine deposition, the bell stage of 
tooth development determines the shape of the crown. The cells from the inner 
dental epithelium which goes on to become ameloblasts are characterised by 
their cuboidal or low columnar shape with poorly developed Golgi complexes and 
centralised nuclei307. When the adjacent odontoblasts form the mantle dentine 
the inner dental epithelial cells elongate, and their nuclei move away from the 
dentine-facing side and become pre-ameloblasts. These cells further elongate 
and become post-mitotic, secretory ameloblasts. In the secretory stage, the 
rough endoplasmic reticulum of ameloblasts produces and secrete the majority 
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Figure 10: Ameloblast differentiation and enamel deposition. 
The inner dental epithelial cells (1) contact the basal membrane. These cells transition 
into pre-ameloblasts upon contact with the mantle dentine matrix (2). Processes spread 
from the pre-secretory ameloblasts and penetrate the resorbing basement membrane to 
secrete enamel matrix proteins on the exterior of the mineralising dentine (3). After the 
establishment of the dentine-enamel junction and the initial layer of aprismatic enamel is 
deposited, the secretory ameloblasts grow Tomes’ processes from which enamel 
proteins are secreted into the surrounding mineralisation front (4). A single enamel rod 
is produced by each ameloblast that elongates from the receding Tomes’ process, and 
as the secretory stage ends, the ameloblasts have completely resorbed their Tomes’ 
process and have produced full thickness immature aprismatic enamel (5). In the final 
transition stage, the ameloblasts become less columnar and adjust their secretome (6). 
Proteases are secreted and digest the protein matrix. Finally, ameloblasts are fully 
matured and interchange between smooth-ended and ruffled phases, which leads to 
maturation and hardening of the enamel layer (7). 
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of the enamel matrix which will support hydroxyapatite crystal growth and define 
the thickness of the fully mineralised enamel305. At the cusps, enamel can reach 
a thickness of about 2,5mm whereas it is at its thinnest where it borders 
the cementum at the cemento-enamel junction307. The enzyme alkaline 
phosphatase then initiates the first wave of mineralisation. The ameloblasts 
retreat from the dentino-enamel junction leading to the protrusion of Tomes’ 
processes from the ameloblasts contacting the dentine. These processes are 
responsible for the hydroxylapatite crystal growth and are angled to allow for 
differences in crystallite orientation. Hence, increasing the strength of the forming 
enamel. 
Initially, the secreted enamel matrix is composed of proteins such as Amelogenin 
(AmelX), Ameloblastin (Ambn) and Enamelin, and inorganic materials such as 
calcium and phosphate ions. The proteins form an extensive extracellular 
network where the inorganic material is incorporated to form hydroxyapatite 
crystals308,309,310,311. Once secretion of the enamel matrix is completed, 
ameloblasts in the maturation stage stimulate the thickening of the hydroxyapatite 
crystals and enamel rod formation. Simultaneously, the removal of the 
extracellular enamel proteins by proteases such as Matrix metalloprotease 20 
(MMP20) in the secretory stage and Kallikrein-Related Peptidase 4 (KLK4) in the 
maturation stage is necessary to achieve the final hardness of fully developed 
enamel312.  
1.4.5 The dental epithelium in the continuously growing mouse incisor 
In mice, each jaw quadrant consists of one continuously growing incisor and three 
molars separated by the diastema. The morphological events between the incisor 
and the molar are similar in early development. During the cap stage, the incisor 
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tooth germ orientates itself along the anteroposterior axis while the epithelial 
cervical loop develop asymmetrically with the labial cervical loop becoming larger 
than the lingual cervical loop313,314. 
The formation of the cervical loop and its maintenance throughout the animal’s 
lifetime is critical for the renewal capacity of the incisor. The constant generation 
of dental hard tissues accompanies the continuous abrasion of the incisor tip. 
This requires both epithelial and mesenchymal tissues to form a gradient of 
differentiation from the cervical loop towards the incisor tip. The self-renewal and 
proliferation of epithelial stem cells take place in the cervical loop78,315. Currently, 
the exact origin of mesenchymal stem cells in the mouse incisor is still under 
debate316–318. The epithelial differentiating cells migrate towards the proximal 
incisor tip in a conveyor belt-like manner. They eventually differentiate into 
columnar, polarised ameloblasts, which produce and secrete enamel319. The 
incisor tooth is asymmetric in the generation of enamel, as the lingual side does 
not produce any enamel. Thus, only the labial cervical loop is capable of 
producing ameloblasts.  
The cervical loop consists of a core of stellate reticulum surrounded by the basal 
epithelium which makes up outer dental epithelium, at the most apical side of the 
cervical loop, and the inner dental epithelium, bordering the mesenchymal dental 
pulp320. The stellate reticulum in the lingual cervical loop is mostly depleted in the 
adult incisor tooth and is therefore not capable of giving rise to ameloblasts. 
However, they are thought to be a source of epithelial rests of Malassez, an 
epithelial remnant of the root sheath321. 
Label-retaining experiments using 3H-Thymidine in the 1970’s gave the first clue 
as to the location of epithelial stem cells in the incisors of rodents322. Whereas 
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others showed that BrdU-retaining cells are present in the stellate reticulum 
region of the mouse incisor labial cervical loop. Moreover, in vitro tissue-ablation 
experiments indicated that dissected cervical loop from P2 mice continues to 
produce dental tissues, showing that the cervical loop contains cells with 
significant growth and differentiation capabilities 315. Recently, Histone 2B-GFP 
(H2B-GFP) technology, a marker for slow-cycling cells, indicated that label-
retaining cells in the adult mouse labial cervical loop were located in the stellate 
reticulum and outer dental epithelium323.  
The molecular signature of the epithelial stem cells in the labial cervical loop 
contains typical stem cell markers such as Lgr5, Bmi1 and Gli182,323,324. The 
lingual cervical loop appears to harbour slow-cycling stem cells as is shown by 
label-retention experiments. However, their numbers are low and are currently 
not well investigated323.  
1.4.6 Molecular regulation of labial cervical loop stem cells 
Up until now, substantial progress has been made on how epithelial stem cells 
are maintained and regulated at the molecular level. It has become evident that 
the epithelial stem cells are controlled by complex and reciprocal interactions 
between the cervical loop epithelium and the surrounding mesenchyme, including 
several signalling pathways, transcription factors and cell adhesion molecules.  
Mesenchymal Fgf3 and Fgf10 were the first extracellular ligands discovered that 
demonstrated the reciprocal control of epithelial stem cells315. Subsequent 
experiments involving mutant mice of both genes have shown that these 
mesenchymal signals affect the self-renewal and lineage differentiation of the 
stem cells320,325. Indeed, Fgf3 and Fgf10 KO mice do not develop enamel320. In 
agreement with this observation down-regulation of epithelial Fgfr2b, the receptor 
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for Fgf3 and Fgf10 exhibits similar phenotypes such as the impaired growth of 
the whole incisor and failure of enamel formation326. Interestingly, an increase in 
Fgf signalling via down-regulation of Sprouty genes (Spry4 KO and Spry2+/-) led 
to ectopic enamel formation on the lingual side of the incisor, thereby, creating 
as described by the authors a ’tusk-like’ incisor tooth completely surrounded by 
enamel327. Loss of the mesenchymal Transforming Growth Factor Beta Receptor 
1 (Tgfβr), a member of the Tgfβ superfamily, severely reduces stem cell 
maintenance and lineage differentiation and appears to be upstream of Fgf3 and 
10 signalling328. 
Mesenchymal Tgfβ1 connects Fgf3 and 10 signalling with multiple conserved 
pathways in the control of dental epithelial stem cells. Tgfβ2r mediates Tgfβ1-
dependent Fgf3 and 10 signalling in the mesenchyme which, in turn, leads to a 
decrease in LDL Receptor Related Protein 5/6 (Lrp5/6) signalling in the 
epithelium. The resulting reduction of Wnt5a signalling favours retention of stem 
cells in the cervical loop over differentiation of its progeny329. Bmp4, another well-
known stem cell marker and under control of Tgfβ family members, reduces 
proliferation of the epithelial stem cells and their progeny while it promotes the 
differentiation of inner dental epithelial cells into ameloblasts. In line with this, 
overexpression of Noggin, an inhibitor of Bmp, in the dental epithelium leads to 
increased proliferation and lack of enamel due to the loss of ameloblasts 330. The 
importance of Bmp signalling in tooth development is also demonstrated in 
conditional Bmpr1a KO mice that lack all teeth. More specifically, the 
development of all teeth is arrested at the bud stage 331. Other examples of 
mouse genotypes that lack all teeth are Lymphoid Enhancer Binding Factor 1 
(Lef1), Paired Like Homeodomain 2 (Pitx2), Pax9, Msx1/2 and Gli2/3 332–336. 
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Figure 11: Overview of the adult mouse incisor and its regulation of stem cells in 
the labial cervical loop. 
A) Schematic overview of the mouse incisor displaying the mesenchyme (light grey) and 
its associated dentine (dark grey), and the epithelium (light orange) responsible for 
enamel (dark orange) production. B) Gene regulatory network of epithelial stem cell 
homeostasis, proliferation and differentiation. Red arrows indicate epithelial-
mesenchymal interactions whereas black arrows indicate epithelial factors. LaCL: Labial 
cervical loop, LiCL: Lingual cervical loop. 
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Previous examples illustrated how the mesenchyme affects epithelial stem cell 
maintenance and proliferation. There also exists a feedback loop in which 
epithelial progeny signal back to the cervical loop to promote lineage 
differentiation. Shh is a well-known mitogen involved in patterning events during 
development 337. Despite the role of Shh in development, its part in adult stem 
cells is less clear as is evidenced by conflicting reports in haematopoietic stem 
cells 338–340. Shh is known to be important in morphogenesis of teeth in the 
embryo 61,336,341.  Its expression in the progeny adjacent to the stem cell region in 
the labial cervical loop points at a role in lineage differentiation. Interestingly, not 
only cells in the labial cervical loop are Shh-responsive as shown by their 
expression of Gli1 and Ptch1 reporters but also cells in the mesenchyme and 
epithelial cells in the lingual cervical loop323. Inhibition of Shh led to a decrease in 
ameloblast differentiation but not the adjacent Stratum intermedium cells323. 
Bmi1, a polycomb group gene, is known to play a role in adult stem cell 
homeostasis in preventing arrested cell division via Ink4a/Arf and its expression 
is often linked with high expression of CD133 in cancer342–344. In the mouse 
incisor tooth, an additional layer of regulation exists to prevent premature 
differentiation of stem cells. Indeed, negative regulation of Homeobox (Hox) 
genes rescues the phenotype caused by loss of BMI182.  
Labial cervical loop stem cells also display Notch pathway activity, and a number 
of Notch receptors and its ligands are expressed in the cervical loop315. Notch 
signalling seems to be implicated in stem cell maintenance as its inhibition leads 
to smaller labial cervical loop315,345. Sox2 is expressed in a wide range of stem 
cells including embryonic stem cells and is one of the four reprogramming factors 
used in generating induced pluripotent stem cells17,346. During mouse incisor 
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development, Sox2 expression becomes progressively restricted during 
morphogenesis to the stem cell niche in the labial cervical loop347. Moreover, 
induced genetic fate mapping of Sox2+ cells in mouse incisor teeth have shown 
that these cells generate all cell types of the dental epithelium78. 
Collectively, these findings point out that the continuously growing incisor is a 
well-characterised organ that is suitable to investigate the role of CD133 in stem 
cells and their progeny. 
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2 Aims and objectives 
Preliminary results in our group have confirmed that CD133 is expressed in the 
developing mouse incisor epithelium. Taken together with the literature study, we 
hypothesized that CD133 is important for incisor tooth development by affecting 
stem cell activation and fate.  
2.1 Aims 
• To test the function of CD133 in incisor epithelial stem cell 
maintenance, activation and differentiation.  
• To examine the molecular binding partners of CD133 in mediating 
the transition of stem cells into transit-amplifying cells.  
2.2 Objectives 
Using mouse lower incisor teeth, I have performed experiments that cover the 
following steps: 
Year 1. CD133 expression in developing tooth, CD133 knockout mice tooth 
phenotype characterization and generation of Cervical Loop Epithelial cells.  
• Assessment of RNA and protein expression of CD133 in Postnatal day 7 
mouse lower incisors; 
• Scanning electron microscopy analysis of CD133 KO mice incisor tooth 
phenotype, including analysis of ameloblast differentiation marker 
expression;   
• Definition of stem cells and transit-amplifying cells in the dental epithelium 
cervical loop including the transition zone between the two regions; 
Year 2. In vitro and in vivo investigation of CD133’s role on stem cell activation in 
the developing mouse incisor tooth. 
• Generation and validation of cervical loop epithelial primary cells; 
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• Alteration of CD133 levels in in vitro cell culture and assessment of its 
effect on the cell cycle and stem cell activation; 
• Comparison of cervical loop population size between WT and CD133 KO 
mice; 
• Generation of Ki67/FUCCI fluorescent cell cycle indicator system in 
cervical loop epithelial cells; 
 
Year 3. Investigation of the role of CD133 in primary cilia dynamics 
• Assessment of primary cilia dimensions in WT and CD133 KO mice; 
• Analysis of primary cilia markers Hdac6 and Arl13b in the context of 
CD133 expression; 
• Examination of CD133 translocation to the nucleus; 
• Analysis of Shh effectors in the dental epithelium of the mouse incisor 
tooth; 
 
Year 4. Analysis of the role of CD133 in Shh signalling. 
• Establishment of CD133 interaction with Glis2 and Arl13b; 
• Determination of common pathways shared between Glis2 and CD133 
using PCR array; 
• Effect of Shh on cell fate with basal or reduced levels of CD133; 
• Assessment of primary cilia dynamics and CD133 expression in 
Bmi1GFP/GFP mice; 
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3 Impact of the work 
The importance of stem cells and their use in regenerative medicine cannot be 
understated. Damaged, dying or malfunctioning cells lead to injuries, diseases or 
aging. Replacement of these cells depends largely on the ability of stem cells to 
react to cues from the environment, facilitate a proper response leading to the 
generation of newly specialised cells, and simultaneously maintain the stem cell 
population to counteract future insults.  
How stem cells communicate with the tissue environment is currently being 
subjected to extensive research. One organelle that is important for mediating 
extracellular signalling is the primary cilium, an antenna-like structure that 
protrudes from the cell membrane. Primary cilia in stem cells have been well 
investigated in in vitro cultures, however, this presents one major limitation. 
Typically, in vitro culture of cells involves maximum two different cell types to be 
investigated and this is not representative of the stem cell environment as 
illustrated in Section 1.1.3. This severely limits the research on extracellular 
signalling between different cell types and the roles primary cilia play in them. 
Our work studies the relationship between primary cilia and stemness of cells 
within the developing dental epithelium. 
One protein that is predominantly found in primary cilia is CD133 and its discovery 
in stem cells happened right upon the advent of stem cell research 20 years ago. 
Initially, its expression was only seen in stem and progenitor cells in a wide range 
of tissues and was, therefore, a so-called stem cell marker. Indeed, since its 
discovery CD133 has been described in 5000 publications with nearly all of them 
of its use as a stem cell marker. Moreover, CD133 became clinically relevant 
when it was discovered that cancer stem cells harbouring CD133 have more 
tumourigenic capacity and are more resistant to treatment than their CD133-
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negative counterparts are. Despite intensive research, the function of CD133 in 
primary cilia remains largely unknown. Our work shows the importance of CD133 
in the dynamic regulation of primary cilia length and its relation to the stemness 
of the epithelial cells in the developing mouse incisor model. Moreover, we have 
proven that dysregulation of the primary cilia architecture leads to an altered stem 
cell response affecting homeostasis of the tissue investigated. Additionally, our 
results clearly indicate the potential of CD133 as a therapeutic target in cancer 
treatment. 
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4 Results 
4.1 The developing mouse incisor as a model to investigate epithelial 
stem and transit-amplifying cells 
The mouse incisor tooth continually grows throughout the animal’s life. This 
continuous growth indicates that there might be stem cells present within the 
incisors. Indeed, previous reports suggest that epithelial stem cells of the incisor 
are presumably remaining in the cervical loop (Figure 12a), a specific epithelial 
structure located at the distal end of the tooth epithelium315. These cells express 
stem cell markers such as Leucine Rich Repeat-Containing G Protein-Coupled 
Receptor 5 (Lgr5) and Sex Determining Region Y-Box 2 (Sox2) and can 
differentiate into distinctive epithelial lineages under the instruction of 
mesenchymal cells78,324. B Lymphoma Mo-MLV Insertion Region 1 Homolog 
(Bmi1) and Glioma-Associated Oncogene Homolog 1 (Gli1) have also been 
shown to mark cells within the cervical loop that coincide with label-retaining 
cells82. 
Immunostaining of the cervical loop in postnatal day (P) 7 C57BL/6 mice revealed 
a large region of stem cells indicated by Sox2 (Figure 12b) which overlaps greatly 
with the stem cell markers mentioned earlier such as Bmi1 and Gli182. Moreover, 
it has been shown that Sox2-positive cells give rise to all dental epithelial 
lineages78. Immediately adjacent to the stem cell region is the inner dental 
epithelium, a region that contains  transit-amplifying cells which is highly positive 
for Marker Of Proliferation Ki-67 (Ki67), a well-known proliferation marker348 
(Figure 12b). Interestingly, both regions are connected by an area positive for 
both Sox2 and Ki67 indicating a transition zone where stem cells become 
activated and enter the cell cycle (Figure 12b).  
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Figure 12: The mouse incisor tooth is an excellent model to study quiescent stem 
cell to transit-amplifying cell transition 
A) Schematical overview of the lower mouse incisor tooth with the epithelium in orange 
and the mesenchyme in light grey. B) Sagittal view of the CLE region of P7 C57BL/6 
mice. Yellow arrowheads mark the beginning and end of quiescent stem cell and transit-
amplifying cell zones. Dotted lines mark the epithelium. C) Real-Time qPCR analysis of 
established stem cell and cell cycle inhibitor markers. D) Real-Time qPCR analysis of 
known mitogenic markers. 
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Laser Capture Microdissection (LCM) was then performed to extract total RNA 
from the Sox2- and Ki67-positive regions. Subsequent Real-Time quantitative 
Polymerase Chain Reaction (qPCR) analysis was done of specific markers 
associated with quiescence and proliferation confirming their quiescent stem cell 
and proliferating transit-amplifying cell status, respectively (Figure 12c & d). Our 
assessment of the cervical loop and its regions revealed two distinct zones based 
on quiescence and cell cycle status, which enables us to investigate the possible 
role and mechanisms of the stem cell marker CD133 in governing these regions. 
4.2 Primary cilia dynamics are linked to the cell cycle in the cervical 
loop 
The primary cilium is a dynamic organelle that is involved in chemical sensation, 
control of cell growth and signal transduction130,349. Its synthesis and resorption 
have been inherently linked with the cell cycle as they both share the same 
machinery. Indeed, the centriole that functions as the base from which the 
primary cilium protrudes into the extracellular matrix functions as a centrosome 
during mitosis. Therefore, it is well established that cell cycle progression and 
ciliogenesis are mutually exclusive within the same cell350. Currently, the precise 
mechanism of ciliogenesis in function of the cell cycle is complicated to 
investigate in vivo due to the heterogeneity of most tissues and the relatively low 
numbers of stem cells. Figure 12 has demonstrated that the mouse incisor tooth 
is enriched with stem cells and is, therefore, an excellent model to investigate 
primary cilium dynamics in the context of the cell cycle.  
One of the most widely used markers to identify primary cilia is acetylated α-
Tubulin (AcTub). AcTub is a stable form of microtubules that is only seen in 
primary cilia, the mitotic spindle and the midbody following mitosis351. Within the 
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primary cilium, AcTub is required for ciliogenesis where it is an integral part of the 
axoneme, a structural support for primary cilia. Clone 6-11B-1, a monoclonal 
antibody raised against acetylated α-Tubulin is the most commonly used antibody 
to detect and quantify primary cilia352–354. Using this antibody, our assessment of 
primary cilia within the stem cells and transit-amplifying cells of the lower mouse 
incisor tooth epithelium revealed interesting, but not entirely surprising, 
characteristics. AcTub immunofluorescence (IF) on 20µm cryo-sections of the 
cervical loop, containing stem cell and transit-amplifying cell populations, from P7 
C57BL/6 mice confirmed that the stem cell population contains a higher density 
of positive staining compared to the transit-amplifying cell population (Figure 13a). 
Quantification of AcTub immunofluorescence using Imaris 9.0 software (Figure 
13b) states that around 60% of stem cells have a primary cilium whereas in the 
transit-amplifying cell region this is decreased by approximately 50% to 30% of 
total cells (Figure 13c-d). In parallel with a higher primary cilium density, primary 
cilia in the stem cell population are longer and have an increased volume 
alongside a higher diameter at the base of the primary cilium compared to the 
transit-amplifying cells (Figure 13e-g). This is in line with the literature where it is 
well established that cells residing in G0 or quiescent phase, such as in our stem 
cell population, generally tend to have longer primary cilia compared to more 
proliferative cells355.  
4.3 CD133 mRNA is present in the developing mouse incisor tooth 
epithelium 
CD133, also referred to as Prominin1, has been used previously to isolate and 
characterise stem and progenitor cells in many tissues of different germ layers 
including but not limited to the prostate, haematopoietic system and 
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Figure 13: Primary cilium characteristics in the cervical loop of P7 C57BL/6 mice.  
A) AcTub (red) immunofluorescence shows the distribution of primary cilia in stem cells 
(top) and transit-amplifying cells (bottom), E-cadherin (green) used as a plasma 
membrane marker. B) Top: Example image of a primary cilium using AcTub as a marker, 
Bottom: 3D reconstruction of top image using Imaris software. C) transverse view of 3D 
reconstructed stem cells (top) and transit amplifying cells (bottom) D) Primary cilia 
quantification using AcTub immunofluorescence versus number of nuclei using 4',6-
diamidino-2-phenylindole (DAPI) in stem cells compared to transit-amplifying cells E-F) 
Comparison of primary cilia dimensions in stem cell and transit-amplifying cell 
populations, n= number of primary cilia counted. ** p<0.01  
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kidney165,195,211. However, its usefulness as a stem cell marker has recently been 
challenged since its expression has also been detected in terminally 
differentiated cells94. CD133 mRNA in the cervical loop has been detected before 
by semi-quantitative PCR356. However, the presence of markers typically 
associated with mesenchymal tissues such as Sca1 suggests that their sample 
contained a fraction of the surrounding mesenchyme357. Therefore, the positive 
signal of CD133 mRNA could be derived from the surrounding mesenchyme 
rather than the epithelial cervical loop.  
To answer the question whether CD133 is expressed in the cervical loop of the 
mouse incisor epithelium, we used LCM to isolate different populations of the 
mouse incisor tooth epithelium of P7 C57BL/6 mice. LCM enables us to avoid 
difficulties arising from analysis of heterogeneous tissues. The ability to isolate 
pure, homogenous cell populations allows the analysis of precise cellular and 
molecular interactions within the tissue microenvironment. Tissue extraction 
using LCM has been used successfully in many downstream applications such 
as RNA transcript profiling, next-generation sequencing, deoxyribonucleic acid 
(DNA) copy number and  loss-of-heterozygosity analysis, mass spectrometry 
proteomics, and signal pathway analysis358,359. 
The LCM system is an inverted microscope with a built-in low power near-infrared 
(IR) laser and a high-power ultraviolet (UV) laser. Tissue sections are mounted 
on polyethylene naphthalate (PEN) membrane slides and are stained with methyl 
green for identification of tissue morphology and region-of-interest (ROI). The 
CapSure HS Cap coated with an ethylene–vinyl acetate film is then placed over 
the ROI. The IF laser provides enough energy to melt this thermoplastic film in a 
precise location, binding it to the targeted cells. The UV laser cuts the section at 
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a predetermined region, which separates the ROI from the surrounding tissue. 
The CapSure HS Cap and the collected samples are removed, and the remaining 
tissue is left behind on the PEN membrane slide. (For a video of this process, 
visit this site.) The ROI is then subjected to total RNA extraction protocol 
described in the Material and Methods section.  
LCM was used to dissect the stem cell and transit-amplifying cell regions as 
defined in Figure 12 as well as the enamel-producing ameloblasts of three P7 
mice (Figure 14a). Three to four consecutive 20µm cryo-sections per cervical 
loop were collected on PEN membrane slides and processed as described above 
within 20 minutes to minimise RNA degradation. RNA was pooled together and 
processed for complementary DNA (cDNA) conversion and analysis of CD133 
mRNA expression using Real-Time qPCR. Primers directed against CD133 
mRNA were carefully designed to include all known isoforms as well as to cross 
exons to eliminate amplification of contaminating DNA. Results showed that 
CD133 mRNA was detected with highest levels seen in stem cells and that 
transit-amplifying cells only had marginally lower levels of mRNA. Our Real-Time 
qPCR was not able to detect CD133 mRNA in the ameloblasts (Figure 14: CD133 
mRNA levels in the mouse incisor epithelium of P7 C57BL/6 mice. 
4.4 At least two different populations of CD133 exist within the mouse 
incisor tooth epithelium. 
To validate the expression of CD133 at the protein level, we looked at the 
expression of two different epitopes: 13A4, which targets the 2nd extracellular loop 
(ECL) of CD133 and ORB129549, which targets the intracellular C-terminal 
domain (ICD) The 13A4 antibody has been used originally to describe CD133 in 
microvilli of the developing mouse neuro-epithelium. Moreover, it has been 
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Figure 14: CD133 mRNA levels in the mouse incisor epithelium of P7 C57BL/6 mice 
A) Top row: methyl green-stained sagittal section of cervical loop (left) and ameloblasts 
(right) region prior to cutting with UV laser. The dotted line represents the boundary of 
tooth epithelium. Middle row: Cut ROI on CapSure HS cap. Black circles are IF-melted 
film. Bottom row: methyl green-stained sagittal section of cervical loop (left) and 
ameloblasts (right) region after cutting with UV laser. Dotted line represents the boundary 
of tooth epithelium. B) Real-Time qPCR analysis of CD133 mRNA expression in stem 
cells, transit-amplifying cells and ameloblast populations. ND= not detected 
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shown that the antibody targets glycosylated and non-glycosylated CD133167. 
Despite its original observation in stem and progenitor cells in a variety of tissues, 
this epitope was also detected in post-mitotic ependymal cells and differentiated 
ductal and luminal epithelial cells in adult organs94,199.  
The ICD-targeting antibody was commercially generated using the following 
immunogen: CKYYRRMDSEDVYDD, which corresponds to a fragment within the 
ICD that is present in all known isoforms with no reported post-translational 
modifications yet. Assessment of CD133 protein expression within the mouse 
incisor using both antibodies revealed similar expression patterns. The ICD 
epitope is more broadly expressed in the whole cervical loop with increased 
expression in the transit-amplifying cells whereas the expression of CD133’s ECL 
epitope is mostly restricted to transit-amplifying cells (Figure 15b&c). To date, 
most research on CD133 has been conducted in neural or epithelial tissues with 
few reports of CD133 expression in mesenchymal tissues and cells such as 
stromal stem cells in the bone marrow, mobilised peripheral blood and umbilical 
cord blood360,361. In our study, CD133 protein expression is also detected in the 
dental mesenchyme using the two antibodies (Figure 15b&c). Therefore, we were 
interested to see whether the mesenchymal cells in the mouse incisor are the 
source of CD133 protein expression in the dental mesenchyme. LCM was 
performed as described earlier in chapter 4.3 to extract four different populations 
of dental mesenchymal tissue from three p7 CD1 mice. Two extracts border the 
dental epithelium and are termed transit-amplifying cells and quiescent stem cells 
as they are directly adjacent to their epithelial counterparts. The dental pulp and 
pre-odontoblasts were also collected (Figure 16: CD133 mRNA expression in the 
dental mesenchyme.a). Of note, the dental pulp region also contains cells from the 
neurovascular bundle and is, therefore, not entirely mesenchymal in nature. RNA 
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extraction and cDNA generation were achieved as described in chapter 4.3 and 
the samples were then subjected to Real-Time qPCR to look at CD133 mRNA 
expression levels. Our results indicate that CD133 expression levels in the four 
mesenchymal extracts (black bars; Figure 16: CD133 mRNA expression in the dental 
mesenchyme.b) are much lower or non-existent compared to the inner dental 
epithelium (white bar; Figure 16: CD133 mRNA expression in the dental 
mesenchyme.b) and that the presence of CD133 protein in the mesenchyme is 
likely to be derived from the dental epithelium. Indeed, CD133 has been linked 
with exosomes, a type of vesicle and a means to transfer macromolecules 
between donor and recipient cells (see Chapter 1.3.6) where it is incorporated in 
the membrane and possibly is involved in exosome targetting to specific cells, 
cargo sorting and/or exosome stability. This phenomenom might explain the 
presence of CD133 protein in the dental mesenchyme despite the absence of its 
mRNA precursor. 
Despite the central dogma in molecular biology, that mRNA translates into protein 
mRNA levels do not always equal similar amounts of protein expression. Indeed, 
several studies have pointed out that there is a weak correlation between mRNA 
and protein levels across many species362,363.  First, there are many post-
transcriptional modifications involved in mRNA translation into protein that is not 
yet completely understood. Second, proteins vary considerably in their in vivo 
half-lives. Finally, there is also the issue of experimental variance and technical 
difficulties between mRNA and protein experiments that restrict our ability to get 
a clear view. 
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Figure 15: CD133 differential epitope expression in the mouse incisor. 
A) Topographical overview of CD133 and its epitope locations. B) Representative 
immunofluorescence of CD133 (13A4) protein expression in P7 C57BL/6 mouse incisor 
tooth. C) Representative immunofluorescence of CD133 (ORB549) protein expression 
in P7 C57BL/6 mouse incisor tooth. White dotted lines mark dental epithelium border. 
SC: stem cell region, TAC: transit-amplifying region, Am: Ameloblasts. 
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Figure 16: CD133 mRNA expression in the dental mesenchyme. 
A) Representative images of LCM-captured mesenchymal dental tissues. Top left: 
methyl green-stained sagittal section of the mouse incisor tooth prior to LCM extraction. 
The dotted line represents the boundary of tooth epithelium. Top right: representation of 
ROI sites in the dental mesenchyme. Middle row: Cut ROI on CapSure HS cap. Black 
circles are IR-melted film. B) Real-Time qPCR analysis of CD133 mRNA expression in 
different mesenchymal extracts (black bars). Epithelial CD133 mRNA expression in the 
inner dental epithelium is represented as reference as white bar. ***: p<0.001; ND = Not 
detected. 
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4.5 CD133 C-terminal antibody validation 
Despite the large overlap in CD133 protein detection, we sought to validate the 
ICD antibody both in vivo and in vitro to make sure that this recently produced 
antibody is specific. Firstly, CD133 ICD epitope expression patterns were 
analysed and compared to the ECL epitope in C57BL/6 wild type (WT) and 
CD133 Knockout (KO) mice.  
CD133 KO mice are viable and fertile but are affected with progressive retinal 
degradation due to delayed photoreceptor differentiation and survival leading 
eventually to blindness236. Knockout of CD133 was achieved by replacing exon 
2 containing the start codon with a neomycin phosphotransferase cassette. The 
knockout was validated at the DNA and protein level using Southern blot and 
Western blot, respectively236.  
Both the ICD and Ecl epitopes are absent in the transit-amplifying cell region in 
CD133 KO mouse incisor compared to their WT counterparts (Figure 17: In vivo 
and in vitro validation of CD133 ICD antibody.a). Slight positive staining is still present, 
but this can be attributed to background noise. Specificity was also confirmed 
using short hairpin RNA (shRNA)-mediated knockdown of CD133 using three 
different shRNA sequences in dental epithelial cells (Figure 17b). CD133 
knockdown at the RNA level was verified using Real-Time qPCR and compared 
to the protein levels using the CD133 ICD antibody (Figure 17b&c). The Western 
blot result (Figure 17c) mimics the RNA expression result in Figure 17b. This 
confirms the result seen in Figure 17, thereby, strengthening the evidence that 
this antibody is specific for CD133. 
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Figure 17: In vivo and in vitro validation of CD133 ICD antibody. 
A)  Representative image of CD133 positivity in the transit-amplifying cell region of 
C57Bl/6 WT (top panel) and CD133 KO (bottom panel) mouse incisor using CD133 ECL 
(left panel) and ICD (right panel) antibodies. B) Real-Time qPCR analysis showing 
downregulation of CD133 mRNA expression using shRNA. C) Western blot revealing 
CD133 ICD epitope expression in dental epithelial cells. **: p<0.01. 
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4.6 Mice lacking CD133 exhibit enamel development defects 
To investigate the biological consequences of losing CD133 in the dental 
epithelium, we examined mouse incisor teeth from 2-month old CD133 KO mice. 
Macroscopic analysis showed that the tooth enamel developed dark spots in 
CD133-deficient mice (yellow arrowheads in Figure 18a). Further microscopic 
analysis of the dark spots using scanning electronic microscopy (SEM) revealed 
that this could be explained by the detachment of the enamel layer (Figure 18b). 
At higher magnification, enamel rods (yellow arrowheads) appear to be reduced 
around the Tomes’ processes compared to their WT counterpart (Figure 18c). 
Enamel rods consist entirely of hydroxyapatite crystals and are the primary unit 
of the enamel. Its function is to provide rigidity and strength to the enamel, and 
any disorder affecting the enamel rods is called amelogenesis imperfecta364. 
Symptoms can vary from relatively mild such as hypersensitivity to temperature 
and discolouration up to very severe such as prone to breaking. Each enamel rod 
is synthesized from one ameloblast that secretes specific proteins within the 
enamel matrix310. The enamel proteins aid in the mineralization of the enamel 
matrix prior to being removed resulting in an inorganic enamel rod exclusively 
consisting of hydroxyapatite. Therefore, amelogenesis imperfecta is a 
manifestation of defects within the ameloblasts and, potentially, its precursors. 
Interestingly, the phenotypes are similar to other tooth epithelium phenotypes of 
small molecule-inhibition of Sonic hedgehog (Shh) and Wingless-Type MMTV 
Integration Site (Wnt) mutant mice323,365.  
Further analysis of the ameloblasts in CD133-deficient mice reveals multiple 
phenotypes that could potentially explain the amelogenesis imperfecta-like 
appearance of the enamel. Micro-computed tomography (µCT) is a high-
resolution imaging technique capable of analysing hard tissues and an ideal tool  
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Figure 18: Macro and microscopic characterisation of CD133 KO phenotype in the 
enamel. 
A) Representative stereoscopic image of the lower incisor of 2-month-old WT and CD133 
KO mice. Yellow arrowheads indicate enamel defects in the CD133 KO mice. B) High-
magnification scanning electron microscopy analysis of the enamel layer. Samples 
indicated in A. Yellow arrowheads indicate enamel rods. C) Representative microCT 
analysis of enamel (yellow arrows) development of 4 months old female mice with 
indicated genotypes. Blue box represents start and endpoint of enamel tissue in WT 
mouse. 
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to analyse macroscopic properties of the enamel. Enamel is the hardest 
substance in the body, and it is, therefore, easy to differentiate from the 
surrounding bone structures.  As a result of these properties, we sought to 
analyse enamel properties such as thickness and starting point of enamel 
secretion. Results show that CD133 KO mice develop shorter and thinner enamel 
tissues compared to WT mice (enamel length of WT incisor indicated by the blue 
box in Figure 18c). 
Morphological evaluation of CD133 KO ameloblasts showed that there was no 
difference in the elongation of the ameloblasts but that their nuclei were not 
polarised adequately compared to WT mice. In addition, CD133 KO ameloblasts 
displayed increased vacuolation implying that exocytosis of the enamel matrix 
might be hampered (indicated by black arrows in Figure 19a). Indeed, CD133 has 
been shown to not only be associated with membrane protrusions but also with 
multivesicular bodies destined for exocytosis where it is present in the membrane 
of exosomes366. Therefore, ameloblasts that lack CD133 might lose the ability to 
secrete membrane vesicles into the extracellular matrix, in turn, possibly leading 
to hampered enamel rod maturation.  
The ameloblast markers Ambn and AmelX are critical components in enamel 
matrix formation and mineralisation367,368. Ambn and Amelx KO mice display 
similar phenotypes as seen in our CD133 KO mice such as ameloblast 
detachment in the case of Ambn-null mice369 and cystic degeneration, as 
mentioned earlier, in Amelx-deficient mice370. Therefore, we sought to investigate 
the expression of these markers in our model. Immunostaining of ameloblasts 
revealed that protein levels of Ambn and Amelx are greatly diminished in CD133-
deficient ameloblasts (Figure 19b). 
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Figure 19: Phenotypical characterisation of CD133 KO ameloblasts. 
A) Representative H&E staining of ameloblasts in WT (left) and CD133 KO (right) mice. 
Black arrows indicate the presence of vacuoles. B) Immunostaining of the ameloblast 
markers Ambn and Amelx in WT (left) and CD133 KO (right) mice. 
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Taken together, our results show that the absence of CD133 affects the mouse 
incisor on multiple levels. First, the process of enamel matrix deposition is 
reduced (Figure 18b) leading to the detachment and, eventually, thinner enamel 
(Figure 18a&c). Underlying those issues are the ameloblasts that suffer from 
multiple defects including nuclear polarisation defects (Figure 19a), vacuole 
accumulation (Figure 19a), and deficiencies in the expression of essential enamel 
proteins (Figure 19b). We then wondered if ameloblast precursors, present in the 
stem cells and transit-amplifying cells of the dental epithelium, were also affected 
in CD133 KO mice. 
4.7 Volume of stem cell and transit-amplifying cells region is affected 
in CD133 KO tooth epithelium. 
The dental epithelium of P7 C57BL/6 mice and their CD133 KO counterparts 
were cryosectioned coronally. All sections containing dental epithelium were kept 
and processed for immunostaining of Sox2 and Ki67, as in Figure 12b, to mark 
the stem cell and transit-amplifying cell region, respectively. The outline of the 
Sox2-positive region of every section was marked using Photoshop CC followed 
by digital reconstruction of the stem cell region in the cervical loop using the 
BioVis 3D 3.1 software (Figure 20a). The volume of each stem cell region (n>=3 
mice) was then quantified using the software’s measurement tool. Our result 
clearly demonstrates a significant decrease in volume in the absence of CD133 
compared to their littermate controls (Figure 20c). No significant change in cell 
size was detected (Figure 20f).  
Interestingly, when we looked at the Ki67-positive fraction within the stem cell 
region, in other words, the stem cells that have entered the cell cycle and are, 
therefore, activated, we can see approximately 40% decrease in activated stem  
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Figure 20: Phenotypical characterisation of the SC and TAC region in CD133 KO 
dental epithelium. 
A) Representative 3D reconstruction of Sox2-positive region in the CL of WT (top) and 
CD133 KO (bottom) mice. Scale bar = 20µm. B) Frontal section of SC and TAC using 
Sox2 (green) and Ki67 (red) to distinguish between quiescence and proliferation in WT 
(top) and CD133 KO (bottom), respectively. Dotted line marks the basement membrane. 
Scale bar = 20µm. C) Quantification of the volume of the Sox2-positive region using 
BioVis 3D measurement tool of WT (top) and CD133 KO (bottom) mice. D) Manual 
quantification of Ki67-positive fraction within the Sox2-positive region. F) Average cell 
density in the SC region in WT and CD133 KO mice. Three animals were analysed per 
condition by quantifying DAPI-positive nuclei number. Ant: anterior; Post: posterior; ns: 
not significant, n>=3; mice, **: p<0.01. 
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cells (Figure 20b&d). Ki67-positive cells were counted manually and compared 
to the total number of nuclei present within the stem cell region using Fiji 
software. This decrease in both volume, as well as a reduced fraction of Ki67-
positive cells, hints at a defect in the self-renewal as well as activation capacity 
of stem cells in the cervical loop. In the absence of CD133, the dental 
epithelium is significantly affected in all stages of its lineage. The stem cells, the 
adjacent transit-amplifying cells and partially overlapping transition zone are 
smaller, and these defects  possibly culminate into the phenotypes observed in 
the mutant ameloblasts. 
4.8 CD133 KO primary cilia are more abundant and display altered 
dynamics compared to their WT counterparts 
Stem cells rely on their entry into the cell cycle to become activated and contribute 
to lineage differentiation in tissues. Our observations (Figure 20b&d) have 
revealed that CD133 KO stem cells display a lower frequency of self-renewal as 
well as activation. This led us to believe that primary cilia in CD133 KO mice might 
be affected due to the shared machinery involved in primary cilia and cell division. 
Indeed, the centrioles which form the basal body from which the primary cilium 
protrudes into the extracellular matrix also take part in mitotic spindle formation 
and subsequent chromosome separation123. Consequently, mature primary cilia 
and cell cycle progression are, therefore, mutually exclusive. 
As a result of these observations, we sought to investigate the effect of loss of 
CD133 on primary cilia in stem cells and transit-amplifying cells. Cryosectioning 
of the cervical loop was performed, and primary cilia were visualised using AcTub 
followed by digital reconstruction with Imaris as mentioned earlier in Chapter 4.2. 
Primary cilia length was measured in stem cell and transit-amplifying cell regions 
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of P7 WT and CD133 KO cervical loops (Figure 21). Interestingly, primary cilia in 
the CD133 KO stem cells were significantly shorter than their WT counterparts, 
whereas, primary cilia in the transit-amplifying cell region were longer. In fact, 
primary cilia in CD133-deficient transit-amplifying cells were longer than primary 
cilia present in WT stem cells (Figure 21c). WT stem cells showed the most 
significant variation in primary cilia length pointing at either a more heterogeneous 
population of stem cells in terms of their cell cycle state and/or a population of 
cells that is relatively homogeneous in their cell cycle state but have different 
needs from the extracellular matrix. Indeed, cilia length has been shown to be 
involved in different cellular responses with regards to mechanical forces in a 
variety of in vitro cell cultures354. This was partially explained by an increased 
anterograde intraflagellar transport but unchanged retrograde transport leading 
to a net influx of ciliary components into the primary cilium. It is not too farfetched 
to believe that a change in primary cilium components has an effect on the 
primary cilium response to cues from the extracellular matrix and, therefore, the 
cell fate decision of any given cell in a population.  
To investigate the mechanism how CD133 regulates primary cilia length and 
function, we extracted the cervical loop and adjacent inner dental epithelium of 
P7 WT and P7 CD133 KO mice. 
4.9 Establishment of mouse dental epithelial primary cells 
The isolation of cervical loop epithelial cells (CLE) from the labial cervical loop of 
P7 mice starts with the removal of the mandible from the animal. The mandibular 
bone is then removed to uncover the dental epithelium including the labial cervical 
loop (Figure 22a). The explant was then treated with Type1 Collagenase to 
dissociate the tissue before propagating them in culture. To favour the growth of  
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Figure 21: Primary cilia characteristics in WT versus CD133 KO dental epithelium. 
A) Top: Representative confocal image of AcTub in the cervical loop of the dental 
epithelium in WT (left) and CD133 KO (right) mice. Bottom: Corresponding 3D 
representation of primary cilia using Imaris for quantification. B) Top: Representative 
confocal image of AcTub in the transit-amplifying region of the dental epithelium in WT 
(left) and CD133 KO (right) mice. Bottom: Corresponding 3D representation of primary 
cilia using Imaris for quantification. C) Quantification of primary cilia dimensions (left) 
and number (right) in indicated tissues., n>=3 mice, **: p<0.01, *: p<0.05. 
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epithelial rather than mesenchymal cells, we subjected the cells to DMEM/F12 
supplemented with B27 supplement, 20ng/ml of EGF and 25ng/ml of FGF2 as 
described earlier371.   
After the first passage, morphological examination of the cells revealed the typical 
cobblestone-like colony formation often seen in many epithelial tissues (Figure 
22b). To ensure that the cultures were purely epithelial in origin without 
contamination from the mesenchyme, gene expression profiling was performed 
after passage 1, the mesenchymal markers are not detectable in the epithelial 
cell culture.  
Furthermore, we checked if our CLE cells were capable of differentiating along 
the dental lineage by looking at the expression of ameloblast markers Ambn and 
Amelx. Induction of differentiation was achieved using normal culture medium 
supplemented with 0.2mM CaCl2 for 12 days (Figure 22g). CaCl2 has been shown 
to restore in part ameloblast differentiation and function in fluoride-treated organ 
cultures372. Moreover, addition of CaCl2 to in vitro culture of primary human 
ameloblast lineage cells leads to an increase of ameloblast differentiation 
markers such as Amelx and were capable of producing Von Kossa-positive 
nodules, an indication of enamel matrix production373. Our results indicate that 
the addition of CaCl2 alone is enough to differentiate CLE cells along the dental 
epithelial lineage as is shown by increased expression of Ambn and Amelx 
(Figure 22g). Of note: consistent with previous observations, the expression of 
Amelx mRNA but absence of Ambn mRNA under normal cell culture conditions 
indicates the presence of pre-secretory ameloblasts but absence of fully 
differentiated, secretory ameloblasts374. 
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Figure 22: Isolation and cell culture of CLE primary cells. 
A) Stereoscopic image of isolated dental epithelium with cervical loop at the top in a 
dashed circle. B) Morphology of p1 CLE colony. C&D) Immunofluorescence staining of 
Krt14 and Pdgfrβ as a marker for epithelial and mesenchymal tissue, respectively. E&F) 
qPCR analysis of Cdh1, Krt14, and Pdgfrβ and Vimentin expression in CLE cells (white 
bars) and mesenchymal cells (black bars). G) qPCR analysis of the ameloblast markers 
Ambn and Amelx on CLE cells. ***: p<0.005; ND = Not detected. 
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4.10 CD133 KO cells fail to survive in vitro 
To investigate if the initial observation of smaller cervical loop in CD133 KO mice 
was due to a failure in stem cell renewal, we performed a clonogenic assay with 
both WT and CD133 KO CLE cells. This assay allows us to quantify the survival 
and proliferation rates of single cells to form colonies under specific conditions375.  
In our case, 4000 single cells were seeded in triplicates on a 12-well plate and 
maintained in normal conditions in the absence or presence of 100ng/ml Shh. 
Colonies were visualised with crystal violet. Stereoscopic images of each well 
were taken, and the number and size of colonies were quantified using ImageJ 
software. Interestingly, comparison of the different conditions showed that CD133 
KO cells fail to survive and proliferate in standard culture conditions compared to 
WT CLE cells (Figure 23a-c). Shh has been shown to play a role in cell survival 
as well as cell proliferation in the developing dental epithelium341. However, the 
addition of Shh failed to increase survival and proliferation in CD133 KO cells 
(Figure 23a-c), thereby, strengthening our observation that Shh signalling is 
positively regulated by CD133. 
Due to the sharp decline in survival rates in CD133 KO as is evidenced by their 
failure to reach passage two in vitro, their use in dissecting the molecular 
mechanisms in which CD133 governs Shh signalling is severely limited. 
Therefore, we sought to use endoribonuclease-prepared short interference RNA 
(esiRNA) instead to induce a milder phenotype that does not entirely inhibit cell 
survival and proliferation. esiRNA is generated from a gene-specific cDNA 
template that is derived from the target mRNA. Subsequent reverse transcription  
into double-stranded RNA is followed by digestion with Escherichia coli RNase III 
to generate a mixture of siRNA that is specific to the target gene376.  
103 
 
 
Figure 23: CD133 KO CLE cells fail to survive and proliferate in vitro. 
A) Clonogenic assay of WT and CD133 KO cells (in triplicate) under normal culture 
conditions in the presence or absence of 100ng/ml Shh. B) Total number of colonies 
(>50 cells) in each condition. C) The average size of each colony in each condition. 
**p<0.01; *p<0.05. 
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Using this technique, WT CLE cells were transfected with 20nM esiCD133 or with 
esiRNA targeting Renilla reniformis Luciferase as a negative control. 24 hours 
later, transfected cells were either incubated in the absence or presence of Shh. 
Assessment of CD133 mRNA levels revealed that esiRNA-mediated 
downregulation leads to a 70% reduction of CD133 mRNA expression (Figure 
25a). Low levels of CD133 is sufficient for CLE cells to survive and proliferate at 
the same level as the control cells (Figure 25b-d). Intriguingly, upon addition of 
Shh for 24h, cells expressing low levels of CD133 form fewer colonies that are 
also smaller compared to no Shh treatment. Our observations reveal that CD133 
directs the outcome of Shh signalling in CLE cells. Basal levels of CD133 favour 
Shh-mediated proliferation and survival in vitro which is completely abolished in 
CD133 KO CLE cells. Whereas, CLE cells with low levels of CD133 leads to no 
changes in survival in the absence of Shh. However, upon addition of Shh, CLE 
cells show lower survival rates. In conclusion, CD133 acts as a molecular switch 
in the outcome of Shh-mediated survival and proliferation pathways. 
4.11 Reduced levels of CD133 favour Shh-mediated apoptosis  
The CD133-mediated changes in growth and apparent survival of CLE might also 
be due to increased rates of cell death. Therefore, we sought to investigate 
whether CD133 might regulate apoptosis in the dental epithelium. Apoptosis or 
programmed cell death is crucial in development and maintaining homeostasis in 
adult tissues and is a tightly regulated process that can be initiated via intra- and 
extracellular cues. Regardless of the source of the initiation signal, apoptosis 
culminates in the activation of executioner caspases, which mediate degradation 
of cellular components. Caspase 3 is such an executioner caspase and its 
cleavage will lead to its activation and is the last step before the initiation of   
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Figure 24: Downregulation of CD133 affects the outcome of Shh in CLE cells. 
A) Representative confocal image showing cleaved caspase 3-positive cells (red) in CLE 
cells under different conditions. B) Percentage of cleaved Caspase 3-positive cells vs 
total cell population in respective conditions shown in A. **: p<0.01. 
 
106 
 
cellular degradation377. Therefore, cleaved caspase 3 is an often used and well-
established marker of apoptosis. 
When CLE cells are cultured in the absence of Shh, CD133 does not have any 
effect on the activation of cleaved Caspase 3 (Figure 24a&b). However, addition 
of Shh reduces apoptosis in normal WT CLE., whereas, the population of cells 
that is undergoing cell death is doubled when CD133 levels are low (Figure 
24a&b). This leads us to believe that CD133 directs Shh-mediated cell fate 
decisions in the dental epithelium. 
4.12 CD133 is involved in cell cycle progression 
Our results so far have shown that different levels of CD133 affect proliferation 
and survival rates in CLE cells and, therefore, might play a role in cell cycle 
progression. Currently, there exist many systems to follow single cells’ progress 
through the cell cycle. G1, S and G2 phases are part of the interphase, and 
typically cells spend the majority of their time in one of these phases to prepare 
for mitosis or cell division (Figure 26: Ki67p-FUCCI cell cycle indicatorb)378. Cells 
can go through an additional fifth phase called the quiescent or G0 phase where 
cells reside that exist in a non-cycling state and are withdrawn from the cell cycle 
in a reversible manner. 
The fluorescence-acquired ubiquitination cell cycle indicator (FUCCI) has been 
developed initially to picture the precise transition of G1 to S phase379. This 
system uses the cell cycle-dependent ubiquitination pathway to generate an 
oscillating reporter system. It either favours the degradation of a truncated, 
inactive version of Geminin conjugated to green fluorescent protein (GFP) in the 
G1 phase or, in the S, G2 and M phase, the degradation of Chromatin Licensing 
And DNA Replication Factor 1 (Cdt1) coupled with red fluorescent protein (RFP).  
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Figure 25: Knockdown of CD133 leads to reduced proliferation and survival in vitro. 
A) Validation of CD133 knockdown experiment. B) Clonogenic assay of WT CLE and 
CLE with reduced expression of CD133 (in triplicate) under standard culture conditions 
in the presence or absence of 100ng/ml Shh. C) Total number of colonies (>50 cells) in 
each condition. D) The average size of each colony in each condition. **p<0.01. 
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Figure 26: Ki67p-FUCCI cell cycle indicator. 
A) Design strategy of the Ki67p-FUCCI cell cycle indicator system. B) Scheme 
demonstrating the various colours associated with cell cycle phase. C) Representative 
images of CLE harbouring the Ki67p-FUCCI system showing cells at different cell cycle 
phases. 
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The alternating degradation of these fluorophore complexes is regulated by the 
temporal activity of specific E3 ligases in a cell cycle-dependent manner leading 
to a robust system that allows the expression of RFP in the G1 and beginning of 
the S phase, and GFP in the S, G2 and M phase. However, there is no way to 
distinguish between cells in the quiescent G0 or G1 phase as Cdt1 is expressed 
in both phases. 
Modifying the classical FUCCI system to incorporate a Ki67 promoter (Figure 26a) 
that controls the expression of the fluorophore complexes allows for the 
discrimination between the G0 phase with the rest of the cell cycle. Ki67 
expression only occurs throughout the cell cycle and is absent in G0380. Therefore, 
expression of the fluorophore complexes only happens during the cell cycle 
leaving cells that do not express either fluorophore complex colourless (Figure 
26a-c)381. To test this system, dual lentiviral infection of  CLE cells was done by 
incubation of CLE cells with the viral supernatant. 48h after infection, cells were 
kept permanently under antibiotic selection. Confocal imaging of the Ki67-FUCCI 
system in CLE cells reveals the presence of four populations of cells depending 
on the cell cycle state (Figure 26c). 
We then employed this system to check if altering levels of CD133 in the 
presence or absence Shh leads to changes in the colourless fraction or quiescent 
cell fraction. To monitor this, we used fluorescence-acquired cell sorting (FACS) 
to count cell population numbers in each cell cycle state. To determine the correct 
gate settings, we used WT CLE cells, isolated the single cell population and 
assessed the background fluorescence (Figure 27a-c). For each sample, the 
same gate settings (Figure 27c) were used except cell determination (Figure 27a) 
followed by doublet discrimination (Figure 27b) were done on a per sample basis.  
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Figure 27: Gating strategy. 
A) Use of FSC and SSC to isolate cell fraction from cell debris based on size and 
complexity, respectively. B) Separation of single cells from doublets using ratio of FSC-
A over FSC-H. C) Gating of WT CLE to determine background fluorescence and setting 
of the gate to include the majority of WT CLE cells in the colourless fraction. PE-Texas 
Red: R-phycoerythrin-Texas Red. 
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Size and complexity were determined using forward scatter (FSC) and sideward 
scatter (SSC) parameters to separate cells from cell debris. The ratio between 
the area (FSC-A) and the pulse height (FSC-H) of FSC was used to mark the 
single cells in the previously isolated cell population. Fluorescence of every single 
cell was then plotted using the gate settings previously acquired with WT CLE. 
To assess the role of CD133 in cell cycle control, CLE Ki67-FUCCI were 
transfected using a polyethylimine derivative to deliver plasmid DNA into the cell. 
Overexpression of CD133 was achieved using the pRC/CMV-CD133 plasmid 
and the pRC/CMV backbone as a negative control for comparison224. Cells were 
then grown under standard conditions for 48h before FACS analysis. 
Overexpression of CD133 leads to a significant increase in cells that reside in the 
G0 phase and G2/M phase compared to its empty vector control as represented 
by the bottom and upper left quadrant, respectively (Figure 28a). Comparable 
results can be seen with cells grown in the presence or absence of Shh for 24h 
(Figure 28b). These results show that both CD133 and Shh are important in stem 
cell cycle control.  
4.13 Arl13b and Hdac6 are expressed in primary cilia in the dental 
epithelium 
Proper primary cilium-dependent communication of cells with their 
microenvironment depends on the precise and sequential coordination of events 
that leads to the growth and resorption of primary cilia and depends on a different 
set of proteins for each of these processes.  
 Arl13b is a mediator of Shh signalling and plays a critical role in several aspects 
of ciliogenesis162,382. Arl13b mutant mice have defects in Shh signalling in the 
neural tube where ligand-independent expansion of Shh signalling activity is seen,  
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Figure 28: Effect of increased levels of CD133 and Shh on CLE cell cycle state. 
A) overexpression of CD133 (right panel) in CLE cells promotes cells to enter G0 and 
G2/M phases compared to empty vector control (left panel) using Ki67-FUCCI reporter 
system as revealed by FACS analysis. B) addition of Shh leads to a larger population of 
cells in the G0 phase using Ki67-FUCCI reporter system as revealed by FACS analysis. 
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however, basal levels of activity are not reached in the ventral neural tube383. At 
the molecular level, Arl13b regulates the entry of Smoothened (Smo), a 
transmembrane protein enriched in Shh-responding cilia, into the primary cilium 
which shifts the balance of Gli repressor proteins to the more activated form384. 
Downregulation of Arl13b in vitro leads to lower primary cilium numbers and 
length in a number of cell lines, whereas overexpression of Arl13b in cells results 
in increased primary cilia length indicating a vital role in primary cilia length control 
of Arl13b162.  Aberrant primary cilia length in Arl13b-null cells is most likely due to 
a structural defect in the axoneme, which suggests a role for Arl13b to regulate 
tubulin modifications within primary cilia. This is confirmed in Arl13bhennin mutant 
mice that have less acetylation of axonemal tubulin383. Hdac6, a class IIb enzyme, 
removes acetyl groups from substrates such as α-tubulin and plays, therefore, a 
central role in the destabilisation of the axoneme and subsequent resorption of 
the primary cilium. Its overexpression correlates with diseases such as the 
ciliopathies: chronic obstructive pulmonary disease, Joubert syndrome and 
polycystic kidney disease, and many cancers385–387. 
To investigate the mechanisms by which CD133 controls primary cilia length and 
function, we used Arl13b and Hdac6 to look for any anomalies in primary cilium 
dynamics in CD133-deficient dental epithelium. Tissues were processed as 
described earlier and protein expression levels of Arl13b and Hdac6 were 
compared in stem cell and transit-amplifying regions regions of WT and CD133 
KO mice. Both proteins were co-stained with AcTub to discriminate against 
primary cilium-associated and cytoplasmic Arl13b and Hdac6. Indeed, contrary 
to Arl13b, Hdac6 has also been shown to have roles in autophagy and 
ubiquitination within the cytoplasm, and its presence is, therefore, not exclusive  
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Figure 29: Arl13b and Hdac6 protein expression in the dental epithelium of P7 
C57BL/6 mice. 
A-C) Immunofluorescence analysis of Arl13b (lateral view) association with primary cilia 
(AcTub) in the stem cell region (A), transition zone (B) and transit-amplifying cell region 
(C). D-F) Immunofluorescence analysis of Hdac6 (top view, blue arrows point to primary 
cilia) association with primary cilia (AcTub) in the stem cell region (D), transition zone 
(E) and transit-amplifying cell region (F).  
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to primary cilia388,389. We found that Arl13b is present in most primary cilia of the 
stem cell region indicating that these primary cilia are still undergoing ciliogenesis 
and are increasing in length, and/or are more susceptible to Shh signalling 
(Figure 29a). Cells within the transition zone show a similar pattern of a high 
density of Arl13b-positive primary cilia (Figure 29b). Slower cycling cells within 
the transit-amplifying cells, specified by their more extended primary cilia, seem 
to retain Arl13b protein expression as opposed to cells with shorter primary cilia 
or the highly proliferating cells (Figure 29c). In contrast, Hdac6 was more tightly 
linked to primary cilia in transit-amplifying cells compared to stem cells (Figure 
29d-f). These results confirm the previous in vitro observations of the role of 
Arl13b and Hdac6 in ciliogenesis and resorption, respectively121,390. 
4.14 CD133 and Arl13b are co-expressed in dental epithelial primary 
cilia 
Previous studies on the subcellular location of CD133 has revealed that its 
expression is associated with curved plasma membrane protrusions on the apical 
often luminal side of epithelial cells. Apart from primary cilia, other membrane 
protrusions expressing CD133 include the midbody, motile cilia and 
microvilli167,219,254. In our model, we sought to investigate whether CD133 co-
localises with Arl13b in primary cilia. Immunofluorescence analysis on primary 
cilia in the dental epithelium revealed that CD133 (13A4 epitope) and Arl13b are 
present within the same cilia (Figure 30a&b). Interestingly, our experiment 
reveals that CD133 is asymmetrically distributed across the primary cilium 
membrane (Figure 30b, top view) whereas Arl13b is closely associated with the 
axoneme as visualised by AcTub staining (Figure 30b). The asymmetric 
distribution of CD133 is seen in all primary cilia investigated, however, the 
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distribution is not polarised and seems to be at random at the tissue level (Figure 
30a). 
4.15 Arl13b expression is decreased in CD133 KO dental epithelium 
Remarkably, a decrease in Arl13b expression is seen in most of the primary cilia 
in CD133 KO stem cells compared to WT stem cells, which has Arl13b in nearly 
all primary cilia (Figure 31a). This observation might explain why primary cilia are 
shorter in the CD133-deficient stem cell region as Arl13b is known to be involved 
in ciliogenesis162.  
Western blot analysis of esiCD133-mediated knockdown in CLE cells leads to a 
decline in Arl13b protein levels of 80% in total lysates (Figure 31b&c). This 
explains that the decrease of Arl13b in the primary cilium is due to lower protein 
levels rather than mislocalisation to the primary cilium.  
Nuclear and cytoplasmic protein extraction illustrates that Arl13b, which has been 
shown before126, can translocate to the nucleus and that this shuttling between 
cytoplasm and nucleus happens independently from CD133 signalling given that 
the ratio between conditions did not change (Figure 31b&d). From our result, it is 
impossible to exclude the presence of ciliary proteins in the cytoplasmic extract. 
The cytoplasmic part is obtained by disruption of the cell membrane using a 
hypotonic buffer that leaves the nuclear membrane intact. Therefore, the positive 
signal of Arl13b in the cytoplasm could well be the ciliary fraction. 
Interestingly, our collaborators, Dr. Corbeil and Dr. Karbanova have 
demonstrated with Co-immunoprecipitation experiments that a fraction of human 
CD133 binds to Arl13b in Madin Darby Canine Kidney cells (MDCK). Moreover, 
this binding is interrupted in CD133 K138Q mutants (Figure 32a-c). The  
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Figure 30: CD133 and Arl13b are co-expressed in primary cilia. 
A) Representative immunofluorescent staining of CD133 (green) and Arl13b (blue) in the 
dental epithelium (top view). Primary cilia are visualised using AcTub (red). B) Two single 
primary cilia (top and lateral view) to illustrate Arl13b and CD133 co-expression. 
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substitution of lysine-138 with Glutamine leads to the neutralisation of the electric 
charge in the first intracellular domain of CD133 (Figure 32a&b). This mutation 
was initially described to inhibit the interaction between CD133 and Hdac6 in 
several cell lines leading to the destabilisation of β-catenin, the central molecule 
in canonical Wnt-signalling391. The absence of a positive band in WT MDCK cells 
can be explained that the human AC133 antibody does not detect endogenous 
levels of canine CD133. From these results, it appears that CD133, both, directly 
or indirectly controls Arl13b expression and binds to Arl13b. It is, however, not 
clear that this protein-protein interaction is required for a feedback loop on Arl13b 
expression or what isoform of CD133 binds to Arl13b as a sizeable portion of 
CD133 appears in the unbound fraction or flow-through (Figure 32a). 
The observation that Arl13b and Hdac6, both key players in ciliogenesis and 
resorption, bind to the same domain in CD133, leads to the assumption that 
CD133 controls cilia length, as seen in Figure 21, and functions through 
competitive binding of these molecules. 
4.16 Expression of Shh effectors in the mouse incisor tooth 
Our results so far have indicated that CD133 partially mediates Shh signalling in 
the mouse incisor tooth epithelium. Gli proteins are members of the Kruppel 
family of zinc finger proteins and are the principal effectors of Shh signalling392. 
Gli2, 3 and Gli-similar (Glis) 2 have been shown to be present in the primary 
cilium where it is sequestered in an inactive form until it is activated via Smo164,393. 
Upon its activation, Gli translocates to the nucleus where it can act as a 
transcriptional repressor or activator392. Many target genes are currently known 
that affect many processes including proliferation and cell survival. In fact, in  
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Figure 31: CD133 affects Arl13b expression in the dental epithelium. 
A) IF staining on Arl13b in the WT SC region (left) and CD133 KO SC region. B) Western 
Blot on Arl13b in total, cytoplasmic and nuclear fraction of esiCD133-mediated 
knockdown vs its control. Lamin B and Glyceraldehyde-3-Phosphate Dehydrogenase 
(GapDH) are used to indicate purity of nuclear and cytoplasmic fraction, respectively. C) 
Quantification of Arl13b in total lysates in esiCD133-mediated knockdown vs its control. 
D) Quantification of Arl13b in cytoplasmic (white) and nuclear (black) fractions in 
esiCD133-mediated knockdown vs its control. 
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Figure 32: CD133 physically interacts with Arl13b through lysine-138 in MDCK 
cells. 
A) Input panel shows CD133 and Arl13b expression in total lysates of WT MDCK, MDCK-
hCD133 and MDCK-hCD133 (K138Q). Immunoprecipitation panel (IP) indicates the 
presence of CD133 in MDCK-hCD133 but not MDCK-hCD133 (K138Q) when using 
Arl13b as bait. B) IP using human AC133 antibosy as bait shows binding of Arl13b in 
MDCK-hCD133 only. Anti- Fluorescein isothiocyanate (FITC) antibody was used as 
negative control. Arrowhead: immunoglobulin. C) Quantification of Arl13b/CD133 ratio in 
MDCK-hCD133 versus MDCK-hCD133 (K138Q) was quantified.  **: p<0.01. 
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oncogenesis pharmaceutical inhibition of Shh leads to a decrease in CD133+ 
cells and negatively affects tumourigenic capability394. 
To explore the mechanisms how CD133 directs the outcome of Shh signalling, 
we looked at the RNA expression levels of Gli family members: Gli1, Gli2 and 
Gli3 as well as members of the Gli Similar family: Glis1 and Glis2 in the stem cell 
and transit-amplifying cell region of the mouse incisor (Figure 33a). The stem cell 
and transit-amplifying cell region were captured as previously described in Figure 
14. The results showed a higher expression of most Gli and Glis family members 
in the stem cell region compared to the transit-amplifying cell region. Interestingly, 
Glis2 expression is increased in the transit-amplifying cell region (Figure 33a).  
This is confirmed at the protein level (Figure 33b) where its expression pattern 
is similar to that of CD133 (Figure 15). Due to the similar protein expression 
pattern of CD133 and Glis2 in the dental epithelium of the mouse incisor, we 
looked at Glis2 protein levels in CD133 KO mice. Immunofluorecence staining 
showed a clear co-localisation of Glis2 with AcTub in the transit-amplifying cell 
region of P7 WT mice (left panel, Figure 34a). This co-localisation is nearly 
completely lost in P7 CD133 KO mice (right panel, Figure 34a).  
Throughout the cervical loop, Glis2 immunoreactivity has been detected in the 
nuclei of P7 WT mice (Figure 34b) as reported earlier164. This might hint at a role 
for Glis2 in the transcriptional regulation of downstream effectors of Shh signalling 
in the dental epithelium. However, whether it represses and/or activates 
transcription is not yet clear at this stage. 
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Figure 33: Expression of Gli and Glis family members in the stem cell and transit-
amplifying cell region of the mouse incisor tooth. 
A) RNA expression levels of Gli and Glis family members in stem cells (white bar) and 
transit-amplifying cells (black bar) region of P7 C57BL/6 mouse incisor tooth. B) 
Representative image of Glis2 protein expression in the mouse incisor tooth. Basement 
membrane separating mesenchyme and epithelium marked in dotted line. Yellow 
arrowheads indicate boundaries of the stem cell and transit-amplifying cell region. 
**p<0.01. 
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Figure 34: Subcellular localisation of Glis2 in the dental epithelium. 
A) Representative immunofluorescence lateral view images of Glis2 and AcTub co-
localisation in primary cilia in the stem cell region of P7 WT and CD133 KO mice. B) 
Glis2 immunoreactivity in the stem cell and transit-amplifying cell region of P7 C57BL/6 
mice. 70% transparency nuclei (DAPI) was achieved using Imaris software. 
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4.17 CD133 translocates to the nucleus 
A closer examination of the subcellular localisation of CD133 in the dental 
epithelium reveals that CD133 extracellular and c-terminal epitopes are both 
present in the nucleus (Figure 35). Presence of nuclear CD133 c-terminal epitope 
was also observed in CLE cells where a significant fraction of cells contains 
nuclear CD133 (Figure 35c). This result could not be replicated using the 
extracellular antibody of CD133. Potentially due to the epitope representing an 
isoform that does not translocate to the nucleus. Western blot analysis of CD133 
c-terminal epitope in the nuclear protein fractions of two different batches of CLE 
confirms the nuclear presence (Figure 35d). The purity of the nuclear fractions 
was confirmed using Lamin A/C as a nuclear marker395. To our surprise, full-
length CD133 is able to translocate to the nucleus. Proteins larger than 40 
kiloDalton (kDa) cannot diffuse freely through the pores in the nuclear membrane 
and require the presence of a nuclear localisation signal (NLS) tag in their 
sequence to facilitate their import into the nucleus396. NLS comes in many forms, 
and currently, prediction websites exist to identify putative sequences within 
proteins. Using the NLS mapper website, examination of the amino acid 
sequence of mouse CD133 isoforms s1 and s2 but not others reveal the presence 
of a putative bipartite NLS signal (IKLAKYYRRMDSEDVYDDVETVPMKNLEI) in 
the intracellular c-terminus directly flanking the transmembrane sequence. Both 
NLS-containing isoforms are the longest isoforms, and this might explain the 
more pronounced higher kDa band seen in the nuclear fraction (Figure 35d). 
Currently, the band seen at 37kDa in both cytoplasmic and nuclear fractions 
cannot be explained. Theoretically, the cleaving of the c-terminal domain of 
CD133 would yield a fragment of  approximately  two to six kDa depending on 
isoform. Therefore, in addition to cleaving, an additional post-translational 
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modification such as phosphorylation should occur to explain a band of that size. 
Indeed, a previous publication has shown that human CD133 contains two 
phosphorylation sites that act as a substrate for Src and Fyn tyrosine kinases397. 
However, cleavage of the CD133 c-terminal domain has not been demonstrated 
yet. Our results clearly indicate that CD133 can translocate to the nucleus similar 
to Glis2. 
4.18 Glis2 and CD133 physically interact in the nucleus 
The golden standard for detecting protein-protein interactions is co-
immunoprecipitation. The protein of interest is sequestered with a specific 
antibody, and binding partners are identified using Western Blot398. However, this 
technique comes with certain drawbacks. Due to the relatively harsh treatments 
of the sample, such as initial lysis and centrifugation steps, high-affinity 
interactions can only be detected with this technique. Dynamic in vivo interactions 
between proteins are also hard to reveal. Moreover, large amounts of sample are 
needed to counteract the relative insensitivity of Western Blotting as well as the 
inevitable loss of interactions during the processing of the samples. Also, co-
immunoprecipitation does not allow to discriminate between direct and indirect 
interactions, i.e., the presence of bridging molecules such as DNA or scaffold 
proteins. In vitro interactions between endogenous CD133 and Glis2 could not 
be detected using standard co-immunoprecipitation protocol. Therefore, to 
circumvent the limitations listed above we employed a technique called Proximity 
Ligation Assay (PLA)399. There are two ways to perform the technique. The direct 
PLA requires the conjugation of DNA probes to the primary antibodies whereas 
the indirect PLA has the probes connected to secondary antibodies allowing for 
more targets to be investigated at the cost of sensitivity. When the PLUS and 
MINUS probe come together (30-40nm) the circular DNA acts as a primer for  
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Figure 35: The presence of CD133 in the nucleus. 
A) Immunoreactivity of CD133 extracellular epitope in the nucleus of TAC in the dental 
epithelium of P7 WT C57BL/6 mice. DAPI staining was made semi-transparent using 
Imaris software to indicate nuclear presence. B) Immunoreactivity of CD133 C-terminal 
epitope in the nucleus of SC and TAC in the dental epithelium of P7 C57BL/6 mice. DAPI 
staining was made semi-transparent using Imaris software to indicate nuclear presence. 
C) In vitro analysis of nuclear CD133 C-terminal epitope in CLE cells. Yellow arrowheads 
highlight cells with nuclear CD133. D) Western blot analysis on cytoplasmic and nuclear 
protein fractions on CD133 expression. Lamin A/C indicates nuclear purity and GapDH 
indicates cytoplasmic purity. C+M = cytoplasm + plasma membrane, N = nucleus. 
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rolling circle DNA amplification. Binding of fluorescently-labelled oligonucleotide 
probes to the amplified circular DNA provide a precise manner to visualise 
protein-protein interactions (Figure 36a). To detect the possible interactions of 
endogenous CD133 and Glis2 in vivo, we used the direct PLA method by initial 
incubation of CD133 C-terminal antibody and Glis2 to the MINUS and PLUS 
probes, respectively. P7 C57BL/6 mouse incisors were sectioned and processed 
as described earlier. Prior to incubation with both antibody-probe conjugates as 
per manufacturer’s recommendations. It is evident from our results that CD133 
and Glis2 interact mainly in the nuclei in a specific population in the stem cell 
region called the outer dental epithelium and transit-amplifying cell regions of the 
dental epithelium. Despite the presence of both proteins in the primary cilia, there 
is little interaction outside of the cell’s nucleus. It is, therefore, possible that at 
least two different queues are necessary for the translocation of either protein 
into the nucleus. With the knowledge that Glis2 is a known transcription factor, 
we sought to investigate the downstream effector genes of this dual partnership.  
4.19 CD133 and Glis2 are connected to Jak/Stat and p53 signalling 
pathways 
To investigate the common effector genes of CD133 and Glis2 we used the RT2 
PCR array to assess the expression profile of 84 key regulators in 10 signal 
transduction pathways (See Appendix 7.5 for a complete list of genes and their 
associated pathways).  
cDNA conversion of transit-amplifying cell regions of C57BL/6 WT, Glis2 KO and 
CD133 KO was achieved from the isolation of RNA using LCM as described in 
chapter 4.3. Real-Time qPCR analysis of these samples reveals that 61 out of 84 
genes are expressed at detectable levels in all three samples (  
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Figure 36: PLA reveals CD133-Glis2 interaction in the nucleus of the dental 
epithelium. 
A) Diagram illustrating the four-step direct PLA workflow. B) Representative confocal 
images showing the interaction of CD133 and Glis2 in the nuclei of the dental epithelium 
of P7 WT C57BL/6 mice. Negative control is incubation of a single primary antibody with 
its conjugated probe. 
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Figure 37: Heatmap of PCR array genes present in the mouse incisor. 
Heatmap showing the differential expression of 61 out of 84 assayed genes and its 
associated pathway in C57BL/6 WT, Glis2 KO, CD133 KO mouse incisor. Gene 
expression of each gene in C57BL/6 WT was used to normalise its counterpart in each 
KO sample. Arrowheads indicate genes with similar trend and at least 50% differential 
expression compared to C57BL/6 WT.  
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Figure 37). After normalisation of the Glis2 KO and CD133 KO samples against 
the C57BL/6 WT control sample (not shown in  
Figure 37), 15 genes remain that cover seven signal transduction pathways and 
show a similar trend in both KO samples of at least 50% difference in expression 
levels compared to the WT control sample (arrowheads,  
Figure 37). Of these 15 genes, ten genes are upregulated, and five genes are 
downregulated compared to the WT control. However, due to the low number of 
technical replicates in the PCR array, we opted to repeat the experiment using 
the same samples but with primers designed for these 15 genes in our lab as the 
primer sequences of the PCR array are not disclosed. Gene expression of these 
15 genes revealed differences compared to the result of the PCR array. Only six 
genes covering Wnt, hypoxia, Tumor protein p53 (p53) and Janus Kinase (Jak) 
Signal Transducer and Activator of Transcription (Stat) signal transduction 
pathways could be confirmed in that they show a similar trend for the KO samples 
as seen in the PCR array. The p53 and Jak/Stat signalling pathways have two 
members that could be confirmed. Whereas Wnt and hypoxia signalling pathways 
have one member each (Figure 38a). 
To investigate the possible mechanisms in which Glis2 and CD133 cooperate to 
control the affected signal transduction pathways, we sought to confirm the 
results in vitro. Knockdown of CD133 and Glis2 was achieved using esiRNA and 
shRNA, respectively. Analysis of the in vitro samples revealed that only Interferon 
Regulatory Factor 1 (Irf1) and Suppressor of Cytokine Signaling 3 (Socs3) 
(Jak/Stat), and Aryl Hydrocarbon Receptor Nuclear Translocator (Arnt) (Hypoxia) 
show a similar trend compared to the in vivo assessments leaving them as the 
only candidates left to pursue (Figure 38a&b). We focused our attention on the 
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Figure 38: In vivo and in vitro validation of PCR array. 
A) real-Time qPCR on selected genes in C57BL/6 WT, Glis2 KO, CD133 KO mouse 
incisor. ND= Not detected. B) In vitro validation of A in esiRNA-mediated knockdown of 
CD133 in CLE cells. B) In vitro validation of A in shRNA-mediated knockdown of Glis2 in 
CLE cells. **p<0.01 
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Jak/Stat signalling transduction pathway due to it being represented by two genes 
(Socs3 and Irf1) as opposed to the single gene in the case of Hypoxia signalling. 
4.20 Assessment of the Jak/Stat signalling pathway in the mouse 
incisor tooth 
The Jak/Stat signalling pathway is evolutionary conserved and has traditionally 
been linked to transmit extracellular signals, often cytokines and hormones, to 
the nucleus leading to changes in proliferation, differentiation, apoptosis and cell 
migration400. Loss of function mutations that lead to reduced activity of the 
pathway affect tissue processes such as haematopoiesis, mammary gland 
development and lactation, adipogenesis, and immune development. On the 
other hand, increased activity is linked with chronic inflammation, gigantism and 
several types of leukaemia401,402. Binding of a ligand to its receptor leads to the 
activation of receptor-bound Jaks. This in turn alters the cytoplasmic tail of the 
receptors creating docking sites for cytoplasmic Stats. Jak-mediated 
phosphorylation of Stats precedes the nuclear translocation and DNA binding of 
Stat resulting in transcription of its effector genes403. Currently, four Jaks and 
seven Stat family members are known in mammals.  
Socs3, a gene that was overexpressed in our PCR array and our follow-up 
studies (Figure 37 & Figure 38), is involved in the suppression of infections and 
autoimmune diseases. Socs3 binds to both the cytokine receptor and Jak kinases 
resulting in the inhibition of Stat3 phosphorylation and activation. However, it has 
been shown that the phosphorylation of Stat is not always required for its nuclear 
translocation and subsequent transcriptional activity400. Additionally, Socs3 
mediates the degradation of the cytokine receptor by ubiquitination leading to a 
decreased response to inflammation404. 
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Figure 39: Jak/Stat expression in the dental epithelium of the mouse incisor tooth. 
A) Real-Time qPCR result of Jak/Stat family members in the transit-amplifying cell region 
of the mouse incisor epithetlium of P7 C57Bl/6 WT, CD133 KO and Glis2 KO mice. B) 
Representative immunofluorescence result of Stat3 in the labial cervical loop of the P7 
C57Bl/6 WT mouse. Yellow arrowheads indicate boundaries between the stem cell and 
transit-amplifying cell region. D) Glis2 consensus sequence. E) Approximate positions of 
Glis2 DNA binding sites in the mouse Stat3 promoter sequence. F) Chromatin 
Immunoprecipitation (ChIP) -qPCR result indicating Glis2 binds to the promoter of Stat3. 
ND= Not Detected. **: p<0.01, *: p<0.05. 
134 
 
Irf1 plays a critical role in the immune response, inhibition of proliferation and 
induction of apoptosis where its expression is regulated by Stats405. Irf in itself is 
a weak transcription factor and depending on its binding partners regulates 
expression of Interferons406. Among its binding partners are several Jaks and 
Stats such as Jak 1, 2, and Stat1 and 3407. 
Due to the involvement of Irf1 and Socs3 in Stat signalling, we sought to assess 
the gene expression levels of all Jak and Stat members in the transit-amplifying 
cell regions of C57BL/6 WT, Glis2 KO and CD133 KO mouse incisor, which has 
not yet been reported previously. Real-Time qPCR analysis showed that all 
members the Jak/Stat familiy are expressed in the transit-amplifying cell region 
of the dental epithelium apart from Stat1 and 4. However, only Stat3 shows a 
similar downregulation in both KO samples compared to the WT control. We then 
looked at the Stat3 promoter, located on chromosome 11:100937600-100940601, 
to investigate whether it contains one or more Glis2 consensus sequence inits 
sequence. The promoter sequence is 3001 base pairs (bp) long and was 
retrieved using Ensembl (Release 91 - December 2017) and was then analysed 
for putative Glis2 transcription factor binding sites using the MatInspector module 
of the Genomatix Software Suite. Two possible Glis2 binding sites were 
uncovered using the consensus sequence determined by the Genomatix 
software (Figure 39d). Binding sites 1 and 2 are located 100 and 1240bp 
upstream of the transcription start site, respectively (Figure 39e) and primers 
were designed around those locations. Immunoprecipitation of Glis2 protein and 
associated DNA was done on CLE cells in the presence (100 and 200ng/ml) or 
absence of Shh for 24 hours. After crosslinking, nuclei were purified with mortar 
and pestle and then sheared by sonication for 6 cycles to achieve DNA fragments 
of 400-500bp (Figure 39c). Glis2-binding sequences were immunoprecipitated 
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and matching IgG isotype controls were used as a negative control. The presence 
of the putative Glis2 binding sites in the Stat3 promoter was then assessed in the 
precipitated Glis2-positive DNA and its negative control using Real-Time qPCR. 
Binding rates were calculated against the input sample. The exact same amount 
of chromatin was used for ChIP and generation of input signal. Our data reveals 
that our DNA samples are enriched with both binding sites compared to the IgG 
isotype controls when CLE cells are cultured in the absence of Shh (Figure 39f). 
Interestingly, Glis2 does not seem to bind to the Stat3 promoter in CLE cells 
cultured with either 100ng/ml or 200ng/ml Shh for 24 hours. Of note, background 
signal seems to be relatively high in the Shh samples and this might mask the 
binding of Glis2 to the Stat3 promoter. 
Taken together, our results indicate that Glis2 only binds to the Stat3 promoter in 
the absence of Shh and this fits with the observation that Stat3 expression is 
downregulated in the transit-amplifying cell region (Figure 39b) where Shh is 
highly expressed323. This also indicates that Glis2 is a positive regulator of Stat3 
transcription in the stem cell region in the cervical loop. 
4.21 Bmi1 acts upstream of CD133-mediated ciliogenesis in the dental 
epithelium 
Stem cell renewal, activation and distinct lineage differentiation patterns is only 
partially controlled by the equilibrium between different transcription factor 
networks408. In addition to these networks, gene expression can be influenced by 
epigenetic regulation of chromatin and has been shown to be crucial in the control 
of stem cell renewal and activation. Indeed, global and local changes in chromatin 
structure determine whether a stem cell will continue and differentiate or self- 
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Figure 40: BMI1 is expressed in the dental epithelium of P7 mouse incisor tooth 
and partially controls CD133 and Glis2 expression. 
A) Representative immunofluorescence image of BMI1 expression in P7 mouse incisor 
tooth. B) Expression of CD133 ICD in the stem cell and transit-amplifying cell region of 
WT (left panel) and BMI1 KO mice (right panel). C) Glis2 expression in the stem cell and 
transit-amplifying cell region of WT (left panel) and BMI1 KO mice (right panel). 
137 
 
renew409. DNA can be directly modified by covalent modifications such as DNA 
methylation of CpG islands, or indirectly such as nucleosome remodelling and 
histone modifications, which controls the accessibility of the transcription 
machinery to DNA.  
Histone modifications can act as scaffolds for protein complexes such as the 
Polycomb Group (PcG) family to alter gene expression. PcG proteins form protein 
complexes to maintain gene silencing during development, lineage commitment 
and differentiation. The PcG  repressive complex (Prc) was initially identified in 
Drosophila and loss-of-function mutations lead to increased expression of Hox 
genes altering the body plan in these organisms410. Prc1 and Prc2 are the two 
canonical PcG complexes although their composition may vary depending on the 
context. Prc1 is built around the E3 ubiquitin-protein ligase Ring1-Posterior sex 
comb (Pse) heterodimer and one example of a Pse homologue in mammals is 
the Bmi1 oncogene. Bmi1 plays a crucial role in stem cell renewal and lineage 
differentiation during embryonic development and in adult organs84,411. The 
importance of BMI1 in adult tissue homeostasis is illustrated in the intestinal 
crypt.The intestinal crypt contains two stem cell populations: a rapidly cycling 
Lgr5-positive population and a quiescent Bmi1-positive population, and the latter 
is capable of replenishing the former after ablation of the Lgr5-positive 
population412. Expression of BMI1 is often upregulated in cancers and BMI1-
expressing tumours often display radio and chemo resistance resulting in poor 
prognosis for patients81,413,414. Inhibition of cell cycle repressors p16 and p19 by 
Bmi1 has been well studied and loss of Bmi1 has been associated with induction 
of senescence, an intrinsic tumour suppressor mechanism415,416. In the adult 
mouse incisor tooth, Bmi1 expression is restricted to the outer dental epithelium 
and overlaps significantly with other stem cell markers such as H2B-GFP and 
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Figure 41: Phenotypical similarities in primary cilia dynamics between Bmi1GFP 
and CD133 KO mice. 
A) Representative Immunofluorescence lateral view images of AcTub localisation in 
primary cilia in the stem cell region of P7 WT (top image) and BMI1GFP (bottom image) 
mice. B) Comparison of primary cilium volume in stem cell populations P7 WT and 
BMI1GFP mice. n= number of primary cilia counted. ** p<0.01 
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Gli1-LacZ82. As with the intestinal crypt, Bmi1-positive stem cells can generate all 
progeny in the incisor tooth. 
In our model, we sought to investigate the protein expression pattern of Bmi1 in 
P7 mice and its relation to CD133, Glis2 and primary cilium dynamics. Bmi1 is 
highly expressed in the outer dental epithelium, stellate reticulum and stellate 
intermedium of the developing dental epithelium (Figure 40a) as opposed to the 
adult dental epithelium where it is restricted to the outer dental epithelium82.  
Deletion of Bmi1, replaced through homologous recombination with the GFP 
gene417, leads to diminished protein expression of both CD133 and Glis2 in the 
dental epithelium (Figure 40b&c). As expected, some expression remains as 
multiple transcription factors often control the expression of genes. Interestingly, 
expression of CD133 and Glis2 remains diminished in the transit-amplifying cell 
region where Bmi1 expression is very low. Bmi1 is commonly regarded as a 
transcriptional repressor suggesting that its control of CD133 and Glis2 
expression is most likely indirect. However, recently, it has been shown that Bmi1 
can act independently of the Prc1 complex as a transcriptional activator in 
prostate cancer81. This observation opens up the possibility of a direct control of 
CD133 and Glis2 expression by Bmi1. 
If Bmi1 regulates directly or indirectly CD133 and Glis2 expression, we were 
wondering if Bmi1GFP mice display similar phenotypical primary cilium 
characteristics as seen with CD133 KO mice (Figure 21). Indeed, 
immunofluorescence staining of AcTub reveals lower primary cilia density in the 
cervical loop of Bmi1GFP mice compared to their littermate controls (Figure 41a). 
Moreover, quantification of primary cilium size shows that the primary cilia are 
smaller in the mutant mice (Figure 41b). 
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Earlier reports have shown that adult Bmi1-deficient mice display smaller cervical 
loop due to depletion of stem cells in the outer dental epithelium of the cervical 
loop leading to enamel defects82. Ablation of CD133 leads to a similar phenotype 
further corroborating a molecular link between CD133 and Bmi1 (Figure 18-
Figure 20). Our results indicate that Bmi1 acts upstream of CD133 to regulate 
ciliogenesis and lineage differentiation in the dental epithelium. 
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5 Discussion 
Our study aims to look at the role of CD133 (Prominin-1) in dental epithelial stem 
cell maintenance, activation and lineage differentiation. In doing so, a novel 
pathway has been uncovered that mainly takes place in the primary cilium, an 
organelle that is present in nearly all cells and plays a crucial role in translating 
extracellular cues into appropriate cell responses. Remarkably, the relationship 
between the primary cilium and stem cell behaviour is understudied, especially in 
the epithelium, given its importance in regulating the cell cycle362.  
At present, CD133, a primary cilium component, is widely used as a stem cell 
marker to identify and isolate stem cells in a wide variety of tissues. However, its 
function remains poorly understood. Our work demonstrates that CD133 acts as 
a scaffold for the successive recruitment of Arl13b and Hdac6 in a cell status-
dependent manner, i.e.: quiescent stem cell or transit-amplifying cell, respectively. 
The primary cilium architecture is cyclical in nature and changes in length 
depending on the cell cycle stage. Our in vivo CD133 KO experiments indicate 
that reduced primary cilium length renders cells less sensitive to the SHH 
morphogen, which requires the primary cilium for signal propagation into the cell. 
In the dental epithelium, SHH is expressed by transit-amplifying cells and acts in 
a positive feedback loop on the epithelial stem cells necessary to fuel the constant 
generation of enamel-secreting ameloblasts323.  
Loss of CD133 leads to a host of changes in primary cilia characteristics in the 
dental epithelium. First, primary cilia are shorter in the stem cell region, meaning 
that affected stem cells either have disturbed cell cycle dynamics, in this case, a 
shorter G0 and/or G1, the typical anagenic phases of ciliogenesis, or stunted 
primary cilium growth independent of the cell cycle. Second, primary cilia are 
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longer in the transit-amplifying zone than their WT’s counterparts, indicating 
either that these cells spend more time in the G0-G1 phase or that primary cilium 
resorption is too slow leading to a slowdown of the cell cycle. In addition, primary 
cilium numbers were up in both CD133 mutant stem cell and transit-amplifying 
cell populations compared to wild-type controls implicating that a smaller fraction 
of affected cells resides in the M phase, the only cell cycle phase where primary 
cilia are completely resorbed.  
These phenotypical changes contribute to a reduction in quiescent and activated 
stem cells as seen in the volume calculations of the Sox2-positive region 
(quiescence) of the cervical loop and the ratio of Ki67/Sox2 (activation) in control 
versus CD133 KO mice. Previously, it has been shown that Sox2-positive cells in 
the cervical loop can give rise to all cell types of the dental epithelium including 
the enamel-secreting ameloblasts78. Therefore, Sox2 is a true and validated stem 
cell marker in the dental epithelium. Ki67 is widely regarded as a proliferation 
marker that shows increasing protein expression levels in cycling cells with the 
highest expression seen in the M phase but whose expression is absent in 
quiescent G0 cells418. Hence, the use of both markers to carefully document 
changes in stem cell dynamics regarding its maintenance as well as activation in 
our study. 
Ultimately, these defects are reflected in the stem cells’ inability to become 
properly matured ameloblasts. CD133 KO ameloblasts are capable of producing 
and secreting enamel but do so less effectively. µCT data clearly shows that the 
onset of enamel deposition is delayed and that its final thickness is reduced 
compared to WT animals. Histological staining revealed that ameloblasts show 
expected elongation during differentiation but their nuclei are not properly 
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polarising away from the secreting front, phenocopied, albeit stronger, by  Krt14-
Cre: Shh mice61. Moreover, white vacuoles are present in KO ameloblasts hinting 
at inhibited secretion of enamel, which would explain the incomplete enamel rod 
maturation. Our study was not able to find out the role of CD133 in enamel 
secretion, but one possibility is the fact that complete differentiation of 
ameloblasts is not achieved as seen with the diminished expression of known 
ameloblast markers and, therefore, important components of the ‘enamel 
production and secretion programme’ are missing.  
Interestingly, using antibodies targeting different epitopes of CD133 revealed 
different protein expression patterns. The entire dental epithelium is positive for 
the ICD epitope with the highest expression seen in the inner dental epithelium 
of the cervical loop, whereas, the ECL epitope is mostly restricted to the inner 
dental epithelium of the cervical loop. The ECL antibody has previously been 
shown to target both glycosylated and non-glycosylated forms of CD133167. 
However, it is likely that the antibody has different affinities for both forms of 
CD133. In addition, the second extracellular loop contains multiple possible N-
glycosylation sites and it is, therefore, likely that the epitope is only recognised in 
its unglycosylated and a specific glycosylation pattern but not all possible 
glycosylation patterns. Our Western Blot results, using the ICD-targeting antibody, 
reveals there is at least four different full-length forms of CD133. This does not 
directly prove the existence of differently-glycosylated forms of CD133 in the 
dental epithelium as these size differences could also be due to different yet 
unknown post-translational modifications or even different isoforms. Indeed, 
according to the NCBI gene database, eight different murine isoforms have been 
confirmed with multiple predicted transcript variants. Whether, multiple transcript 
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variants are present within the dental epithelium and if these different isoforms 
perform different roles remains to be investigated.  
Overall, the phenotype in the dental epithelium of CD133 KO mice is relatively 
mild with fully functional, albeit thinner, enamel. In mammals, the Prominin family, 
of which CD133 is part of, contains an additional member: Prominin-2.  The 
expression pattern of both members overlaps in most tissues apart from the eye 
where only CD133 is detected173. Given that the photoreceptor cells of CD133 
KO mice display an overt phenotype with the gradual loss of eyesight, it is likely 
that Prominin-2 rescues the phenotype in other CD133-expressing tissues. 
Indeed, elevated levels of Prominin-2 RNA has been detected in the developing 
mouse incisor tooth cervical loop419. Hence, a partial rescue by Prominin-2 is 
likely explaining the relatively mild phenotype. To date, research on Prominin-2 
has been largely non-existent with only 17 publications so far and more research 
needs to be done on the mechanisms of the Prominin-2 rescue of CD133 KO 
phenotype in different tissues including tooth development. 
To understand the underlying mechanisms governing stem cell maintenance and 
activation, we isolated the dental cervical loop of P7 mice containing quiescent 
and activated stem cells, and the adjacent inner dental epithelium harbouring the 
transit-amplifying cells (CLE). To validate these cells, we used key epithelial 
(Krt14, Cdh1) and mesenchymal (Pdgfrβ, Vimentin) markers to determine their 
purified epithelial nature. In addition, these cells can express the ameloblast-
specific differentiation markers, Ameloblastin and Amelogenin.  
Addition of Shh to WT CLE cells leads to an increase in proliferation, which is 
completely prevented by simultaneously reducing CD133 expression using 
esiRNA. Shh is important for growth control in tooth development. Indeed, Cre-
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mediated deletion of Shh after epithelial placode formation (~E11.5-E12.5) leads 
to rudimentary tooth development, which does not affect enamel and dentine 
deposition, albeit structurally disorganised61. In addition, Shh decreases cell 
survival as seen by increased levels of activated Caspase 3, a critical executioner 
of apoptosis. Reduction of CD133 expression in the absence of Shh does not 
have any effect on colony size or number of CLE cells. However, complete loss 
of CD133 leads to failure of CLE to form colonies independent of SHH. In vivo 
loss of CD133 does not lead to such a strong phenotype, as the cervical loop is 
still present, although smaller, in two-month-old CD133 KO mice and is likely due 
to epithelial-mesenchymal rescue mechanisms. 
Whether Shh directly interacts with CD133 remains to be investigated. So far, 
Ptch1 is the only receptor known to directly bind to the ligand420. Given the strong 
phenotypes associated with changes in CD133 expression in Shh signalling and 
the importance of cholesterol in the correct membrane localisation and long range 
signalling of CD133421 and Shh61, 422, respectively, there is a possibility of both 
molecules directly interacting in a cholesterol-dependent manner. Of note: the 
recombinant Shh used in our in vitro experiments lack any sterol modifications 
but it is also possible it only requires CD133 bound to membrane-incorporated 
cholesterol. A follow-up study is necessary to prove both proteins can interact in 
a direct manner.  
Our study does highlight an indirect role for CD133 in Shh signal propagation. 
Arl13b, a small GTPase responsible for cilia assembly, has also been implicated 
in the regulation of Shh signalling protein localisation to the primary cilium. Mouse 
embryonic fibroblasts (MEF) harbouring inactivating Arl13b mutations (hennin) 
show a similar phenotype to CD133 KO mice in that their primary cilia are shorter 
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compared to WT. However, hennin mutant MEF are capable to be cultured ex 
vivo and respond to Shh unlike CD133 KO through an increase in Smo, though 
less pronounced than in control cells, to the primary cilium. Hennin mutants also 
display ciliary Smo even in the absence of Shh162,383. This leads to a shallow 
gradient response to Shh as is confirmed with the hennin mutant’s defective 
patterning during development383. Our in vivo study shows that Arl13b’s 
localisation to the primary cilium is almost completely diminished in the absence 
of CD133 and that both molecules interact directly as shown in our CoIP 
experiments. It remains to be determined if the primary cilium localisation of Shh 
effector proteins is similarly affected in our model.  
Arl13b binds to the same intracellular loop of CD133 as Hdac6, a key effector in 
cilia resorption. A previous study has shown that substitution of lysine with 
glutamate (K138Q) in CD133 neutralises the electric charge and prevents Hdac6 
from binding to CD133 through its first intracellular loop391. Using the same 
K138Q construct, we confirmed that Arl13b loses its ability to bind to CD133. 
Arl13b and Hdac6 are responsible for cilium assembly and disassembly, 
respectively. This result opens up the possibility of a sequential binding 
mechanism between Arl13b and Hdac6, i.e.:  cells present in the G0 or G1 will 
favour the CD133-Arl13b complex to stimulate primary cilium growth, whereas, 
from the S phase onwards, this complex dissociates and CD133 recruits Hdac6 
to enable cilia resorption in preparation for mitosis. The question remains how 
exactly this transition happens. Several studies have shown that cells with long 
primary cilia were more receptive to mechano-transduction and fluid flow 
compared to cells with shorter cilia354,423. Our model demonstrates that this is also 
the case with chemo-sensation and that quiescent stem cells become more 
responsive over time to extracellular cues such as Shh stimulation. 
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Several Shh downstream effector genes are expressed in the dental epithelium. 
Gli proteins are the best-studied effectors of Hedgehog signalling. The family 
comprises of three members: Gli1, Gli2 and Gli3, and are all expressed in the 
developing dental epithelium of the incisor. Glis2, a member of the Gli similar 
family, has high sequence similarity with Gli proteins and acts in a similar fashion 
by translating extracellular cues into appropriate gene transcription. Profiling the 
expression of Glis2 in the dental epithelium revealed that Glis2 shows similar 
expression patterns as CD133 at both the RNA and protein level. As with Gli2 
and 3, Glis2 activation in primary cilia leads to its translocation to the nucleus 
where it acts mainly as a repressor of gene transcription with some evidence of 
promoting gene expression424. Loss of Glis2 in human and mice leads to 
nephronophthisis, an end-stage autosomal recessive kidney disease. CD133 
expression is particularly high in kidney as well211. So far, limited evidence exists 
linking Shh signalling to Glis2. Expression patterns of both molecules are 
remarkably similar in the developing kidney425–427. Moreover, in developing lungs, 
co-expression of both molecules points Glis2 to a role in branching 
morphogenesis and cell proliferation, a function attributed to CD133 in mammary 
glands261,428. However, Shh signalling is considered paracrine in nature, therefore, 
its exact co-localisation hints at an upstream role for Glis2 in Shh signalling. Glis2 
has also been shown to interact with SuFu, which is involved in the activation of 
Gli proteins in primary cilia upon Shh stimulation. This interaction leads to 
ubiquitination of the complex in the kidney, which consequently leads to its 
degradation and negative regulation of Shh signalling424.  
Our study shows for the first time that CD133 can translocate to the nucleus under 
normal physiological conditions. Previous observations of nuclear CD133 was 
only reported in cancers. Indeed, this atypical localisation of CD133 has been 
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detected in non-small cell lung cancer, hepatocellular carcinoma, 
rhabdomyosarcoma and triple-negative breast cancer, and correlates with poor 
prognosis due to radio- and chemotherapy rsistance, and increased rates of 
metastasis233–235,429. Interestingly, this study illustrates that full-length CD133 is 
capable of nuclear translocation. In general, proteins that are larger than 60kDa 
cannot diffuse passively though the nuclear pore430. Instead, large proteins and 
macromolecules require an active transport mechanism to cross the nuclear pore 
barrier and relies on the presence of a special amino acid sequence, better known 
as the nuclear localisation signal, in the protein431. In general, this signal is made 
up of one or more short sequences of positively charged arginines or lysines, 
which are exposed on the protein surface and can be predicted using online 
resources432. CD133 lacks such classical sequences and it remains elusive as to 
how it translocates to the nucleus. Several alternative possibilities might explain 
its nuclear presence.  
First, several nuclear localisation sequences exist, and new ones are being 
discovered regularly. Indeed, the recent discovery of the DFP motif being 
responsible for the Importin α5-mediated nuclear translocation of O-GlcNAc 
transferase attests to the divergent nature of the nuclear localisation sequence433. 
Interestingly, all murine and human isoforms of CD133 contain the motif in their 
extracellular N-terminal domain opening a future avenue for follow-up research. 
Second, the nuclear membrane in mammalian cells is a dynamic structure and is 
completely broken down during mitosis temporarily exposing the DNA to the 
cytosolic environment434. This event presents an opportunity for proteins to 
localise to the DNA periphery and, subsequently, to be encapsulated by the newly 
formed nuclear envelope during telophase of mitosis. Third, a previous report has 
implicated that a fraction of the resorbed primary cilium remains attached to the 
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mother centriole and governs asymmetric cell division. Therefore, the possibility 
of CD133 being part of the so-called ciliary remnant might be the principal 
mechanism of its nuclear translocation. In particular, the presence of Arl13b, a 
binding partner of CD133, in the ciliary remnant substantiates this hypothesis229.  
Finally, the interaction with Glis2 might facilitate its nuclear localisation. This has 
been shown previously to be the case with Type I insulin-like growth factor 
receptor that uses the Insulin receptor to translocate to the nucleus435. 
Regardless of the mechanism of translocation, this study conclusively proves that 
CD133 translocates to the nucleus under normal physiological conditions where, 
in the dental epithelium, it interacts with Glis2. This interaction could only be 
detected using the Proximity Ligation Assay but not classical co-
immunoprecipitation. This indicates that the complex is only bound very weakly 
and that the interaction is disrupted due to the harsh conditions of co-
immunoprecipitation. Another possibility is that binding of both proteins is also 
controlled by factors delivered by the extracellular environment (See chapter 
1.1.3 Somatic stem cells and the extracellular micro-environment) as the 
Proximity Ligation Assay was performed on in vivo samples whereas the co-
immunoprecipitation experiments were performed on in vitro CLE cells.  
Investigation in the downstream signalling pathways that are controlled by CD133 
and Glis2 leads to two major pathways commonly affected in the cervical loop of 
the two different mutants. In vitro assessment using siRNA on CLE cells could 
only confirm the in vivo observation of Jak/Stat signalling but not Hypoxia 
signalling. Hence, the focus of this study on Stat3. In addition to having Glis2 
consensus sequences within the Stat3 promoter, Stat3 is also an essential 
transcription factor involved in the regulation of stem cell maintenance and 
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activation436,437. In the cervical loop, Stat3 protein is highly expressed in the 
quiescent stem cell region whereas its expression is diminished in the transit-
amplifying cell region where both CD133 and Glis2 are highly expressed. ChIP-
qPCR confirmed that Stat3 is a direct transcriptional target of Glis2. Together with 
the observation of Stat3 protein expression in the cervical loop, this study 
concludes that Glis2 is a negative regulator of Stat3 in the dental epithelium. To 
find additional effector genes of the Shh-CD133-Glis2 axis, it would be beneficial 
to perform RNA-Seq on the dental epithelium as the PCR array only provides a 
limited scope on gene expression. In addition, the novel pathway should be 
verified in other model systems such as the kidney epithelium where both CD133 
and Glis2 are highly expressed. 
Finally, the present study shows that CD133 and Glis2 are both controlled by 
Bmi1, a master regulator of stem cells in a variety of tissues including the dental 
epithelium82,412. Not only does loss of Bmi1 lead to diminished expression of 
CD133 and Glis2, it also leads to a reduction in primary cilium length, which 
phenocopies CD133 KO dental epithelium. 
Taken together, this study provides insight in the control of stem cell maintenance 
and activation by the Shh-CD133-Glis2-Stat3 axis in the developing epithelium. 
Moreover, the discovery that CD133 directly mediates the Shh signal might have 
big implications in cancer therapy and treatment. Cells that contain low levels of 
CD133 show no gross phenotypes but favour apoptosis when exposed to excess 
Shh as seen in cancer. Currently, three models exist that describe Shh activity in 
cancer.  Type I cancers are Shh ligand independent, such as basal cell 
carcinomas and medulloblastomas, and are characterised by activating 
mutations of Ptch and Smo. Type II tumours are autocrine (or juxtacrine) Shh 
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dependent, implicating that Shh is produced and responded to by the same (or 
neighbouring) cancer cells. Finally, type III tumours, which are paracrine Shh 
dependent where Shh is produced by the tumour and is received by the 
surrounding stroma, which in turn sends different signals back to the tumour to 
promote its growth and survival438. Within these three models, it would be 
worthwhile to investigate whether CD133 plays a role in the tumourigenic 
potential of Shh signalling. 
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6. Future research 
Several avenues can be pursued to investigate the precise mechanisms of 
CD133 in governing the SHH signalling pathway in the dental epithalial stem cell 
renewal and activation. First, does SHH interact direcly with CD133 and if so, 
how is this binding facilitated? So far, only one receptor (Patched1) for SHH has 
been discovered. I propose to first perform a ligand-binding assay to 
establish/exclude direct binding of both proteins. However, due to technical 
limitations, such as limited resolution with in vivo ligand-binding assays, it is only 
feasible with in vitro cell cultures. Of note, it is well-established that both proteins 
require binding of sterols to function properly and it is essential to keep in mind 
that perhaps the interaction is also facilitated by cholesterol. Commercial 
recombinant SHH ligand conjugated with sterols is currently unavailable. 
Therefore, I propose to use primary cells that are capable of expressing and 
secreting SHH such as the CLE cells used in this study. It might well be that 
CD133 acts as a co-receptor to Patched1 or facilitates the translocation of 
Smoothened to the primary cilium to affect the SHH signalling pathway. To 
investigate these possible interactions co-immunoprecipitation or proximity 
ligation assays could be performed. 
Second, how does CD133 translocate to the nucleus? The recent discovery of 
the DFP motif, which is present in all CD133 isoforms, is a good candidate to 
investigate as it directs Importin α5-mediated translocation to the nucleus. Again, 
direct interaction between Importin α5 and CD133 could be investigated using 
co-immunoprecipitation or proximity ligation assay combined with selective 
deletion of the DFP motif in the N-terminal domain of CD133. However, care 
needs to be taken when deleting the DFP motif as the N-terminal domain also 
contains te plasma membrane localisation signal. 
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It is also possible that CD133 translocates to the nucleus as a component of the 
ciliary remnant, which directs the outcome of the daugther cells, I.e.: stem cell 
renewal versus activation. This will require high-resolution time-lapse imaging of 
single cells undergoing mitosis as performed by Paridaen et al. 
In our study, common downstream signalling pathways shared between Glis2 KO 
and CD133 KO inner dental epithelial cells were revealed using commercially 
available PCR arrays and led us to focus eventually on STAT3, a protein recently 
shown independently to be important in dental epithelial stem cell renewal and 
activation. It would be beneficial to cover the whole transcriptome using micro 
array or RNAseq to uncover all shared downstream signalling pathways. 
The mouse incisor tooth phenotype observed in CD133 KO mice is relatively mild 
as CD133 KO teeth are still fully functional without discomfort to the animal. 
Prom2, a second member of the Prominin family is co- expressed with CD133 in 
nearly all tissues except photoreceptor cells. Our study has shown that Prom2 is 
also expressed in the dental epithelium of P7 CD1 and C57/BL6 mice, albeit at 
low levels. It would be interesting to generate double CD133-Prom2 KO mice to 
investigate the severity of the mouse incisor tooth phenotype. It is possible that 
double KO mice are embryonically lethal and, therefore, postnatal conditional 
deletion of CD133/Prom2 might be necessary to be able to investigate the 
cervical loop and enamel phenotype. 
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7 Materials & Methods 
7.1 Mice 
ICR (CD-1®) Mice (CD1) were purchased from Charles River UK Ltd. and CD1 
mouse colonies were maintained at the Plymouth University Animal Facility with 
food and water provided ad libitum. CD1 mouse pups were euthanized humanely 
at postnatal day 7 by cervical dislocation in accordance to Home Office regulation 
under the UK Animals Scientific Procedures Act 1986 (ASPA). The heads were 
immediately submerged in dry ice-cooled 2-methylbutane (M32631, Sigma-
Aldrich) for 10 minutes. Frozen heads were then removed and stored at -80°C.  
Plymouth University Animal Welfare and Ethical Review Board granted ethical 
approval for all experiments.  
BMI1GFP/GFP 417, CD133 KO236, GlisLacZ/LacZ 164 mice and their littermate controls 
used in this study were generated and kindly donated by our collaborators Prof. 
Ophir Klein (University of California, San Francisco), Dr. Denis Corbeil (Biotec, 
Dresden) and Dr. Massimo Attanasio (University of Iowa, Iowa city), respectively. 
7.2 Extraction and culture of Cervical Loop epithelial cells 
Cell culture media compositions are presented in Appendix section 7.1 and 7.2 
Cervical loop epithelial cells (CLE) were extracted from incisor explants from p7 
CD1 and CD133 KO mice. The cervical loops were dissected under a Leica M80 
stereomicroscope. Explants were incubated in 1% Collagenase I (C0130-1G, 
Sigma-Aldrich) in Hank's balanced salt solution (HBSS; 14175-053, Gibco) with 
1% penicillin-streptomycin (SV30079.01, Hyclone) and 1% Fungizone® 
Antimycotic (15290-018, Gibco) for 60 minutes. Collagenase was deactivated 
with Dulbecco modified Eagle’s medium/F-12 (DMEM; 31331-028, Gibco) 
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containing 10% fetal bovine serum (FBS; F7524, Sigma-Aldrich) and 1% 
penicillin-streptomycin (SV30079.01, Hyclone). The cell suspension was then 
centrifuged at 1000rcf for 5 min before supernatant was removed and pellet was 
re-suspended and plated in DMEM/F-12 (31331-028, Gibco) containing B27 
supplement minus vitamin A (12587-010, Gibco), with recombinant mouse 
carrier-free Egf (20ng/ml) (2028-EG-200, R&D Systems) and recombinant mouse 
carrier-free Fgf basic (25ng/ml) (3139-FB-025/CF, R&D Systems).  
7.3 Passaging of CLE cells 
CLE cells were passaged when reaching approximately 80% confluency. After 
removal of growth medium, CLE cells were washed with HBSS to remove trypsin-
inhibiting components typically present in cell culture media. TrypLE Select 
(12563029, Gibco) was then added to the washed cells to dislodge them from the 
cell culture vessel. During this step, cells were incubated at 37ᵒC and 5% CO2. 
TrypLE Select was then neutralised with equal volume of DMEM supplemented 
with 10% FBS and the resulting cell suspension was collected and spun down at 
1500 rpm for 5 minutes. The cell pellet was resuspended in complete growth 
medium and re-plated at the appropriate density in a suitable culture vessel and 
incubated under normal growth conditions. 
7.4 Freezing and thawing of CLE cells for long term storage 
Dislodged CLE cells were collected and spun down as described in Section 6.3. 
The resulting cell pellet was then resuspended in chilled 90% FBS + 10% 
dimethyl sulfoxide (DMSO) (D2650, Sigma-Aldrich) and 1ml added to chilled 
cryovials (374080, Nunc). Cells were then slowly frozen to -80ºC. The following 
day, frozen cells were transferred to liquid nitrogen tanks for long-term storage. 
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Thawing of CLE cells was done at 37ºC and immediately diluted 10x with DMEM 
+ 10% FBS. Cells were then spun down and plated as described in Section 6.3. 
7.5 Knockdown of CD133 in CLE using esiCD133 
Upon reaching 50-60% confluency, CLE cells were transfected with esiRNA 
using INTERFERin® (409-10, Polyplus) according to the manufacturer’s 
specifications. In short, 20nM of esiRNA and INTERFERin® was prepared in 
normal growth medium and left to incubate for 20 minutes to allow for transfection 
complex formation. During incubation, fresh medium was applied to the CLE cells 
to stimulate growth and to enhance transfection. The transfected CLE cells were 
then left to incubate at 37ᵒC and 5% CO2 for 48h. 
7.6 Colony Forming Assay 
CLE cells at the exponential growth phase were harvested with TrypLE Select 
(12563029, Invitrogen) and counted using a Countess II Automate Cell Counter 
(AMQAX1000, Invitrogen). Following this, cells were diluted and seeded at 5000 
cells per well of a twelve-well plate. After 48h incubation, cells were transfected 
with esiCD133 or esiRLUC. After incubation for 24h, cells were cultured with or 
without SHH-N (464-SH-025, Bio-techne) at a concentration of 100ng/ml for 24h. 
Cells were washed with HBSS twice, fixed with 10% neutral-buffered formalin 
(HT501128, Sigma-Aldrich) for 30’, and stained with 1% crystal violet solution 
(V5265, Sigma-Aldrich) for 1 hour at room temperature. 
7.7 Vector construction and site-directed mutagenesis of lysine 138 
Construction of the human CD133 expression plasmid was achieved by 
introducing the full-length coding sequence (CDS) of human CD133 splice variant 
s2 (Genbank Accession number AF027208.1) into the enhanced Yellow 
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Fluorescent Protein (eYFP)-N1 plasmid (632445, Clontech). NotI and XhoI 
restriction sites were exploited for directional cloning of the CDS and excision of 
eYFP. Mutation of lysine 138 was achieved using the QuikChange® II Site-
Directed Mutagenesis Kit (200523, Stratagene) according to manufacturer’s 
directions. The forward and reverse primers were 5’-
CGTTGCTGTAACCAATGTGGTGGAG-3’ and 5-
CTCCACCACATTGGTTACAGCAACG-3’, respectively. The single nucleotide 
modification from adenine to cytosine (underlined) leads to the translation of a 
glutamine residue. WT and mutated CD133 CDS expression vectors were 
sequenced in order to exclude the presence of any reading mistakes introduced 
by the cloning steps and/or DNA polymerase. Sequencing was performed using 
the Applied Biosystems 3730 Genetic Analyzer at the MPI-CBG facility (Dresden, 
Germany). 
7.7 Lentiviral production, shRNA Knockdown and Selection 
Two short hairpin RNA (shRNA) plasmids targeting the mouse gene sequence of 
CD133 (See appendix section 7.8 for sequence) were provided in the pLKO.1 
plasmid (SHCLND-NM_008935, Sigma-Aldrich). 
The Ki67-FUCCI system pLenti-mCherry-hCdt-2k7bsd and pLenti-mAG-hGem-
Neo were a kind gift from Dr. Alexander Zambon (Pharmacology University of 
California). 
Lentiviral shCD133 and Ki67-FUCCI plasmids were produced in 293FT cell line 
by co-transfection of pLKO.1 containing the different shRNA constructs and the 
Ki67-FUCCI plasmids with the MISSION lentiviral packaging mix (SHP001, 
Sigma-Aldrich). The viral supernatant was collected after 48h and passed 
through a 0.45µm filter to remove cell debris. 
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CLE cells were incubated for 2 hours at 37ᵒC with the viral supernatant containing 
10µg/ml polybrene (TR-1003-G, Millipore). After 2 hours, the viral supernatant 
was replaced with normal growth medium. CLE cells infected with shCD133 
plasmids were continuously selected using 10µg/ml puromycin (P8833, Sigma-
Aldrich). CLE cells infected with the Ki67-FUCCI system were selected using 
250µg/ml Geneticin (10131-035, Gibco) and blasticidine S hydrochloride (15205, 
Sigma-Aldrich). 
7.8 Generation of Ki67p-Fucci lentiviral reporters, cell transfection 
and infection 
Ki67p-Fucci lentiviral reporter plasmids were kindly donated by Dr. Alexander 
Zambon (Keck Graduate Institute, Claremont). Generation of the lentiviral 
reporters was achieved using open reading frames of the 
mCherryhCdt1(30/120)-pCSII-EF-MCS and mAG-hGeminin(1/110)-pCSII-EF-
MCS plasmids which were kindly supplied by Dr. Astsushi Miyawaki and were 
subcloned into the pENTR-D-Topo vectors (K240020 Life Technologies). 
Subcloning using Gateway recombination of the 1.5kb Ki67 proximal promoter 
(Ki67p) upstream of mAG and mCherry FUCCI reporters was performed into 2k7 
lentiviral vectors, allowing for neomycin and/or blasticidine selection for cells 
expressing Ki67p-mAG-hGem(1-110) and Ki67p-mCherry-hCdt1(30-120), 
respectively440,441.  
The resulting Ki67p-Fucci vectors were transfected into the HEK293FT (R70007, 
Life Technologies) cell line together with pCMV-VSV-G (Envelope plasmid) and 
pCMV delta R8.2 (Packaging plasmid), producing lentiviral particles for cell 
infection. Viral supernatants were collected after 48h and 72 hours yielding two 
batches. 
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CLE cells were incubated with both viral supernatants containing the Ki67p-mAG-
hGem (1-110) and Ki67p-mCherry-hCdt1(30-120) plasmids and 10μg/ml 
polybrene (TR-1003-G, EMD Millipore) for 2 hours under normal culture 
conditions. After 2 hours, the viral supernatant was removed, and cells were 
washed with HBSS prior to adding normal growth medium. After 24h, infected 
CLE cells (CLE-Ki67-FUCCI) were continuously selected using 10μg/ml 
blasticidine (15205, Sigma-Aldrich) and 250μg/ml G418 (11811023, Gibco). 
7.9 Flow cytometry 
For flow cytometry,  CLE-Ki67-FUCCI  were either transfected with the empty 
pRc/CMV vector or mouse pRc/CMV-CD133167 and then harvested after 72 
hours or cultured in the absence or presence of 100ng/ml carrier-free Shh for 24h 
(461-SH-025/CF, Bio-Techne). Treated CLE cells were then fixed in 4% 
paraformaldehyde (PFA) for 30min at room temperature followed by washing with 
Phosphate-buffered Saline (PBS; P4417, Sigma-Aldrich) for three times. Analysis 
was done using the BD FACSCanto™ II SOR (Beckman Coulter) and data was 
acquired using the blue laser (488 nm) for mAzamiGreen signal and theyellow-
green laser (561 nm) for mCherry. Results were analysed using the FlowJo® 
software v10.3 (Tree Star Inc.). 
7.10 Laser Capture Microdissection for RNA extraction 
Frozen heads were cryosectioned at 10µm thickness on a Leica CM1850 cryostat. 
Sections were mounted onto PEN Membrane Glass Slides (LCM0522, Applied 
Biosystems) and immediately stained using 1% Methyl Green (67060, Fluka 
Analytical) in 0.1% diethylpyrocarbonate (D5758, Sigma-Aldrich) distilled water, 
then washed four times for 30 seconds in 0.1% diethylpyrocarbonate (D5758, 
Sigma-Aldrich) distilled water and then allowed to dry for 5 minutes. Laser 
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Capture Microdissection (LCM) was achieved using CapSure® Macro LCM Caps 
(LCM0211, Applied Biosystems) on an ArcturusXT™ LCM instrument within 30 
minutes of sectioning. Samples were lysed in Tri-Reagent (T9424-100ML, 
Sigma-Aldrich) and stored at -80ºC until further processing. 
7.11 RNA extraction & cDNA production  
RNA was extracted and purified using the acid guanidinium thiocyanate-phenol-
chloroform extraction protocol. The total RNA was extracted using Tri-Reagent. 
The samples were vortexed and incubated for 5 minutes at room temperature 
before addition of Chloroform (C2432, Sigma-Aldrich) at a ratio of 5:1 (lysate: 
chloroform). The samples were then incubated for a further 5 minutes before 
centrifugation for 15 minutes at 13000rpm. The aqueous phase was then 
collected and added 1:1 with 2-propanol (34965, Fluka Analytical) supplemented 
with 1µl GlycoBlue (AM9515, Ambion). The sample was incubated at -20°C 
overnight before centrifugation at 13000rpm for 15 minutes at 4°C. The 
subsequent pellet was then washed in 1ml 70% Ethanol (20821.321, VWR 
Chemicals) and centrifuged for 10 minutes at room temperature at 9000rpm. The 
resulting pellet was resuspended in 10µl of 0.1% diethylpyrocarbonate-treated 
(DEPC; D5758, Sigma-Aldrich) distilled water. 
Purified RNA was quantified on a NanoDrop™ 2000 UV-Vis Spectrophotometer 
(Thermo Scientific). Quality control was assessed by analysis of the 260/280 and 
260/230 ratios and corresponding graphs, which is an indicator for the presence 
of contaminants. 
Reverse transcription was performed using High-Capacity cDNA Reverse 
Transcription Kit (4368814, Applied Biosystems) in accordance with the 
manufacturers protocol on a Veriti™ Thermal Cycler 96 well (Applied Biosystems).  
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1µg of total RNA was reverse transcribed using the Multiscribe™ Reverse 
Transcriptase polymerase and random hexamer primers. See appendix section 
7.10.2 for programme details. Samples were then diluted in 180µl of DEPC-
treated water and stored at -20°C. 
7.12 Real-Time qPCR 
Real Time qPCR was performed in triplicate.  Samples were combined with 
LightCycler® 480 SYBR Green I master kit (4887352001, Roche Life Science) 
(diluted 1:1 with the water provided in accordance with the manufacturer’s 
instructions) and appropriate primers in a ratio of 1:8:1 totalling 10µl. This equates 
to a final primer concentration of 1µM. The samples were analysed with each 
primer in triplicate as a technical control. Primers were designed against the CDS 
sequence for each gene, provided by NCBI gene 
(http://www.ncbi.nlm.nih.gov/gene/) using Primer 3 website 
(http://biotools.umassmed.edu/bioapps/primer3_www.cgi) and validated on 
UCSC In-SilicoPCR (http://genome.ucsc.edu/cgi-bin/hgPcr?command=start). 
Primers were designed to give an amplicon length that reduces the risk of dimers 
and hairpins. If possible, the primers were also designed to cross an exon to 
negate the problems of genomic DNA contaminants being amplified. To reduce 
the risk of RNA degradation leading to non-binding of primers, primers were 
designed to bind towards the centre of the cDNA. Primers (listed in appendix 
section 7.9) were all validated against cDNA extracted from mouse embryonic 
fibroblasts, to ensure that they can detect cDNA and that the amplicons produced 
are of the anticipated length. The instrument used was a Roche Lightcycler® 480 
Instrument II 384-well block real-time PCR machine, used according to the 
manufacturer’s instructions. Programme details are explained in appendix 
section 7.10.1. Results were analysed using Comparative Ct methods. PCR 
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amplification was checked to ensure appropriate amplification curves and 
annealing temperature was obtained. Results were exported into Prism (version 
5.04). 
7.13 Immunofluorescence 
Frozen heads were cryosectioned at 20µm thickness for immunofluorescence 
application on a Leica CM1850 UV cryostat (Leica, Germany). Sections were 
mounted onto Polysine™ Microscope Adhesion Slides (J2800AMNZ, Thermo 
Scientific) and allowed to air dry for 30 minutes. Fixation of cryosections and CLE 
cells was dependant on the protein of interest being analysed. Typically, fixation 
was performed for 30 minutes and then washed three times in washing buffer 
(PBS or PBS with 0.1% Triton-X100, Sigma-Aldrich) for 5 minutes per wash. To 
prevent non-specific binding of antibodies, fixed and washed cryosections or CLE 
cells were blocked using 5% donkey serum (D9663, Sigma-Aldrich), 0.25% cold 
water fish gelatine (G7765, Sigma-Aldrich) and 0.25% Albumin from Bovine 
Serum (BSA; A2153, Sigma-Aldrich) in washing buffer for 12 hours at room 
temperature.  Primary antibodies were diluted in blocking buffer and incubated 
overnight at 4ºC (See appendix section 7.6 and 7.7 for experimental details 
regarding each antibody). The following day, samples were washed three times 
in washing buffer at room temperature. Incubation with secondary antibodies, 
diluted in blocking buffer, was done for 2 hours at room temperature obscured 
from light. Samples were then washed three times for 5 minutes at room 
temperature. Nuclei were counterstained with 2µg/ml 4’,6-diamidino-2-
phenylindole (DAPI; D9542, Sigma-Aldrich) for 10 minutes. Finally, cryosections 
were mounted and sealed using DAKO mounting medium (S3023, Dako) and 
slides were stored at 4ºC for minimum 2 hours before imaging to allow the 
mounting medium to polymerise. 
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7.14 Confocal imaging 
Immunofluorescence images were captured using a Leica DMI6000 confocal 
microscope with a Leica TCS SP8 attachment at a resolution of 2048x2048. The 
microscope runs on LAS AF software from Leica. Post-imaging processing was 
conducted using Adobe Photoshop CC. 
7.15 Three-dimensional reconstruction of primary cilia 
Fluorescence z-stack images were acquired using the Leica DMI6000 confocal 
microscope with a Leica TCS SP8 attachment with a Z-step size of 1µm. Imaris 
8.3 (Bitplane) was used to generate a 3D reconstruction of primary cilia from the 
acquired images using acetylated Tubulin as a primary cilium marker. 
Measurements of primary cilium dimensions were performed manually using the 
Imaris Measurement Pro tool in Imaris 8.3. When required, 3D-reconstructed 
primary cilium images were rotated to render a cross-section appropriate for 
quantification. 
7.16 Three-dimensional reconstruction of the cervical loop 
Volume analysis of the P7 mouse incisor tooth cervical loop was achieved by 
outlining the structure based on the basement membrane from approximately 20 
consecutive 20μm thick coronal sections of the apical side of the mouse incisor 
tooth (n = 3 animals per genotype). Rendering of the Sox2-positive region within 
the cervical loop was done using BioVis 3D software (version: 3.1.1.11; BioVis3D) 
and allowed us to calculate the volume. 
7.17 Total protein extraction  
Total protein content was collected as follows. CLE cells were washed with ice-
cold HBSS to remove cell debris. Cells were then collected using a cell scraper 
in 1ml HBSS. Collected cells were then spun down at 10,000rpm for 10 minutes 
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at4ºC. Supernatant was removed and the remaining cell pellet was resuspended 
in ice-cold Radioimmunoprecipitation assay (89901, Pierce) buffer supplemented 
with Protease & Phosphatase Inhibitor Cocktail (78442, Pierce). The cell 
suspension was then incubated for 30 minutes on ice with periodical vortexing 
and the lysate was then spun down at 10,000rpm for 10 minutes at 4ºC to pellet 
the cell debris. The supernatant was then transferred to a new, chilled tube and 
stored at -20ºC until protein quantification. 
7.18 Cytoplasmic and nuclear protein extraction 
Approximately 10x106 CLE cells were washed once with ice-cold HBSS and then 
collected. Cells were spun down at 10000rpm for 10 min. Supernatant was 
removed and pellet was used to extract nuclear and cytoplasmic protein fraction 
according to NE-PER™ Nuclear and Cytoplasmic Protein Extraction (78833, 
Pierce). In brief, the pellet was resuspended in lysis buffer 1 (CER I) and vortexed 
to obtain a homogenous mixture. The lysate was then incubated on ice for 10 
minutes before addition of lysis buffer 2 (Cer II) at a ratio of 200:11 (Cer I: Cer II) 
for 1 minute on ice. Intact nuclei were then pelleted at 16,000rcf for 5 minutes. 
The cytoplasmic protein-containing supernatant was then transferred into a new 
tube and stored at -80ᵒC until protein quantification. The insoluble, intact nuclei 
fraction was then subjected to a third lysis step (Ner) to release the nuclear 
proteins into solution before nuclear debris was pelleted at 16,000rcf for 5 
minutes. The nuclear protein-containing supernatant was then transferred to a 
chilled tube and stored at -80ᵒC until further processing. 
7.19 Protein quantification 
Total, nuclear and cytoplasmic protein fractions were quantified using BCA 
Protein Assay (23225, Pierce). A standard curve was generated from a set of 
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nine protein standards, which were prepared as follows. Protein standards were 
made from an BSA Standard (2mg/ml) and serially diluted in PBS to give the 
following protein concentrations: 0 (100% PBS); 25; 125; 250; 500; 750; 1000; 
1500; 2000µg/ml. 25µl of each standard was used to determine the standard 
curve of the assay. At the same time, 2,5µl of each protein sample was added to 
22,5µl of PBS to minimise the usage of sample as well as to mimic the protein 
standard diluent as close as possible. The BCA Working Reagent was then 
prepared as described in the manufacturer’s protocol, added to the samples and 
standards and allowed to incubate for 25 minutes at 37ᵒC. Following incubation, 
the absorbance of each well was measured at 562nm using a FLUOstar® Omega 
platereader (Firmware version: 1.43) and the Omega software (Software version: 
5.11). The absorbance readouts of the standards were used to plot the linear 
regression line and its associated equation. The equation was then used to 
calculate the protein concentration of each sample. 
7.20 Western blotting 
Western blotting of total, nuclear and cytoplasmic lysates were processed as 
follows. All samples used were normalised based on their concentration obtained 
according to section 6.19. Normalised samples were then supplemented with 4x 
NuPAGE® Lithium Dodecyl Sulphate (LDS) Sample Buffer (NP0007, Invitrogen) 
and 10x NuPAGE® Reducing Agent (NP0004, Invitrogen) to linearize and reduce 
the net charge of individual proteins within the samples. Finally, distilled water 
was added up to 20 or 25µl depending on the well size of the running gel. 
Samples were then incubated at 37ᵒC for 30 minutes when blotting for CD133 or 
at 95ᵒC for 5 minutes for all other epitopes. Samples were then cooled on ice and 
spun down to collect all sample components. In the meantime, NuPAGE® MOPS 
running buffer (NP0001, Invitrogen) was prepared according to manufacturer’s 
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instructions. 4-12% NuPAGE® Novex™ Bis-Tris gels were used in all Western 
Blotting experiments. XCell SureLock® Mini-Cell (EI0001, Invitrogen) was 
assembled with a 4-12% NuPAGE® Novex™ Bis-Tris gel and dummy cassette 
to create a closed circuit consisting of an inner and outer chamber. 200ml and 
600ml of NuPAGE® MOPS running buffer was added to the inner and outer 
chamber, respectively. Samples and protein ladders were then added into the 
wells and protein separation was initiated at 200V for ~50 minutes. PageRuler™ 
Prestained Protein Ladder (SM0671, Fermentas) was used to assess protein 
migration and transfer during the experiment. Novex™ MagicMark™ XP (LC5602, 
Invitrogen) protein ladder was used to assess to assess protein size after 
development. During the running step, NuPAGE® Transfer Buffer (NP0006, 
Invitrogen) was prepared as per manufacturer’s recommendations and 
supplemented with 100% methanol (322415, Sigma-Aldrich) up to 10% of the 
total transfer buffer volume. 
When protein separation was completed, the gel was removed from its casing 
and the blot module was assembled in the following order from top to bottom in 
the cathode core:  two blotting pads, filter paper, gel, methanol-activated 
Polyvinylidene fluoride (PVDF) membrane (0,45µm; LC2005, Invitrogen), filter 
paper, two blotting pads. After assembly, the blot module was then filled with 
transfer buffer and inserted into the XCell SureLock® Mini-Cell. The protein 
content was then transferred onto the PVDF membrane at 36V for approximately 
1 hour 45 minutes until the high kDa bands of the PageRuler™ ladder are 
transferred on to the membrane. Following transfer, the membrane was washed 
in distilled water to remove methanol residue. 
167 
 
Detection of proteins was performed using the iBind™ Flex Western Device 
(SLF2000S, Invitrogen) and the iBind™ Flex Solution (SLF2020, Invitrogen) was 
used as a blocking buffer, washing buffer and antibody diluent throughout the 
process. During the assembly of the iBind™ Flex Western Device, the membrane 
is blocked in the iBind™ Flex Solution for 5 minutes at room temperature. 
Antibody solutions are prepared in the iBind™ Flex Solution and concentrations 
are listed in appendix section 7.6 and 7.7. Following the blocking step, the 
membrane is laid protein side down on to the iBind™ card. The mechanical force 
exerted by the lid allows for lateral sequential flow of the antibody and wash 
solutions over the protein side of the membrane. After the run, the membrane is 
washed three times in distilled water to remove non-bound antibodies. 
Detection of Horseradish Peroxidase-conjugated (HRP) secondary antibodies 
was achieved with incubation of WesternSure™ PREMIUM ECL substrate (926-
95000, Li-Cor) for 5 minutes at room temperature. The membrane was then 
digitally imaged ON the C-DiGit® Chemiluminescent Western Blot Scanner 
(3600-00, Li-Cor) using the Image Studio™ software (version: 3.1; Li-Cor). 
7.21 Duolink® Proximity Ligation Assay 
In situ protein interactions were detected by the proximity ligation assay kit 
Duolink® II (DUO92101, Sigma-Aldrich). The Duolink® proximity ligation assay 
(DPLA) probe anti-rabbit minus binds to the CD133 antibody, whereas the PLA 
probe anti-rabbit plus binds to the GLIS2 antibody. The DPLA secondary 
antibodies only generate a signal when the two DPLA probes have bound, which 
only takes place if both proteins are closer than 40nm, indicating their 
interaction442.  
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Frozen CD1 mouse heads were prepared as described in section 6.7. After 
blocking, conjugated CD133 and GLIS2 antibody were added to the slides at a 
concentration of 1:100 in antibody diluent. Incubation was done overnight in a 
humidity chamber at 4°C. Slides were washed two times in Wash Buffer A for 5 
min to remove unbound conjugated antibodies. The samples were incubated with 
the Ligation Solution consisting of Duolink® II Ligation stock (1:5) and Duolink® 
Ligase (1:40) diluted in high purity water for 30 min at 37 °C. After ligation the 
Duolink® Amplification and Detection stock, diluted 1:5 with addition of 
polymerase (1:80), was applied to the slides for 100 min. DAPI was used as 
described in section 6.13 to identify the nuclei. After the final washing steps using 
Wash Buffer A and B the slides were dried and cover slips were mounted using 
Fluorescence Mounting medium (S3023, DAKO). 
7.22 Co-Immunoprecipitation 
Co-Immunoprecipitatation (CoIP) was achieved using the μMACS™ isolation 
procedure (Miltenyi Biotec). 16 hours prior to protein extraction, Madin-Darby 
Canine Kidney (MDCK) cells were supplemented with 10 mM sodium butyrate. 
Cells were then lysed for 30 minutes on ice in lysis buffer containing (0.2% Triton 
X-100, 150mM NaCl, 20mM Tris/HCl, pH 7.5) containing Complete™ protease 
inhibitor cocktail (04 693 159 001, Roche Diagnostics), 2mM sodium 
orthovanadate (P0758, New England Biolabs), 10mM sodium fluoride (P0759, 
New England Biolabs) and 10mM β-glycerophosphate (G9422 Sigma-Aldrich). 
Cell debris was pelleted by centrifugation for 10 minutes at 16,000rcf at 4°C and 
the supernatant was collected in a chilled tube and pre-cleared by incubation with 
magnetic Basic MicroBeads (130-048-001, Miltenyi Biotec) for 30 minutes. The 
lysate was then passed through a MS column (130-042-201, Miltenyi Biotec) to 
remove proteins that non-specifically bind to magnetic beads. Pre-cleared lysates 
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were incubated with either 65μl anti-CD133–magnetic MicroBeads (130-097-049, 
Miltenyi Biotec) or 130μl anti-FITC–magnetic MicroBeads ( 130-048-701, 
Miltenyi Biotec) as negative control for 1,5 hours at 4°C before proceeding to 
magnetic separation using MS columns. For Arl13b CoIP, pre-cleared lysates 
were incubated first with 3.5μl of anti-Arl13b polyclonal antibody at 4ᵒC for 30 
minutes. Followed by incubation with 100μl μMACS Protein A MicroBeads for 1 
hour at 4ᵒC. Retained magnetic beads were washed 6 times with 1ml of ice-cold 
PBS containing 2mM EDTA and 0.1% Triton X-100. Followed by elution with pre-
heated (95°C) Laemmli sample buffer. Flow-through samples were collected and 
subjected to methanol/chloroform precipitation and re-suspended in Laemmli 
sample buffer. 
7.23 Chromatin Immunoprecipitation  
Chromatin Immunoprecipitation (ChIP) assays were performed using Chip-IT® 
Express (53008, Active Motif) according to the manufacturer's instructions. Pre-
treated cells were fixed with 40µl of 37% (wt/vol) formaldehyde (Sigma-Aldrich) 
per 1ml of overlaying medium for 10 minutes at room temperature, followed by 5 
minutes of glycine stop-fix solution. Cells were washed twice with ice-cold PBS, 
PBS was poured off and discarded and cells were scraped, pelleted by 
centrifugation for 10 minutes at 2000rcf at 4°C. Cells were resuspended in 400μl 
of ice-cold ChIP-It® lysis buffer followed by 30 minutes incubation on ice. Nuclei 
release was further enhanced using an ice-cold dounce homogeniser and visually 
checked using a phase-contrast microscope. Pellets were spun down for 10 
minutes at 2400rcf, resuspended in 350μl of Shearing Buffer and transferred to 
1.5ml Bioruptor® microtubes (C30010016, Diagenode). Chromatin was sheared 
using Bioruptor® pico (B01060001, Diagenode) with the following optimised 
settings to generate DNA fragments of approximately 500 bp: 15’’ ON/ 30’’ OFF; 
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10 cycles.  Sheared chromatin was cleared by centrifugation at 18000 rcf for 10 
minutes at 4°C. For each ChIP, 60μl of the total sonicated chromatin was used. 
Immunoprecipitations were performed overnight at 4°C with 2μl of the Glis2 
antibody (kindly gifted by Dr. Massimo Attanasio). Chromatin–antibody 
complexes were captured using Protein G magnetic beads (101945, Active Motif) 
and chromatin was eluted as described in manufacturer's instructions. The cross-
links were reversed, and DNA purified by proteinase K. DNA was analysed by 
real-time qPCR (See appendix section 7.10.1 for programme details). 
7.24 Scanning Electron Microscopy 
Four-week-old C57BL/6 WT and CD133 KO mice were killed and their lower jaws 
dissected and fixed in ethanol at increasing concentrations: 50%, 70%, 90%, 95% 
for 5 minutes each and then then three times 100% for 30 minutes. After fixation 
for 24 hours, a segment of the erupted part of the incisors was cut off with a 
watercooled diamond wheel, air-dried and glued to brass cylinders with 
cyanoacrylate glue443. The incisor segments were sputter-coated with a 50nm 
layer of gold-palladium in order to protect the enamel surface from the 
subsequent acid etching. All segments were ground transversely (at the incisal 
end), some also longitudinally, tangentially, or oblique transversely (at the apical 
end), using 3M waterproof silicon carbide paper and a specially designed 
apparatus444 operated under a stereomicroscope. After grinding, the specimens 
were cleaned by light brushing under running tap water and etched for three times 
10 seconds in 0.1 % nitric acid. The specimens were air-dried, sputter-coated 
with 30nm gold-palladium and observed in a Philips XL20 operated at 15kV, using 
a specially designed holder allowing multiangular viewing of the specimens445.  
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7.25 X-Ray microscopy-based microCT analysis 
Mouseheads were scanned at the Small Animal Imaging Core of the University 
of Iowa using the Zeiss Xradia 520 Versa (Pleasanton, CA). The 3D X-ray source 
acquisition settings were 10W, 120kV, and 0.4x magnification. Source distance 
from the mouse heads was 27mm, and the detector distance was 170mm. A total 
of 1,601 projections with a 1s exposure time over 360 degrees of rotation were 
acquired using the Reconstructor Scout-and-Scan software (Zeiss, Pleasanton, 
CA), projections were reconstructed with downsampling of 1, with beam 
hardening correction to yield a pixelsiye of 25µm. The generated DCOM files 
were reconstructed into 3D images and analzsed in Imaris software programme. 
(9.0, Bitplane). 
7.26 Statistics 
Statistical analyses were performed using GraphPad Prism® version 5.00. For 
box-whisker plots, the boxes represent data between 25th-75th percentiles and 
all data is contained within the whiskers. Median values are represented by the 
horizontal lines within the box. Unpaired t-test with Welch’s correction was 
applied to all measurements involving primary cilium dimensions, except for 
primary cilium length measurements in the stem cell and transit-amplifying 
regions of WT and mutant mice where one-way ANOVA was applied. Unpaired 
t-test was applied to cervical loop volume measurements.  All quantification and 
real time RT-PCR results were presented using style of Mean and Standard 
Deviation (error bars). Observed differences were regarded as significant if the 
calculated p-values were ≤ 0.05. *, p < 0.05; **, p < 0.01; ***, p <0.001.  
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8 Appendices 
8.1 B27 Serum-free Medium Composition 
Component Concentration (per L)446 
Vitamins  
Biotin 125mg 
DL Alpha Tocopherol Acetate 50mg 
DL Alpha Tocopherol  50mg 
  
Proteins  
BSA, fatty acid-free fraction V 125g 
Catalase 125mg 
Human Recombinant Insulin 156.25mg 
Human Holo-Transferin 250mg 
Superoxide Dismutase 375.000 U 
  
Other Components  
Corticosterone 1mg 
D-Galactose 750mg 
Ethanolamine HCl 50µg 
Glutathione (reduced) 50mg 
Linoleic Acid 50mg 
Linolenic Acid 50mg 
Progesterone 315µg 
Putrescine 2HCl 805mg 
Sodium Selenite 625µg 
T3 (triodo-l-thyronine) 100µg 
L-Carnithine HCl 100mg 
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8.2 DMEM/F12 Medium Composition 
Components Concentration (mg/L)447,448 
Amino Acids  
Glycine 18.75 
L-Alanine 4.45 
L-Alanyl-L-Glutamine 542 
L-Arginine hydrochloride 147.5 
L-Asparagine-H2O 7.5 
L-Aspartic acid 6.65 
L-Cysteine hydrochloride-H2O 17.56 
L-Cystine 2HCl 31.29 
L-Glutamic Acid 7.35 
L-Histidine hydrochloride-H2O 31.48 
L-Isoleucine 54.47 
L-Leucine 59.05 
L-Lysine hydrochloride 91.25 
L-Methionine 17.24 
L-Phenylalanine 35.48 
L-Proline 17.25 
L-Serine 26.25 
L-Threonine 53.45 
L-Tryptophan 9.02 
L-Tyrosine disodium salt dihydrate 55.79 
L-Valine 52.85 
  
Vitamins  
Biotin 0.0035 
Choline chloride 8.98 
D-Calcium pantothenate 2.24 
Folic Acid 2.65 
Niacinamide 2.02 
Pyridoxine hydrochloride 2 
Riboflavin 0.219 
Thiamine hydrochloride 2.17 
Vitamin B12 0.68 
i-Inositol 12.6 
  
Inorganic Salts  
Calcium Chloride 116.6 
Cupric sulfate 0.0013 
Ferric Nitrate 0.05 
Ferric sulfate 0.417 
Magnesium Chloride 61 
Magnesium Sulfate 100 
Potassium Chloride 311.8 
Sodium Bicarbonate 2438 
Sodium Chloride 6995.5 
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Components (continued) Concentration (mg/L) 
Sodium Phosphate dibasic 134 
Sodium Phosphate monobasic 62.5 
Zinc sulfate 0.432 
  
Other Components  
D-Glucose (Dextrose) 3151 
Hypoxanthine Na 2.39 
Linoleic Acid 0.042 
Lipoic Acid 0.105 
Phenol Red 8.1 
Putrescine 2HCl 0.081 
Sodium Pyruvate 55 
Thymidine 0.365 
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8.3 Gene list RT2 Pathway finder 
GeneBank Symbol Description Pathway 
NM_009741 Bcl2 B-cell leukemia/lymphoma 2 Hedgehog Signaling 
NM_007553 Bmp2 Bone morphogenetic protein 2 Hedgehog Signaling 
NM_007554 Bmp4 Bone morphogenetic protein 4 Hedgehog Signaling 
NM_008957 Ptch1 Patched homolog 1 Hedgehog Signaling 
NM_021279 Wnt1 Wingless-related MMTV integration site 1 Hedgehog Signaling 
NM_009520 Wnt2b Wingless related MMTV integration site 2b Hedgehog Signaling 
NM_009522 Wnt3a Wingless-related MMTV integration site 3A Hedgehog Signaling 
NM_009524 Wnt5a Wingless-related MMTV integration site 5A Hedgehog Signaling 
NM_009526 Wnt6 Wingless-related MMTV integration site 6 Hedgehog Signaling 
NM_009627 Adm Adrenomedullin Hypoxia Signaling 
NM_009709 Arnt 
Aryl hydrocarbon receptor nuclear 
translocator 
Hypoxia Signaling 
NM_139305 Car9 Carbonic anhydrase 9 Hypoxia Signaling 
NM_007942 Epo Erythropoietin Hypoxia Signaling 
NM_010699 Ldha Lactate dehydrogenase A Hypoxia Signaling 
NM_008871 Serpine1 
Serine (or cysteine) peptidase inhibitor, 
clade E, member 1 
Hypoxia Signaling 
NM_011400 Slc2a1 
Solute carrier family 2 (facilitated glucose 
transporter), member 1 
Hypoxia Signaling 
NM_009505 Vegfa Vascular endothelial growth factor A Hypoxia Signaling 
NM_008390 Irf1 Interferon regulatory factor 1 
JAK1 & JAK2/STAT1-
Induced 
NM_013517 Fcer2a 
Fc receptor, IgE, low affinity II, alpha 
polypeptide 
JAK1 & JAK3/STAT6-
Induced 
NM_008091 Gata3 GATA binding protein 3 
JAK1 & JAK3/STAT6-
Induced 
NM_009742 Bcl2a1a 
B-cell leukemia/lymphoma 2 related protein 
A1a 
NFκB Signaling 
NM_007464 Birc3 Baculoviral IAP repeat-containing 3 NFκB Signaling 
NM_013653 Ccl5 Chemokine (C-C motif) ligand 5 NFκB Signaling 
NM_007778 Csf1 Colony stimulating factor 1 (macrophage) NFκB Signaling 
NM_010493 Icam1 Intercellular adhesion molecule 1 NFκB Signaling 
NM_008337 Ifng Interferon gamma NFκB Signaling 
NM_009283 Stat1 
Signal transducer and activator of 
transcription 1 
NFκB Signaling 
NM_013693 Tnf Tumor necrosis factor NFκB Signaling 
NM_009743 Bcl2l1 Bcl2-like 1 
NFκB Signaling, 
STAT3/STAT5-Induced 
NM_008235 Hes1 
Hairy and enhancer of split 1 (Drosophila) 
  
Notch Signaling  
NM_010419 Hes5 Hairy and enhancer of split 5 (Drosophila) Notch Signaling 
NM_010423 Hey1 
Hairy/enhancer-of-split related with YRPW 
motif 1 
Notch Signaling 
NM_013904 Hey2 
Hairy/enhancer-of-split related with YRPW 
motif 2 
Notch Signaling 
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GeneBank Symbol Description Pathway 
NM_013905 Heyl 
Hairy/enhancer-of-split related with YRPW 
motif-like 
Notch Signaling 
NM_010495 Id1 Inhibitor of DNA binding 1 Notch Signaling 
NM_013822 Jag1 Jagged 1 Notch Signaling 
NM_008494 Lfng 
LFNG O-fucosylpeptide 3-beta-N-
acetylglucosaminyltransferase 
Notch Signaling 
NM_008714 Notch1 Notch gene homolog 1 (Drosophila) Notch Signaling 
NM_010239 Fth1 Ferritin heavy chain 1 Oxidative Stress 
NM_010295 Gclc Glutamate-cysteine ligase, catalytic subunit Oxidative Stress 
NM_008129 Gclm Glutamate-cysteine ligase, modifier subunit Oxidative Stress 
NM_010344 Gsr Glutathione reductase Oxidative Stress 
NM_008706 Nqo1 NAD(P)H dehydrogenase, quinone 1 Oxidative Stress 
NM_011018 Sqstm1 Sequestosome 1 Oxidative Stress 
NM_011660 Txn1 Thioredoxin 1 Oxidative Stress 
NM_015762 Txnrd1 Thioredoxin reductase 1 Oxidative Stress 
NM_010442 Hmox1 Heme oxygenase (decycling) 1 
Oxidative Stress, 
Hypoxia Signaling 
NM_007527 Bax Bcl2-associated X protein p53 Signaling 
NM_133234 Bbc3 BCL2 binding component 3 p53 Signaling 
NM_007570 Btg2 
B-cell translocation gene 2, anti-
proliferative 
p53 Signaling 
NM_007669 Cdkn1a Cyclin-dependent kinase inhibitor 1A (P21) p53 Signaling 
NM_007912 Egfr Epidermal growth factor receptor p53 Signaling 
NM_007987 Fas Fas (TNF receptor superfamily member 6) p53 Signaling 
NM_007836 Gadd45a 
Growth arrest and DNA-damage-inducible 
45 alpha 
p53 Signaling 
NM_011045 Pcna Proliferating cell nuclear antigen p53 Signaling 
NM_009029 Rb1 Retinoblastoma 1 p53 Signaling 
NM_001033606 Acsl3 
Acyl-CoA synthetase long-chain family 
member 3 
PPAR Signaling 
NM_019477 Acsl4 
Acyl-CoA synthetase long-chain family 
member 4 
PPAR Signaling 
NM_027976 Acsl5 
Acyl-CoA synthetase long-chain family 
member 5 
PPAR Signaling 
NM_009949 Cpt2 Carnitine palmitoyltransferase 2 PPAR Signaling 
NM_017399 Fabp1 Fatty acid binding protein 1, liver PPAR Signaling 
NM_138648 Olr1 
Oxidized low density lipoprotein (lectin-like) 
receptor 1 
PPAR Signaling 
NM_011989 Slc27a4 
Solute carrier family 27 (fatty acid 
transporter), member 4 
PPAR Signaling 
NM_009166 Sorbs1 Sorbin and SH3 domain containing 1 PPAR Signaling 
NM_007707 Socs3 Suppressor of cytokine signaling 3 STAT3/STAT5-Induced 
NM_007679 Cebpd 
CCAAT/enhancer binding protein (C/EBP), 
delta 
STAT3-Induced 
NM_029796 Lrg1 Leucine-rich alpha-2-glycoprotein 1 STAT3-Induced 
NM_008562 Mcl1 Myeloid cell leukemia sequence 1 STAT3-Induced 
NM_009716 Atf4 Activating transcription factor 4 TGFβ Signaling 
NM_009875 Cdkn1b Cyclin-dependent kinase inhibitor 1B TGFβ Signaling 
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GeneBank Symbol Description Pathway 
NM_010128 Emp1 Epithelial membrane protein 1 TGFβ Signaling 
NM_008655 Gadd45b 
Growth arrest and DNA-damage-inducible 
45 beta 
TGFβ Signaling 
NM_022331 Herpud1 
Homocysteine-inducible, endoplasmic 
reticulum stress-inducible, ubiquitin-like 
domain member 1 
TGFβ Signaling 
NM_013562 Ifrd1 
Interferon-related developmental regulator 
1 
TGFβ Signaling 
NM_009425 Tnfsf10 
Tumor necrosis factor (ligand) superfamily, 
member 10 
TGFβ Signaling 
NM_015732 Axin2 Axin2 WNT Signaling 
NM_009829 Ccnd2 Cyclin D2 WNT Signaling 
NM_023118 Dab2 Disabled homolog 2 (Drosophila) WNT Signaling 
NM_010235 Fosl1 Fos-like antigen 1 WNT Signaling 
NM_010810 Mmp7 Matrix metallopeptidase 7 WNT Signaling 
NM_011145 Ppard 
Peroxisome proliferator activator receptor 
delta 
WNT Signaling 
NM_018865 Wisp1 
WNT1 inducible signaling pathway protein 
1 
WNT Signaling 
NM_007631 Ccnd1 Cyclin D1 
WNT Signaling, 
STAT3/STAT5-Induced 
NM_010849 Myc Myelocytomatosis oncogene 
WNT Signaling, TGFβ 
Signaling 
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8.4 Primary antibodies used in this study
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8.5 Secondary antibodies used in this study 
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8.6 esiRNA and shRNA sequences used in this study 
esiRNA (Sigma) Sequence 
CD133 EMU055321 
ATCGCAGGATGGATTCAGAGGATGTATACGACGATGTTG
AGACTGTGCCCATGAAAAATTTGGAAATCGATAGTAATG
GTTATCATAAAGATCATTTATATGGTGTTCACAATCCTGT
TATGACAAGCCCGTCTCGATACTGACAACTGGAGTTGAA
GCTGCTTGAACAACAAGATAGTCAACATGGAAAGCATCA
CAGATTTTGGATAGTTTCTGAGTCTTCTAGAACGTTCCAA
GTGCAGAAGAAACCTGGTGGAGACTCAGGCGGGCACTA
GGAACATGGCATCAGTGGTCTTAGGGATGCACTTTGTCA
GGAATGAACAGTCATCATGGTTATAAGCCACATATCCATT
GCAACTCATGAATGATTCTCTCCTGTTTTGTTTTTAACTTT
TCTTTTTACACTGATTTTCTATTTAGACACTAAAACATATA
GGGGTGCTTATTCCCCCTGGATACATTTACCTGTGAACC
AGCTATTCCGGT 
RLUC EHURLUC 
GATAACTGGTCCGCAGTGGTGGGCCAGATGTAAACAAAT
GAATGTTCTTGATTCATTTATTAATTATTATGATTCAGAAA
AACATGCAGAAAATGCTGTTATTTTTTTACATGGTAACGC
GGCCTCTTCTTATTTATGGCGACATGTTGTGCCACATATT
GAGCCAGTAGCGCGGTGTATTATACCAGACCTTATTGGT
ATGGGCAAATCAGGCAAATCTGGTAATGGTTCTTATAGG
TTACTTGATCATTACAAATATCTTACTGCATGGTTTGAACT
TCTTAATTTACCAAAGAAGATCATTTTTGTCGGCCATGAT
TGGGGTGCTTGTTTGGCATTTCATTATAGCTATGAGCATC
AAGATAAGATCAAAGCAATAGTTCACGCTGAAAGTGTAG
TAGATGTGATTGAATCATGGGATGAATGG 
 
shRNA 
(Sigma) Clone ID 
Legacy Clone 
Name Target Sequence 
shCD133-1 
TRCN000011531
6 
NM_008935.1
-3396s1c1 CCTGCGGTTTAGAAATAGAAT 
shCD133-2 
TRCN000011531
9 
NM_008935.1
-1442s1c1 
GCTGGAAGAATATGACTCGT
A 
shCD133-3 
TRCN000011532
0 
NM_008935.1
-1800s1c1 CTATTCAATAACCCAGACATT 
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8.7 Primers used in this study 
Gene name Forward primer ('5-'3) Reverse primer ('5-'3) Size 
Acsl4 agaagggaagcaagggtgat gattacaaagaggggcgtca 198 
Arnt ccatcgttgtgtggctactg aaggagctcgttctcatcca 201 
Axin2 taatgctaggcggaatgaag aacccattacaagcaaacca 192 
Bmi1 ccgctctttccgggatcttt tgttcaggagtggtctggtt 237 
Cdk5r1 taacaggattccagctttgc ctagcggtcgttcctttaca 201 
Cdkn1c tctaggggaatggttgttga gatttttgttgggcctcttt 189 
Cdkn2b cattttctgcagctggatct ttcacaggggaaggtactga 228 
cMyc ccagatccctgaattggaaa tcgtctgcttgaatggacag 93 
Egfr gtgatccaagctgtcccaat cttggaacttttggcagacc 198 
Gadd45a tgcgagaacgacatcaacat tcccggcaaaaacaaataag 200 
Gclc aacacagacccaacccagag ccgcatcttctggaaatgtt 201 
Gli1 atagggtctcggggtctcaa cggctgactgtgtaagcaga 137 
Gli2 aggcagtcagtgcctgggtat accgcagccagggatga 246 
Gli3 tgccgctggcttgattgt tggcccgatctgaagcat 241 
Glis1 ctccaagcatccacactgtt gacaggatgcctgaagcaag 128 
Glis2 caacgaccatcatgtcaagc cggttgtggatcttcaggtt 198 
Irf1 cctgggtcaggacttggata ttcggctatcttcccttcct 202 
Jak1 catgactcgctgcatgaact tcaaccttcccaaagtgacc 201 
Jak2 gtccacccgtggaatttatg gaagggaaaggtccctgaag 198 
Jak3 gtggcatcctgcctgtttat ggatggcactggtcaaatct 204 
Lgr5 ccttccctgtgactgggtta cactgttgccgtcgtcttta 201 
Lrg1 tcccatgtcagtgtgcagat tcagcctaggagccgtttta 203 
p16 caagagcggggacatcaagacatc agctctgctcttgggattggcc 175 
p21 cttgtcgctgtcttgcactc tctcttgcagaagaccaatctg 142 
p27 ttgggtctcaggcaaactct tctgttggcccttttgtttt 152 
Prom1 tgtggatgtcatcaaagacg gggcagctcctggtttaagt 149 
Rb1 gcctcctaccttgtcaccaa tgtcccaaatgattcaccaa 199 
Shh tccactgttctgtgaaagca gtccaggaaggtgaggaagt 188 
Slc2A1 aaacatggaaccaccgctac gagaagcccataagcacagc 202 
Socs3 gcccctttgtagacttcacg aacttgctgtgggtgaccat 232 
Sox2 aaccccaagatgcacaactc ctccgggaagcgtgtactta 202 
Stat3 tgatcgtgactgaggagctg tggcggcttagtgaagaagt 203 
Stat3 ChIP neg ctrl 1 gcaattcgacaacaaaagaaa ttgagaagggtgttgtttcc 250 
Stat3 ChIP neg ctrl 2 gacacatggttcacattctcc agtcacttgatggcacctgt 164 
Stat3_s1 cactgcagtacgcagagttca tccacactttcccactactgc 218 
Stat3_s2 cagcaggacattccgctaat gcgagcgctgtacttcctaa 209 
Stat5a gtgaagcgctcaacatgaaa gaaccactgccagaaggtgt 200 
Stat5b cccaagtcatggggagagta agcatgcagataggggacac 199 
Stat6 ccctgttcaagaacctgctc agctttggcgttgttgtctt 200 
Tyk2 acatggtcccttggatgtgt tagcttgatgaaggggttgg 199 
Wisp1 agatatgtgcccagcagctt ttgtacctgcagttgggttg 199 
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8.8 PCR programme details 
8.8.1 Real-Time qPCR 
 
8.8.2 cDNA Reverse Transcription PCR 
 
 
 
 
 
 
 
 
 
 
 
Column1 Temperature (ᵒC) Duration (mm:ss) Cycle (nᵒ)
Step1 Initial denaturation 95 05:00 1
Denaturation 95 00:10
Annealing 60 00:20
Elongation 72 00:10
Final denaturation 95 00:05 1
Start melting curve 65 01:00 1
End melting curve up to 96 Continuous 1
Step 2 45
Step 3
Column1 Temperature (ᵒC) Duration (mm:ss)
Annealing 25 10:00
Elongation 37 120:00:00
Denaturation 85 05:00
Final hold 4  ∞ 
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